<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Elevance Health, Inc.</td><td># Elevance Health, Inc. ì‹¤ì  ë°œí‘œ ë²ˆì—­<br><br>*ì°¸ê³ : ì‹¤ì œ ì‹¤ì  ë°œí‘œ ë‚´ìš©ì´ ì œê³µë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ì‹¤ì  ë°œí‘œ ì›ë¬¸ì„ ì œê³µí•´ ì£¼ì‹œë©´ ì „ë¬¸ì ì´ê³  ì •í™•í•œ í•œêµ­ì–´ ë²ˆì—­ì„ ì œê³µí•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.*<br><br>---<br><br>**ë²ˆì—­ ì‹œ ì ìš©ë˜ëŠ” ì›ì¹™:**<br><br>1. **ì¬ë¬´ ìš©ì–´ì˜ ì •í™•ì„±**: EPS(ì£¼ë‹¹ìˆœì´ìµ), EBITDA, revenue(ë§¤ì¶œ), operating margin(ì˜ì—…ì´ìµë¥ ) ë“± ì¬ë¬´ ìš©ì–´ëŠ” ì—…ê³„ í‘œì¤€ í•œêµ­ì–´ ìš©ì–´ë¡œ ë²ˆì—­<br><br>2. **í™”ìì˜ ì–´ì¡° ìœ ì§€**: ê²½ì˜ì§„ì˜ ê³µì‹ì ì¸ í†¤, ì• ë„ë¦¬ìŠ¤íŠ¸ì˜ ì§ˆë¬¸ ì–´ì¡° ë“±ì„ ìì—°ìŠ¤ëŸ¬ìš´ í•œêµ­ì–´ë¡œ ë³´ì¡´<br><br>3. **ìˆ«ì ë° ë°ì´í„°**: ì›ë¬¸ì˜ ìˆ˜ì¹˜ë¥¼ ì •í™•íˆ ìœ ì§€í•˜ë©°, í•„ìš”ì‹œ í•œêµ­ ë…ìë¥¼ ìœ„í•œ ë§¥ë½ ì¶”ê°€<br><br>4. **ì „ë¬¸ì„±**: í•œêµ­ íˆ¬ììë“¤ì´ ê¸°ëŒ€í•˜ëŠ” ìˆ˜ì¤€ì˜ ì „ë¬¸ì ì´ê³  ìœ ì°½í•œ ë²ˆì—­ ì œê³µ<br><br>ì‹¤ì  ë°œí‘œ ì›ë¬¸ì„ ì œê³µí•´ ì£¼ì‹œë©´ ì¦‰ì‹œ ë²ˆì—­ ì‘ì—…ì„ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>(ELV) Q4 2025 Earnings Call January 28, 2026 8:30 AM EST<br><br>Company Participants<br><br>Nathan Rich - Vice President of Investor Relations<br>Gail Boudreaux - President, CEO & Director<br>Mark Kaye - Executive VP & CFO<br>Felicia Norwood - Executive VP & President of Government Health Benefits<br>Peter Haytaian - Executive VP and President of Carelon & CarelonRx<br>Morgan Kendrick<br><br>Conference Call Participants<br><br>Albert Rice - UBS Investment Bank, Research Division<br>Andrew Mok - Barclays Bank PLC, Research Division<br>Justin Lake - Wolfe Research, LLC<br>Lance Wilkes - Bernstein Institutional Services LLC, Research Division<br>Joshua Raskin - Nephron Research LLC<br>Lisa Gill - JPMorgan Chase & Co, Research Division<br>Ann Hynes - Mizuho Securities USA LLC, Research Division<br>Christian Borgmeyer - TD Cowen, Research Division<br>Scott Fidel - Goldman Sachs Group, Inc., Research Division<br>Kevin Fischbeck - BofA Securities, Research Division<br>Erin Wilson Wright - Morgan Stanley, Research Division<br>Benjamin Hendrix - RBC Capital Markets, Research Division<br>David Windley - Jefferies LLC, Research Division<br>Sarah James - Cantor Fitzgerald & Co., Research Division<br>Jason Cassorla - Guggenheim Securities, LLC, Research Division<br>George Hill - Deutsche Bank AG, Research Division<br><br>Presentation<br><br>Operator<br><br>Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health Fourth Quarter Earnings Conference Call.</td><td>(ELV) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2026ë…„ 1ì›” 28ì¼ ì˜¤ì „ 8ì‹œ 30ë¶„ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>Nathan Rich - íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br>Gail Boudreaux - ì‚¬ì¥, CEO ê²¸ ì´ì‚¬<br>Mark Kaye - ì „ë¬´ì´ì‚¬ ê²¸ CFO<br>Felicia Norwood - ì „ë¬´ì´ì‚¬ ê²¸ ì •ë¶€ ê±´ê°• ê¸‰ì—¬ ì‚¬ì—…ë¶€ ì‚¬ì¥<br>Peter Haytaian - ì „ë¬´ì´ì‚¬ ê²¸ Carelon & CarelonRx ì‚¬ì¥<br>Morgan Kendrick<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>Albert Rice - UBS Investment Bank, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Andrew Mok - Barclays Bank PLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Justin Lake - Wolfe Research, LLC<br>Lance Wilkes - Bernstein Institutional Services LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Joshua Raskin - Nephron Research LLC<br>Lisa Gill - JPMorgan Chase & Co, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Ann Hynes - Mizuho Securities USA LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Christian Borgmeyer - TD Cowen, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Scott Fidel - Goldman Sachs Group, Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Kevin Fischbeck - BofA Securities, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Erin Wilson Wright - Morgan Stanley, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Benjamin Hendrix - RBC Capital Markets, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>David Windley - Jefferies LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Sarah James - Cantor Fitzgerald & Co., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Jason Cassorla - Guggenheim Securities, LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>George Hill - Deutsche Bank AG, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ì‚¬íšŒì<br><br>ì‹ ì‚¬ ìˆ™ë…€ ì—¬ëŸ¬ë¶„, ê¸°ë‹¤ë ¤ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. Elevance Health 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>[Operator Instructions] As a reminder, today's conference is being recorded. I would now like to turn the conference over to the company's management. Please go ahead. Nathan Rich<br>Vice President of Investor Relations<br><br>Good morning, and welcome to Elevance Health's Fourth Quarter 2025 Earnings Conference Call. My name is Nathan Rich, Vice President of Investor Relations. With us on the earnings call are Gail Boudreaux, President and CEO; Mark Kaye, our CFO; Pete Haytaian, President of Carelon; Morgan Kendrick, President of our Commercial Health Benefits business; and Felicia Norwood, President of our Government Health Benefits business.</td><td>[êµí™˜ì› ì•ˆë‚´] ì°¸ê³ ë¡œ ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ëŠ” ë…¹ìŒë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ íšŒì‚¬ ê²½ì˜ì§„ì—ê²Œ íšŒì˜ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ì§„í–‰í•´ ì£¼ì‹­ì‹œì˜¤.<br><br>ë„¤ì´ì„  ë¦¬ì¹˜<br>íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br><br>ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. Elevance Healthì˜ 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ì €ëŠ” íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥ ë„¤ì´ì„  ë¦¬ì¹˜ì…ë‹ˆë‹¤. ì˜¤ëŠ˜ ì‹¤ì  ë°œí‘œì—ëŠ” ê²Œì¼ ë¶€ë“œë¡œ(Gail Boudreaux) ì‚¬ì¥ ê²¸ CEO, ë§ˆí¬ ì¼€ì´(Mark Kaye) CFO, í”¼íŠ¸ í—¤ì´íƒ€ì´ì–¸(Pete Haytaian) Carelon ì‚¬ì¥, ëª¨ê±´ ì¼„ë“œë¦­(Morgan Kendrick) ìƒì—… ê±´ê°•ë³´í—˜ ì‚¬ì—…ë¶€ ì‚¬ì¥, ê·¸ë¦¬ê³  í ë¦¬ìƒ¤ ë…¸ìš°ë“œ(Felicia Norwood) ì •ë¶€ ê±´ê°•ë³´í—˜ ì‚¬ì—…ë¶€ ì‚¬ì¥ì´ í•¨ê»˜ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Gail will begin the call with a discussion of our fourth quarter performance, our 2026 guidance and the progress we continue to make on our strategic priorities. Mark will then discuss our financial results and outlook in greater detail. After our prepared remarks, the team will be available for Q&A. During the call, we will reference certain non-GAAP financial measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website, elevancehealth.com. We will also be making forward-looking statements on this call.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤. ê²Œì¼ì´ 4ë¶„ê¸° ì‹¤ì , 2026ë…„ ê°€ì´ë˜ìŠ¤, ê·¸ë¦¬ê³  ì „ëµì  ìš°ì„ ìˆœìœ„ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ë‹¬ì„±í•˜ê³  ìˆëŠ” ì§„ì „ ì‚¬í•­ì— ëŒ€í•´ ë¨¼ì € ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ì–´ì„œ ë§ˆí¬ê°€ ì¬ë¬´ ì‹¤ì ê³¼ ì „ë§ì— ëŒ€í•´ ë”ìš± ìƒì„¸íˆ ì„¤ëª…ë“œë¦´ ì˜ˆì •ì…ë‹ˆë‹¤. ì¤€ë¹„ëœ ë°œí‘œê°€ ëë‚œ í›„, íŒ€ì´ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ì»¨í¼ëŸ°ìŠ¤ ì½œ ì¤‘ì— íŠ¹ì • ë¹„-GAAP ì¬ë¬´ì§€í‘œë“¤ì„ ì–¸ê¸‰í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë¹„-GAAP ì§€í‘œë“¤ê³¼ ê°€ì¥ ì§ì ‘ì ìœ¼ë¡œ ë¹„êµ ê°€ëŠ¥í•œ GAAP ì§€í‘œë“¤ ê°„ì˜ ì¡°ì •ë‚´ì—­ì€ ì €í¬ ì›¹ì‚¬ì´íŠ¸ elevancehealth.comì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì´ë²ˆ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ (forward-looking statements)ì„ í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Elevance Health. These risks and uncertainties may cause actual results to differ materially from our current expectations. We advise listeners to carefully review the risk factors discussed in today's press release and in our quarterly filings with the SEC. I will now turn the call over to Gail. Gail Boudreaux<br>President, CEO & Director<br><br>Good morning, and thank you for joining us today. Affordability remains the central challenge in healthcare.</td><td>ì²­ì·¨ì ì—¬ëŸ¬ë¶„ê»˜ì„œëŠ” ì´ëŸ¬í•œ ì§„ìˆ ë“¤ì´ íŠ¹ì • ë¦¬ìŠ¤í¬ì™€ ë¶ˆí™•ì‹¤ì„±ì— ì˜í–¥ì„ ë°›ì„ ìˆ˜ ìˆìŒì„ ìœ ì˜í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤. ì´ëŸ¬í•œ ë¦¬ìŠ¤í¬ì™€ ë¶ˆí™•ì‹¤ì„±ì˜ ìƒë‹¹ìˆ˜ëŠ” ì˜ˆì¸¡í•˜ê¸° ì–´ë µê³  ì¼ë°˜ì ìœ¼ë¡œ Elevance Healthì˜ í†µì œ ë²”ìœ„ë¥¼ ë²—ì–´ë‚˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë¦¬ìŠ¤í¬ì™€ ë¶ˆí™•ì‹¤ì„±ìœ¼ë¡œ ì¸í•´ ì‹¤ì œ ê²°ê³¼ê°€ í˜„ì¬ì˜ ê¸°ëŒ€ì¹˜ì™€ í¬ê²Œ ë‹¤ë¥¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì²­ì·¨ì ì—¬ëŸ¬ë¶„ê»˜ì„œëŠ” ì˜¤ëŠ˜ ë³´ë„ìë£Œì™€ SECì— ì œì¶œí•œ ë¶„ê¸°ë³„ ë³´ê³ ì„œì—ì„œ ë…¼ì˜ëœ ìœ„í—˜ ìš”ì¸ë“¤ì„ ì£¼ì˜ ê¹Šê²Œ ê²€í† í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤. ì´ì œ Gailì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Gail Boudreaux<br>ì‚¬ì¥, CEO ê²¸ ì´ì‚¬<br><br>ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. ì˜¤ëŠ˜ ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì˜ë£Œë¹„ ë¶€ë‹´ ëŠ¥ë ¥(affordability)ì€ ì—¬ì „íˆ í—¬ìŠ¤ì¼€ì–´ ë¶„ì•¼ì˜ í•µì‹¬ ê³¼ì œë¡œ ë‚¨ì•„ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>At Elevance Health, our focus is on improving outcomes, making care easier to access and navigate and managing costs responsibly. Our commitment to whole person health shapes how we deliver on our strategy by strengthening care coordination, reducing unnecessary complexity and creating a simpler experience for those we serve. Before I go through the business, there are 3 points I want to underscore. First, 2026 is a year of execution and repositioning. And the outlook we provided today reflects prudent, achievable assumptions, grounded in pricing discipline, operational rigor and targeted investments.</td><td>Elevance Healthì—ì„œ ìš°ë¦¬ì˜ ì´ˆì ì€ ì„±ê³¼ ê°œì„ , ì˜ë£Œ ì ‘ê·¼ì„± ë° ì´ìš© í¸ì˜ì„± í–¥ìƒ, ê·¸ë¦¬ê³  ì±…ì„ ìˆëŠ” ë¹„ìš© ê´€ë¦¬ì— ìˆìŠµë‹ˆë‹¤. ì „ì¸ì  ê±´ê°•(whole person health)ì— ëŒ€í•œ ìš°ë¦¬ì˜ í—Œì‹ ì€ ì§„ë£Œ ì¡°ì • ê°•í™”, ë¶ˆí•„ìš”í•œ ë³µì¡ì„± ê°ì†Œ, ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ëŠ” ë¶„ë“¤ì„ ìœ„í•œ ë³´ë‹¤ ê°„í¸í•œ ê²½í—˜ ì°½ì¶œì„ í†µí•´ ì „ëµì„ ì‹¤í–‰í•˜ëŠ” ë°©ì‹ì„ í˜•ì„±í•©ë‹ˆë‹¤. ì‚¬ì—… í˜„í™©ì„ ì„¤ëª…ë“œë¦¬ê¸° ì „ì—, ê°•ì¡°í•˜ê³  ì‹¶ì€ ì„¸ ê°€ì§€ ì‚¬í•­ì´ ìˆìŠµë‹ˆë‹¤. ì²«ì§¸, 2026ë…„ì€ ì‹¤í–‰ê³¼ ì¬í¬ì§€ì…”ë‹ì˜ í•´ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ì œì‹œí•œ ì „ë§ì€ ê°€ê²© ê²°ì • ì›ì¹™(pricing discipline), ìš´ì˜ ì—„ê²©ì„±(operational rigor), ê·¸ë¦¬ê³  ëª©í‘œ ì§€í–¥ì  íˆ¬ìì— ê¸°ë°˜í•œ ì‹ ì¤‘í•˜ê³  ë‹¬ì„± ê°€ëŠ¥í•œ ê°€ì •ë“¤ì„ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Second, even in a dynamic environment, we are acting decisively in the areas within our control to strengthen margins, reduce volatility and improve the consistency of our performance. And third, as those actions take hold, we expect to return to at least 12% adjusted EPS growth in 2027 off our ending 2026 earnings baseline, supported by the earnings power of our diversified platform. Consistent with that approach, we are establishing 2026 adjusted diluted earnings per share guidance of at least $25.50. As you consider the year-over-year comparison, it's important to remember that our 2025 results included approximately $3.75 per share of favorable nonrecurring items.</td><td>ë‘˜ì§¸, ì—­ë™ì ì¸ í™˜ê²½ ì†ì—ì„œë„ ìš°ë¦¬ëŠ” ë§ˆì§„ ê°•í™”, ë³€ë™ì„± ì¶•ì†Œ, ì‹¤ì ì˜ ì¼ê´€ì„± ê°œì„ ì„ ìœ„í•´ ìš°ë¦¬ê°€ í†µì œí•  ìˆ˜ ìˆëŠ” ì˜ì—­ì—ì„œ ë‹¨í˜¸í•˜ê²Œ í–‰ë™í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì…‹ì§¸, ì´ëŸ¬í•œ ì¡°ì¹˜ë“¤ì´ íš¨ê³¼ë¥¼ ë°œíœ˜í•¨ì— ë”°ë¼, ìš°ë¦¬ì˜ ë‹¤ê°í™”ëœ í”Œë«í¼ì˜ ìˆ˜ìµ ì°½ì¶œë ¥ì— í˜ì…ì–´ 2026ë…„ ë§ ì‹¤ì  ê¸°ì¤€ì„ ì„ ë°”íƒ•ìœ¼ë¡œ 2027ë…„ì—ëŠ” ìµœì†Œ 12%ì˜ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ ì„±ì¥ë¥ ë¡œ ë³µê·€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì ‘ê·¼ë²•ì— ë”°ë¼, ìš°ë¦¬ëŠ” 2026ë…„ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ ê°€ì´ë˜ìŠ¤ë¥¼ ìµœì†Œ $25.50ë¡œ ì„¤ì •í•©ë‹ˆë‹¤. ì „ë…„ ëŒ€ë¹„ ë¹„êµë¥¼ ê³ ë ¤í•˜ì‹¤ ë•Œ, 2025ë…„ ì‹¤ì ì—ëŠ” ì•½ ì£¼ë‹¹ $3.75ì˜ ì¼íšŒì„± í˜¸ì¬ í•­ëª©ì´ í¬í•¨ë˜ì–´ ìˆì—ˆë‹¤ëŠ” ì ì„ ê¸°ì–µí•˜ì‹œëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Let me walk through how we are positioning the portfolio. In Medicaid, we continue to see our rates lag elevated acuity and utilization, and we are working urgently with state partners on both rate actions and program design changes that support the long-term sustainability of the Medicaid program. We continue to view 2026 as a trough year. We expect our Medicaid operating margin to be approximately negative 1.75% with improvement over time as rates incorporate more current experience and our actions take hold. We are also preparing for new eligibility and community engagement requirements under recently enacted federal legislation, the One Big Beautiful Bill Act.</td><td>ë‹¤ìŒìœ¼ë¡œ í¬íŠ¸í´ë¦¬ì˜¤ í¬ì§€ì…”ë‹ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œì˜ ê²½ìš°, ìˆ˜ê°€ê°€ ì—¬ì „íˆ ë†’ì•„ì§„ ì¤‘ì¦ë„ì™€ ì´ìš©ë¥ ì— ë¯¸ì¹˜ì§€ ëª»í•˜ê³  ìˆìœ¼ë©°, ì €í¬ëŠ” ë©”ë””ì¼€ì´ë“œ í”„ë¡œê·¸ë¨ì˜ ì¥ê¸°ì  ì§€ì†ê°€ëŠ¥ì„±ì„ ë’·ë°›ì¹¨í•˜ëŠ” ìˆ˜ê°€ ì¡°ì •ê³¼ í”„ë¡œê·¸ë¨ ì„¤ê³„ ë³€ê²½ ëª¨ë‘ì— ëŒ€í•´ ì£¼ì •ë¶€ íŒŒíŠ¸ë„ˆë“¤ê³¼ ê¸´ê¸‰íˆ í˜‘ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” 2026ë…„ì„ ì €ì ì˜ í•´ë¡œ ê³„ì† ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œ ì˜ì—…ì´ìµë¥ ì€ ì•½ ë§ˆì´ë„ˆìŠ¤ 1.75%ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ìˆ˜ê°€ì— ë³´ë‹¤ ìµœê·¼ì˜ ê²½í—˜ì´ ë°˜ì˜ë˜ê³  ì €í¬ì˜ ì¡°ì¹˜ë“¤ì´ íš¨ê³¼ë¥¼ ë°œíœ˜í•¨ì— ë”°ë¼ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ê°œì„ ë  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ë˜í•œ ì €í¬ëŠ” ìµœê·¼ ì œì •ëœ ì—°ë°©ë²•ì¸ 'One Big Beautiful Bill Act'ì— ë”°ë¥¸ ìƒˆë¡œìš´ ìê²©ìš”ê±´ ë° ì§€ì—­ì‚¬íšŒ ì°¸ì—¬ ìš”ê±´ì—ë„ ëŒ€ë¹„í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As these changes are phased in by states, we expect Medicaid membership may decline and the acuity of the population may shift over time, and we have reflected that in our planning assumptions. We believe this is manageable within the context of our diversified enterprise and long-term growth strategy, and we're approaching these changes constructively with state partners with a focus on continuity of care and program stability. Turning to Medicare. Our execution during the annual election period was aligned with our emphasis on delivering greater value for members and strengthening our performance while maintaining stable share in markets that are core to our long-term growth.</td><td>ì´ëŸ¬í•œ ë³€í™”ë“¤ì´ ê° ì£¼ë³„ë¡œ ë‹¨ê³„ì ìœ¼ë¡œ ì‹œí–‰ë¨ì— ë”°ë¼, ë©”ë””ì¼€ì´ë“œ ê°€ì…ì ìˆ˜ê°€ ê°ì†Œí•  ìˆ˜ ìˆê³  ëŒ€ìƒ ì¸êµ¬ì˜ ì¤‘ì¦ë„ê°€ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ë³€í™”í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ë¥¼ ê³„íš ê°€ì •ì— ë°˜ì˜í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ê²ƒì´ ë‹¤ê°í™”ëœ ì‚¬ì—… êµ¬ì¡°ì™€ ì¥ê¸° ì„±ì¥ ì „ëµì˜ ë§¥ë½ì—ì„œ ê´€ë¦¬ ê°€ëŠ¥í•˜ë‹¤ê³  ë¯¿ìœ¼ë©°, ì§„ë£Œì˜ ì—°ì†ì„±ê³¼ í”„ë¡œê·¸ë¨ ì•ˆì •ì„±ì— ì´ˆì ì„ ë§ì¶° ì£¼ì •ë¶€ íŒŒíŠ¸ë„ˆë“¤ê³¼ ê±´ì„¤ì ìœ¼ë¡œ ì´ëŸ¬í•œ ë³€í™”ì— ëŒ€ì‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì–´ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì—°ë¡€ ê°€ì… ê¸°ê°„ ë™ì•ˆ ìš°ë¦¬ì˜ ì‹¤í–‰ì€ íšŒì›ë“¤ì—ê²Œ ë” í° ê°€ì¹˜ë¥¼ ì œê³µí•˜ê³  ìš°ë¦¬ì˜ ì„±ê³¼ë¥¼ ê°•í™”í•˜ëŠ” ë™ì‹œì— ì¥ê¸° ì„±ì¥ì˜ í•µì‹¬ì´ ë˜ëŠ” ì‹œì¥ì—ì„œ ì•ˆì •ì ì¸ ì ìœ ìœ¨ì„ ìœ ì§€í•˜ëŠ” ë° ì¤‘ì ì„ ë‘” ìš°ë¦¬ì˜ ë°©ì¹¨ê³¼ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect Medicare Advantage membership to decline in the high teens percentage range in 2026, reflecting deliberate portfolio actions and stability in our dual eligible membership. The actions we've taken and the composition of our membership should support meaningful margin improvement in 2026. In the individual ACA market, we've repositioned our plans with discipline to reflect higher costs observed this year and the expiration of enhanced subsidies while maintaining value and access for consumers.</td><td>ì €í¬ëŠ” 2026ë…„ ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ ê°€ì…ì ìˆ˜ê°€ 10%ëŒ€ í›„ë°˜ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì˜ë„ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ ì¡°ì •ê³¼ ì´ì¤‘ ìê²© ëŒ€ìƒ ê°€ì…ìì˜ ì•ˆì •ì„±ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì €í¬ê°€ ì·¨í•œ ì¡°ì¹˜ë“¤ê³¼ ê°€ì…ì êµ¬ì„±ì€ 2026ë…„ ì˜ë¯¸ ìˆëŠ” ë§ˆì§„ ê°œì„ ì„ ë’·ë°›ì¹¨í•  ê²ƒì…ë‹ˆë‹¤. ê°œì¸ ACA(ê±´ê°•ë³´í—˜ê°œí˜ë²•) ì‹œì¥ì—ì„œëŠ” ì˜¬í•´ ê´€ì°°ëœ ë†’ì€ ë¹„ìš©ê³¼ ê°•í™”ëœ ë³´ì¡°ê¸ˆ ë§Œë£Œë¥¼ ë°˜ì˜í•˜ì—¬ ê·œìœ¨ ìˆê²Œ ìƒí’ˆì„ ì¬í¸ì„±í–ˆìœ¼ë©°, ë™ì‹œì— ì†Œë¹„ìë“¤ì„ ìœ„í•œ ê°€ì¹˜ì™€ ì ‘ê·¼ì„±ì€ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our Commercial business continues to have healthy momentum, particularly in national accounts, supported by a productive selling season, favorable client retention and new opportunities to expand our reach through the second Blue bid process. We remain disciplined in our pricing and focused on delivering sustainable margins while helping employers address affordability through whole health solutions that integrate a member's medical, pharmacy and behavioral health needs. Our integrated approach continues to resonate in the market, and we are pleased that 40 employers over the past 5 years have selected our Anthem-affiliated plans as their sole carrier.</td><td>ìš°ë¦¬ì˜ ìƒì—… ë³´í—˜ ì‚¬ì—…ì€ ê±´ê°•í•œ ëª¨ë©˜í…€ì„ ì§€ì†í•˜ê³  ìˆìœ¼ë©°, íŠ¹íˆ ì „êµ­ ë‹¨ìœ„ ê³„ì •(national accounts)ì—ì„œ ìƒì‚°ì ì¸ íŒë§¤ ì‹œì¦Œ, ìš°í˜¸ì ì¸ ê³ ê° ìœ ì§€ìœ¨, ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ Blue ì…ì°° í”„ë¡œì„¸ìŠ¤ë¥¼ í†µí•œ ì‹œì¥ í™•ëŒ€ ê¸°íšŒì— í˜ì…ì–´ ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê°€ê²© ì±…ì •ì— ìˆì–´ ê·œìœ¨ì„ ìœ ì§€í•˜ê³  ì§€ì† ê°€ëŠ¥í•œ ë§ˆì§„ì„ ì œê³µí•˜ëŠ” ë° ì§‘ì¤‘í•˜ëŠ” ë™ì‹œì—, íšŒì›ì˜ ì˜ë£Œ, ì•½ì œ, í–‰ë™ ê±´ê°• ë‹ˆì¦ˆë¥¼ í†µí•©í•˜ëŠ” ì „ì¸ ê±´ê°• ì†”ë£¨ì…˜(whole health solutions)ì„ í†µí•´ ê³ ìš©ì£¼ë“¤ì´ ë¹„ìš© ë¶€ë‹´ ë¬¸ì œë¥¼ í•´ê²°í•  ìˆ˜ ìˆë„ë¡ ì§€ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ í†µí•© ì ‘ê·¼ ë°©ì‹ì€ ì‹œì¥ì—ì„œ ì§€ì†ì ìœ¼ë¡œ í˜¸ì‘ì„ ì–»ê³  ìˆìœ¼ë©°, ì§€ë‚œ 5ë…„ê°„ 40ê°œ ê³ ìš©ì£¼ê°€ ìš°ë¦¬ì˜ Anthem ì œíœ´ í”Œëœì„ ë‹¨ë… ë³´í—˜ì‚¬ë¡œ ì„ íƒí–ˆë‹¤ëŠ” ì ì— ëŒ€í•´ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And finally, Carelon is increasingly recognized as a differentiated platform in the market with growing demand for its solutions in managing high-cost, complex areas of healthcare. Near-term growth will be moderated by lower health plan membership, most pronounced in CarelonRx, while Carelon Services is less impacted by membership dynamics, reflecting its broad mix of external relationships and value-based arrangements. As our business mix evolves and we make targeted investments to strengthen the foundation, we are also refining certain long-term margin expectations to reflect a more prudent view of the forward environment. Our long-term enterprise margin target is 5% to 6%.</td><td>ë§ˆì§€ë§‰ìœ¼ë¡œ, Carelonì€ ê³ ë¹„ìš©, ë³µì¡í•œ ì˜ë£Œ ì˜ì—­ ê´€ë¦¬ ì†”ë£¨ì…˜ì— ëŒ€í•œ ìˆ˜ìš” ì¦ê°€ì™€ í•¨ê»˜ ì‹œì¥ì—ì„œ ì°¨ë³„í™”ëœ í”Œë«í¼ìœ¼ë¡œ ì ì  ë” ì¸ì •ë°›ê³  ìˆìŠµë‹ˆë‹¤. ë‹¨ê¸°ì ìœ¼ë¡œëŠ” ê±´ê°•ë³´í—˜ ê°€ì…ì ê°ì†Œë¡œ ì¸í•´ ì„±ì¥ì´ ë‘”í™”ë  ê²ƒì´ë©°, íŠ¹íˆ CarelonRxì—ì„œ ê°€ì¥ ë‘ë“œëŸ¬ì§ˆ ê²ƒì…ë‹ˆë‹¤. ë°˜ë©´ Carelon ServicesëŠ” ê´‘ë²”ìœ„í•œ ì™¸ë¶€ íŒŒíŠ¸ë„ˆì‹­ê³¼ ê°€ì¹˜ ê¸°ë°˜ ê³„ì•½ êµ¬ì¡°ë¥¼ ë°˜ì˜í•˜ì—¬ ê°€ì…ì ë³€ë™ì˜ ì˜í–¥ì„ ëœ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ì‚¬ì—… êµ¬ì„±ì´ ì§„í™”í•˜ê³  ê¸°ë°˜ ê°•í™”ë¥¼ ìœ„í•œ ì „ëµì  íˆ¬ìë¥¼ ì§„í–‰í•¨ì— ë”°ë¼, í–¥í›„ í™˜ê²½ì— ëŒ€í•œ ë³´ë‹¤ ì‹ ì¤‘í•œ ê´€ì ì„ ë°˜ì˜í•˜ì—¬ íŠ¹ì • ì¥ê¸° ë§ˆì§„ ì „ë§ì„ ì¡°ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ì¥ê¸° ì „ì‚¬ ë§ˆì§„ ëª©í‘œëŠ” 5%ì—ì„œ 6%ì…ë‹ˆë‹¤.</td></tr>
<tr><td>For Health Benefits, Carelon and CarelonRx, we are targeting mid-single-digit margins with our Carelon Services target unchanged. These updates are intended to provide a clearer, more durable framework for evaluating performance, and they do not change our focus on disciplined execution, durable earnings growth and strong cash generation. Stepping back, we view 2026 as a year of execution and repositioning. Across Medicaid, Medicare Advantage and ACA, the dynamics we've described reflect a combination of policy-driven changes and deliberate portfolio and pricing actions designed to strengthen performance consistency.</td><td>ê±´ê°•ë³´í—˜ ë¶€ë¬¸(Health Benefits), ì¼€ì–´ë¡ (Carelon), ê·¸ë¦¬ê³  ì¼€ì–´ë¡ Rx(CarelonRx)ì˜ ê²½ìš°, ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ë§ˆì§„ìœ¨ì„ ëª©í‘œë¡œ í•˜ê³  ìˆìœ¼ë©°, ì¼€ì–´ë¡  ì„œë¹„ìŠ¤(Carelon Services)ì˜ ëª©í‘œëŠ” ë³€ë™ì´ ì—†ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì—…ë°ì´íŠ¸ëŠ” ì‹¤ì  í‰ê°€ë¥¼ ìœ„í•œ ë³´ë‹¤ ëª…í™•í•˜ê³  ì§€ì† ê°€ëŠ¥í•œ í”„ë ˆì„ì›Œí¬ë¥¼ ì œê³µí•˜ê¸° ìœ„í•œ ê²ƒì´ë©°, ê·œìœ¨ ìˆëŠ” ì‹¤í–‰, ì§€ì† ê°€ëŠ¥í•œ ìˆ˜ìµ ì„±ì¥, ê·¸ë¦¬ê³  ê°•ë ¥í•œ í˜„ê¸ˆ ì°½ì¶œì— ëŒ€í•œ ìš°ë¦¬ì˜ ì§‘ì¤‘ì€ ë³€í•¨ì´ ì—†ìŠµë‹ˆë‹¤. í•œ ê±¸ìŒ ë¬¼ëŸ¬ì„œì„œ ë³´ë©´, 2026ë…„ì€ ì‹¤í–‰ê³¼ ì¬í¬ì§€ì…”ë‹ì˜ í•´ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œ(Medicaid), ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€(Medicare Advantage), ê·¸ë¦¬ê³  ACA(ì˜ë£Œë³´í—˜ê°œí˜ë²•) ì „ë°˜ì— ê±¸ì³, ìš°ë¦¬ê°€ ì„¤ëª…í•œ ì—­í•™ê´€ê³„ëŠ” ì •ì±… ì£¼ë„ ë³€í™”ì™€ ì‹¤ì  ì¼ê´€ì„±ì„ ê°•í™”í•˜ê¸° ìœ„í•´ ì„¤ê³„ëœ ì˜ë„ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ ë° ê°€ê²© ì¡°ì¹˜ì˜ ì¡°í•©ì„ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And we are aligning our cost structure and operating priorities accordingly. That's why we believe we have a clear line of sight to improve performance as we move through this year and into 2027. Now let me turn to the actions we have underway. We are strengthening our ability to anticipate emerging utilization trends and improve care coordination by leveraging actionable data and advanced analytics. These capabilities help us identify trends earlier and address inefficiencies in the system while supporting timely access to appropriate high-quality care.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì´ì— ë”°ë¼ ë¹„ìš© êµ¬ì¡°ì™€ ìš´ì˜ ìš°ì„ ìˆœìœ„ë¥¼ ì¡°ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ì˜¬í•´ë¥¼ ê±°ì³ 2027ë…„ìœ¼ë¡œ ë‚˜ì•„ê°€ë©´ì„œ ì‹¤ì ì„ ê°œì„ í•  ìˆ˜ ìˆë‹¤ëŠ” ëª…í™•í•œ ì „ë§ì„ ê°€ì§€ê³  ìˆë‹¤ê³  ë¯¿ëŠ” ì´ìœ ì…ë‹ˆë‹¤. ì´ì œ ìš°ë¦¬ê°€ ì§„í–‰ ì¤‘ì¸ ì¡°ì¹˜ë“¤ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‹¤í–‰ ê°€ëŠ¥í•œ ë°ì´í„°ì™€ ê³ ê¸‰ ë¶„ì„ì„ í™œìš©í•˜ì—¬ ìƒˆë¡­ê²Œ ë‚˜íƒ€ë‚˜ëŠ” ì´ìš©ë¥  ì¶”ì„¸ë¥¼ ì˜ˆì¸¡í•˜ê³  ì§„ë£Œ ì¡°ì •ì„ ê°œì„ í•˜ëŠ” ëŠ¥ë ¥ì„ ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­ëŸ‰ì€ ìš°ë¦¬ê°€ ì¶”ì„¸ë¥¼ ì¡°ê¸°ì— íŒŒì•…í•˜ê³  ì‹œìŠ¤í…œì˜ ë¹„íš¨ìœ¨ì„±ì„ í•´ê²°í•˜ëŠ” ë™ì‹œì— ì ì ˆí•œ ê³ í’ˆì§ˆ ì§„ë£Œì— ëŒ€í•œ ì ì‹œ ì ‘ê·¼ì„ ì§€ì›í•˜ëŠ” ë° ë„ì›€ì´ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>In Medicaid, we're strengthening our analytics to identify outlier utilization and billing patterns in high-cost substance use disorder treatment settings while maintaining access to clinically appropriate care. These insights are enabling targeted actions, including provider education, claims review enhancements and payment accuracy and compliance initiatives where appropriate, consistent with program requirements and clinical guidelines. We're able to execute with confidence because we've built and are scaling capabilities that improve outcomes and reduce costs in complex areas of healthcare.</td><td>ë©”ë””ì¼€ì´ë“œì—ì„œëŠ” ê³ ë¹„ìš© ì•½ë¬¼ ì‚¬ìš© ì¥ì•  ì¹˜ë£Œ í™˜ê²½ì—ì„œ ì´ìƒ í™œìš© ë° ì²­êµ¬ íŒ¨í„´ì„ ì‹ë³„í•˜ê¸° ìœ„í•´ ë¶„ì„ ì—­ëŸ‰ì„ ê°•í™”í•˜ê³  ìˆìœ¼ë©°, ë™ì‹œì— ì„ìƒì ìœ¼ë¡œ ì ì ˆí•œ ì¹˜ë£Œì— ëŒ€í•œ ì ‘ê·¼ì„±ì€ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¸ì‚¬ì´íŠ¸ë¥¼ í†µí•´ í”„ë¡œê·¸ë¨ ìš”êµ¬ì‚¬í•­ ë° ì„ìƒ ê°€ì´ë“œë¼ì¸ì— ë¶€í•©í•˜ëŠ” ê³µê¸‰ì êµìœ¡, ì²­êµ¬ ê²€í†  ê°œì„ , ê·¸ë¦¬ê³  ì ì ˆí•œ ê²½ìš° ì§€ê¸‰ ì •í™•ì„± ë° ì»´í”Œë¼ì´ì–¸ìŠ¤ ì´ë‹ˆì…”í‹°ë¸Œë¥¼ í¬í•¨í•œ í‘œì í™”ëœ ì¡°ì¹˜ë¥¼ ì‹¤í–‰í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ìì‹ ê°ì„ ê°€ì§€ê³  ì‹¤í–‰í•  ìˆ˜ ìˆëŠ” ì´ìœ ëŠ” ì˜ë£Œì˜ ë³µì¡í•œ ì˜ì—­ì—ì„œ ì„±ê³¼ë¥¼ ê°œì„ í•˜ê³  ë¹„ìš©ì„ ì ˆê°í•˜ëŠ” ì—­ëŸ‰ì„ êµ¬ì¶•í•˜ê³  í™•ì¥í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>In 2026, we will further strengthen specialty pharmacy management, advance behavioral health support and expand care management programs for members with elevated care needs. Established programs in oncology and serious mental illness are delivering savings for our health plans in the face of heightened utilization trend. Our patient advocacy programs now serve over 7 million members, up nearly 20% from last year. Through proactive tailored support, we help members navigate the system with greater confidence, remove points of friction and close gaps in care, especially for individuals with greater care needs where early engagement can materially improve outcomes and reduce downstream costs.</td><td>2026ë…„ì—ëŠ” ì „ë¬¸ì•½êµ­ ê´€ë¦¬ë¥¼ ë”ìš± ê°•í™”í•˜ê³ , í–‰ë™ê±´ê°• ì§€ì›ì„ í™•ëŒ€í•˜ë©°, ê³ ë„ì˜ ì¼€ì–´ê°€ í•„ìš”í•œ íšŒì›ë“¤ì„ ìœ„í•œ ì¼€ì–´ ê´€ë¦¬ í”„ë¡œê·¸ë¨ì„ í™•ì¥í•  ê²ƒì…ë‹ˆë‹¤. ì¢…ì–‘í•™ ë° ì¤‘ì¦ ì •ì‹ ì§ˆí™˜ ë¶„ì•¼ì˜ ê¸°ì¡´ í”„ë¡œê·¸ë¨ë“¤ì€ ë†’ì•„ì§„ ì´ìš©ë¥  ì¶”ì„¸ì—ë„ ë¶ˆêµ¬í•˜ê³  ìš°ë¦¬ ê±´ê°•ë³´í—˜ í”Œëœì— ë¹„ìš© ì ˆê° íš¨ê³¼ë¥¼ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ í™˜ì ì˜¹í˜¸ í”„ë¡œê·¸ë¨ì€ í˜„ì¬ 700ë§Œ ëª… ì´ìƒì˜ íšŒì›ì—ê²Œ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì‘ë…„ ëŒ€ë¹„ ê±°ì˜ 20% ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì„ ì œì ì´ê³  ë§ì¶¤í™”ëœ ì§€ì›ì„ í†µí•´, ìš°ë¦¬ëŠ” íšŒì›ë“¤ì´ ë” í° í™•ì‹ ì„ ê°€ì§€ê³  ì‹œìŠ¤í…œì„ ì´ìš©í•  ìˆ˜ ìˆë„ë¡ ë•ê³ , ë§ˆì°° ì§€ì ì„ ì œê±°í•˜ë©°, íŠ¹íˆ ì¡°ê¸° ê°œì…ì´ ê²°ê³¼ë¥¼ ì‹¤ì§ˆì ìœ¼ë¡œ ê°œì„ í•˜ê³  í›„ì† ë¹„ìš©ì„ ì ˆê°í•  ìˆ˜ ìˆëŠ” ê³ ë„ì˜ ì¼€ì–´ê°€ í•„ìš”í•œ ê°œì¸ë“¤ì˜ ì¼€ì–´ ê³µë°±ì„ ë©”ìš°ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And we remain deeply committed to improving the experience of care providers. We remain on track to exceed our commitment that 80% of prior authorization decisions will be made in real time in 2027, particularly for routine approved services, supporting faster access to care and reducing administrative burden for care providers. Through our HealthOS platform, we're enabling real-time data exchange that aligns information across the system, streamlines interactions with care providers and makes it easier to deliver care. In summary, while the environment we operate in continues to evolve, our strategic direction remains clear.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì˜ë£Œ ì œê³µìë“¤ì˜ ê²½í—˜ì„ ê°œì„ í•˜ëŠ” ë° ê¹Šì´ ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2027ë…„ê¹Œì§€ ì‚¬ì „ìŠ¹ì¸ ê²°ì •ì˜ 80%ë¥¼ ì‹¤ì‹œê°„ìœ¼ë¡œ ì²˜ë¦¬í•˜ê² ë‹¤ëŠ” ì•½ì†ì„ ì´ˆê³¼ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ê¶¤ë„ì— ìˆìœ¼ë©°, íŠ¹íˆ ì¼ìƒì ìœ¼ë¡œ ìŠ¹ì¸ë˜ëŠ” ì„œë¹„ìŠ¤ì˜ ê²½ìš° ë”ìš± ê·¸ëŸ¬í•©ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ë” ë¹ ë¥¸ ì˜ë£Œ ì ‘ê·¼ì„±ì„ ì§€ì›í•˜ê³  ì˜ë£Œ ì œê³µìë“¤ì˜ í–‰ì • ë¶€ë‹´ì„ ì¤„ì´ê³  ìˆìŠµë‹ˆë‹¤. HealthOS í”Œë«í¼ì„ í†µí•´ ìš°ë¦¬ëŠ” ì‹œìŠ¤í…œ ì „ë°˜ì— ê±¸ì³ ì •ë³´ë¥¼ ì •ë ¬í•˜ê³ , ì˜ë£Œ ì œê³µìë“¤ê³¼ì˜ ìƒí˜¸ì‘ìš©ì„ ê°„ì†Œí™”í•˜ë©°, ì˜ë£Œ ì„œë¹„ìŠ¤ ì œê³µì„ ë”ìš± ìš©ì´í•˜ê²Œ í•˜ëŠ” ì‹¤ì‹œê°„ ë°ì´í„° êµí™˜ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš”ì•½í•˜ìë©´, ìš°ë¦¬ê°€ ì˜ì—…í•˜ëŠ” í™˜ê²½ì´ ê³„ì† ì§„í™”í•˜ê³  ìˆì§€ë§Œ, ìš°ë¦¬ì˜ ì „ëµì  ë°©í–¥ì€ ëª…í™•í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We are entering 2026 with prudent planning assumptions, focused execution and targeted investments to unlock the embedded earnings power of our diversified platform. And based on the actions underway this year, we remain confident in our long-term algorithm and our expectation to return to at least 12% adjusted EPS growth in 2027. Before closing, I want to thank our associates for their unwavering commitment to our purpose throughout 2025. In the face of a challenging year for our industry, our teams operated with integrity, compassion and a deep sense of responsibility to the people and communities we serve.</td><td>ìš°ë¦¬ëŠ” ì‹ ì¤‘í•œ ê³„íš ê°€ì •, ì§‘ì¤‘ëœ ì‹¤í–‰, ê·¸ë¦¬ê³  ë‹¤ê°í™”ëœ í”Œë«í¼ì˜ ë‚´ì¬ëœ ìˆ˜ìµ ì°½ì¶œë ¥ì„ ì‹¤í˜„í•˜ê¸° ìœ„í•œ ëª©í‘œ ì§€í–¥ì  íˆ¬ìë¥¼ ë°”íƒ•ìœ¼ë¡œ 2026ë…„ì„ ë§ì´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¬í•´ ì§„í–‰ ì¤‘ì¸ ì¡°ì¹˜ë“¤ì„ ê¸°ë°˜ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ì¥ê¸° ì•Œê³ ë¦¬ì¦˜ê³¼ 2027ë…„ì— ìµœì†Œ 12%ì˜ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ ì„±ì¥ë¥ ë¡œ ë³µê·€í•  ê²ƒì´ë¼ëŠ” ê¸°ëŒ€ì— ëŒ€í•´ í™•ì‹ ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆë¬´ë¦¬í•˜ê¸° ì „ì—, 2025ë…„ ë‚´ë‚´ ìš°ë¦¬ì˜ ëª©ì ì— ëŒ€í•œ ë³€í•¨ì—†ëŠ” í—Œì‹ ì„ ë³´ì—¬ì¤€ ì„ì§ì›ë“¤ì—ê²Œ ê°ì‚¬ì˜ ë§ì”€ì„ ì „í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ìš°ë¦¬ ì—…ê³„ì— ì–´ë ¤ìš´ í•œ í•´ì˜€ìŒì—ë„ ë¶ˆêµ¬í•˜ê³ , ìš°ë¦¬ íŒ€ì€ ìš°ë¦¬ê°€ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ëŠ” ì‚¬ëŒë“¤ê³¼ ì§€ì—­ì‚¬íšŒì— ëŒ€í•œ ì„±ì‹¤í•¨, ì—°ë¯¼, ê·¸ë¦¬ê³  ê¹Šì€ ì±…ì„ê°ì„ ê°€ì§€ê³  ì—…ë¬´ë¥¼ ìˆ˜í–‰í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Their dedication is the foundation of our performance today and the progress we are building for the future, and I am deeply grateful for the impact they continue to make across Elevance Health. With that, I'll turn the call over to Mark for a more detailed review of our financial results and outlook. Mark Kaye<br>Executive VP & CFO<br><br>Thank you, Gail, and good morning. Elevance Health reported adjusted diluted earnings per share of $3.33 for the fourth quarter and $30.29 for the full year. Relative to our guidance, fourth quarter results benefited from greater tax favorability than anticipated, increasing the full year contribution from nonrecurring items to $3.75 per share.</td><td>ê·¸ë“¤ì˜ í—Œì‹ ì€ ì˜¤ëŠ˜ë‚  ìš°ë¦¬ ì‹¤ì ì˜ ê¸°ë°˜ì´ì ë¯¸ë˜ë¥¼ ìœ„í•´ êµ¬ì¶•í•˜ê³  ìˆëŠ” ë°œì „ì˜ í† ëŒ€ì´ë©°, ì €ëŠ” ê·¸ë“¤ì´ Elevance Health ì „ë°˜ì— ê±¸ì³ ê³„ì†í•´ì„œ ë§Œë“¤ì–´ë‚´ëŠ” ì˜í–¥ë ¥ì— ê¹Šì´ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Markì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê²¨ ì¬ë¬´ ì‹¤ì ê³¼ ì „ë§ì— ëŒ€í•œ ë³´ë‹¤ ìƒì„¸í•œ ê²€í† ë¥¼ ì§„í–‰í•˜ê² ìŠµë‹ˆë‹¤.<br><br>Mark Kaye<br>ë¶€ì‚¬ì¥ ê²¸ ìµœê³ ì¬ë¬´ì±…ì„ì(CFO)<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Gail. ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. Elevance HealthëŠ” 4ë¶„ê¸° ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ 3.33ë‹¬ëŸ¬, ì—°ê°„ 30.29ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ê°€ì´ë˜ìŠ¤ ëŒ€ë¹„ 4ë¶„ê¸° ì‹¤ì ì€ ì˜ˆìƒë³´ë‹¤ í° ì„¸ê¸ˆ í˜œíƒì˜ ì˜í–¥ì„ ë°›ì•˜ìœ¼ë©°, ì´ë¡œ ì¸í•´ ë¹„ê²½ìƒ í•­ëª©ì˜ ì—°ê°„ ê¸°ì—¬ë„ê°€ ì£¼ë‹¹ 3.75ë‹¬ëŸ¬ë¡œ ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Solid underlying performance in the quarter enabled us to advance a portion of the investments we had planned for 2026 and to support our workforce as we enter the year. Throughout 2025, we remain focused on aligning pricing to elevated cost trends, refining our product portfolio and investing selectively in capabilities that differentiate our model and support sustainable growth. We ended the year with 45.2 million members, a decrease of approximately 500,000 year-over-year, principally reflecting a decline in Medicaid membership due to continued eligibility reverifications.</td><td>ë¶„ê¸° ì¤‘ ê²¬ê³ í•œ ê¸°ì € ì‹¤ì  ë•ë¶„ì— 2026ë…„ì— ê³„íší–ˆë˜ íˆ¬ìì˜ ì¼ë¶€ë¥¼ ì•ë‹¹ê¸°ê³ , ì—°ì´ˆì— ìš°ë¦¬ ì¸ë ¥ì„ ì§€ì›í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. 2025ë…„ ë‚´ë‚´ ìš°ë¦¬ëŠ” ìƒìŠ¹í•œ ë¹„ìš© ì¶”ì„¸ì— ë§ì¶° ê°€ê²©ì„ ì¡°ì •í•˜ê³ , ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì •êµí™”í•˜ë©°, ìš°ë¦¬ ëª¨ë¸ì„ ì°¨ë³„í™”í•˜ê³  ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ì„ ë’·ë°›ì¹¨í•˜ëŠ” ì—­ëŸ‰ì— ì„ ë³„ì ìœ¼ë¡œ íˆ¬ìí•˜ëŠ” ë° ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—°ë§ ê¸°ì¤€ ê°€ì…ì ìˆ˜ëŠ” 4,520ë§Œ ëª…ìœ¼ë¡œ, ì „ë…„ ëŒ€ë¹„ ì•½ 50ë§Œ ëª… ê°ì†Œí–ˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ ì§€ì†ì ì¸ ìê²© ì¬ê²€ì¦ìœ¼ë¡œ ì¸í•œ ë©”ë””ì¼€ì´ë“œ ê°€ì…ì ê°ì†Œë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operating revenue for the quarter totaled $49.3 billion, an increase of 10% from the prior year, driven by premium rate adjustments in recognition of higher cost trends and acquisitions completed in the past year. Our consolidated benefit expense ratio was 93.5% for the quarter and 90% for the full year, in line with our guidance. Cost trend development was consistent with our expectations across major lines of business. Our adjusted operating expense ratio was 10.8% for the fourth quarter and 10.5% for the full year. We are managing the enterprise with discipline while making targeted investments to support our long-term performance.</td><td>ì´ë²ˆ ë¶„ê¸° ì˜ì—…ìˆ˜ìµì€ 493ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 10% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë†’ì•„ì§„ ë¹„ìš© ì¶”ì„¸ë¥¼ ë°˜ì˜í•œ ë³´í—˜ë£Œìœ¨ ì¡°ì •ê³¼ ì§€ë‚œ 1ë…„ê°„ ì™„ë£Œëœ ì¸ìˆ˜í•©ë³‘ì— ê¸°ì¸í•©ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ì—°ê²° ê¸‰ë¶€ë¹„ìš©ë¥ (benefit expense ratio)ì€ ì´ë²ˆ ë¶„ê¸° 93.5%, ì—°ê°„ 90%ë¡œ ê°€ì´ë˜ìŠ¤ì— ë¶€í•©í–ˆìŠµë‹ˆë‹¤. ë¹„ìš© ì¶”ì„¸ ì „ê°œëŠ” ì£¼ìš” ì‚¬ì—…ë¶€ë¬¸ ì „ë°˜ì— ê±¸ì³ ë‹¹ì‚¬ì˜ ì˜ˆìƒê³¼ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤. ì¡°ì • ì˜ì—…ë¹„ìš©ë¥ (adjusted operating expense ratio)ì€ 4ë¶„ê¸° 10.8%, ì—°ê°„ 10.5%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ì¥ê¸° ì„±ê³¼ë¥¼ ë’·ë°›ì¹¨í•˜ê¸° ìœ„í•œ ì „ëµì  íˆ¬ìë¥¼ ì§„í–‰í•˜ëŠ” ë™ì‹œì— ê·œìœ¨ ìˆëŠ” ê²½ì˜ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>During the quarter, we pulled forward 1/4 of the approximately $1 per share of incremental investments that we had anticipated in 2026. Our Medicaid operating margin ended the year slightly favorable to the outlook provided last quarter. We are encouraged by the initial results of our targeted efforts to better coordinate care and support high-quality, low-cost treatment pathways. While the benefit of these actions will build over the course of the year, we continue to expect cost trend to be in the mid-single-digit percent range in 2026 with rates lagging this level of trend.</td><td>ë¶„ê¸° ì¤‘ ë‹¹ì‚¬ëŠ” 2026ë…„ì— ì˜ˆìƒí–ˆë˜ ì£¼ë‹¹ ì•½ 1ë‹¬ëŸ¬ì˜ ì¶”ê°€ íˆ¬ì ì¤‘ 1/4ì„ ì•ë‹¹ê²¨ ì§‘í–‰í–ˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œ ì˜ì—…ì´ìµë¥ ì€ ì§€ë‚œ ë¶„ê¸°ì— ì œì‹œí•œ ì „ë§ ëŒ€ë¹„ ì†Œí­ ì–‘í˜¸í•œ ìˆ˜ì¤€ìœ¼ë¡œ ì—°ë„ë¥¼ ë§ˆê°í–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ê³ í’ˆì§ˆì˜ ì €ë¹„ìš© ì¹˜ë£Œ ê²½ë¡œë¥¼ ë” íš¨ê³¼ì ìœ¼ë¡œ ì¡°ì •í•˜ê³  ì§€ì›í•˜ê¸° ìœ„í•œ ëª©í‘œ ì§€í–¥ì  ë…¸ë ¥ì˜ ì´ˆê¸° ì„±ê³¼ì— ê³ ë¬´ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¡°ì¹˜ë“¤ì˜ íš¨ê³¼ëŠ” ì—°ì¤‘ ì ì§„ì ìœ¼ë¡œ í™•ëŒ€ë  ê²ƒì´ì§€ë§Œ, ë‹¹ì‚¬ëŠ” 2026ë…„ ë¹„ìš© ì¶”ì„¸ê°€ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ í¼ì„¼íŠ¸ ë²”ìœ„ì— ìˆì„ ê²ƒìœ¼ë¡œ ê³„ì† ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ìˆ˜ê°€ëŠ” ì´ëŸ¬í•œ ì¶”ì„¸ ìˆ˜ì¤€ì— ë¯¸ì¹˜ì§€ ëª»í•  ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As such, we anticipate our Medicaid operating margin for 2026 to be approximately minus 1.75%, in line with what we shared last quarter. Medicare cost trend in the quarter was consistent with our expectations. For 2026, we made deliberate changes to our plan offerings and intentionally exited select geographies, prioritizing plans that deliver value to members while producing sustainable financial performance. As you heard from Gail, we now expect Medicare Advantage membership to decline in the high teens percentage range in 2026 while achieving meaningful margin improvement.</td><td>ì´ì— ë”°ë¼ 2026ë…„ ë©”ë””ì¼€ì´ë“œ ì˜ì—…ì´ìµë¥ ì€ ì§€ë‚œ ë¶„ê¸°ì— ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ì•½ ë§ˆì´ë„ˆìŠ¤ 1.75%ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ë©”ë””ì¼€ì–´ ë¹„ìš© ì¶”ì„¸ëŠ” ì €í¬ ì˜ˆìƒê³¼ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤. 2026ë…„ì„ ìœ„í•´ ì €í¬ëŠ” í”Œëœ ìƒí’ˆ êµ¬ì„±ì— ì˜ë„ì ì¸ ë³€í™”ë¥¼ ì£¼ì—ˆìœ¼ë©°, ì§€ì† ê°€ëŠ¥í•œ ì¬ë¬´ ì„±ê³¼ë¥¼ ì°½ì¶œí•˜ë©´ì„œ íšŒì›ë“¤ì—ê²Œ ê°€ì¹˜ë¥¼ ì œê³µí•˜ëŠ” í”Œëœì„ ìš°ì„ ì‹œí•˜ì—¬ ì¼ë¶€ ì§€ì—­ì—ì„œ ì „ëµì ìœ¼ë¡œ ì² ìˆ˜í–ˆìŠµë‹ˆë‹¤. Gailì´ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì´ì œ ì €í¬ëŠ” 2026ë…„ ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ íšŒì› ìˆ˜ê°€ 10%ëŒ€ í›„ë°˜ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ë™ì‹œì— ì˜ë¯¸ ìˆëŠ” ë§ˆì§„ ê°œì„ ì„ ë‹¬ì„±í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We have also repositioned our individual ACA business for higher expected morbidity following the expiration of enhanced subsidies. Similarly, our Commercial Group risk membership reflects our focus on margin stability and disciplined pricing. Carelon continues to experience strong customer demand for its solutions. However, near-term growth will be moderated by lower health plan membership. The guidance provided today reflects the impact of our anticipated membership headwinds as well as investments we plan to make as we scale our dispensing and home health assets. Operating cash flow was $4.3 billion for the year or approximately 0.8x GAAP net income.</td><td>ë˜í•œ ìš°ë¦¬ëŠ” ê°•í™”ëœ ë³´ì¡°ê¸ˆ ë§Œë£Œ ì´í›„ ë” ë†’ì€ ìœ ë³‘ë¥ (morbidity)ì„ ì˜ˆìƒí•˜ì—¬ ê°œì¸ ACA(Affordable Care Act) ì‚¬ì—…ì„ ì¬í¸í–ˆìŠµë‹ˆë‹¤. ë§ˆì°¬ê°€ì§€ë¡œ, ìš°ë¦¬ì˜ ìƒì—…ìš© ê·¸ë£¹ ë¦¬ìŠ¤í¬ ê°€ì…ì ìˆ˜ëŠ” ë§ˆì§„ ì•ˆì •ì„±ê³¼ ì—„ê²©í•œ ê°€ê²© ì±…ì •ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì§‘ì¤‘ì„ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. Carelonì€ ì†”ë£¨ì…˜ì— ëŒ€í•œ ê°•ë ¥í•œ ê³ ê° ìˆ˜ìš”ë¥¼ ì§€ì†ì ìœ¼ë¡œ ê²½í—˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ë‹¨ê¸° ì„±ì¥ì€ ê±´ê°•ë³´í—˜ ê°€ì…ì ìˆ˜ ê°ì†Œë¡œ ì¸í•´ ì™„í™”ë  ê²ƒì…ë‹ˆë‹¤. ì˜¤ëŠ˜ ì œê³µëœ ê°€ì´ë˜ìŠ¤ëŠ” ì˜ˆìƒë˜ëŠ” ê°€ì…ì ìˆ˜ ì—­í’ì˜ ì˜í–¥ê³¼ ì¡°ì œ ë° ì¬íƒ ê±´ê°• ìì‚°ì„ í™•ì¥í•˜ë©´ì„œ ê³„íší•˜ê³  ìˆëŠ” íˆ¬ìë¥¼ ë°˜ì˜í•©ë‹ˆë‹¤. ì—°ê°„ ì˜ì—…í˜„ê¸ˆíë¦„ì€ 43ì–µ ë‹¬ëŸ¬ë¡œ GAAP ìˆœì´ìµì˜ ì•½ 0.8ë°° ìˆ˜ì¤€ì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Cash flow in December was negatively impacted by the timing of certain Medicaid-related payments, which were subsequently received in early January. Incorporating these items, we expect our 2026 operating cash flow to be at least $5.5 billion. Days in claims payable was 41.3 days, a decrease of 0.1 days sequentially. For 2026, we expect days in claims payable to remain in the low 40s range, consistent with our long-term target. In the fourth quarter, we repurchased 1.4 million shares for $470 million, bringing full year repurchases to $2.6 billion. Combined with dividends paid during the year, we returned $4.1 billion of capital to shareholders. Turning to our outlook.</td><td>12ì›” í˜„ê¸ˆíë¦„ì€ íŠ¹ì • ë©”ë””ì¼€ì´ë“œ ê´€ë ¨ ì§€ê¸‰ê¸ˆì˜ ì‹œê¸° ë¬¸ì œë¡œ ë¶€ì •ì ì¸ ì˜í–¥ì„ ë°›ì•˜ìœ¼ë©°, ì´ëŠ” 1ì›” ì´ˆì— í›„ì† ìˆ˜ë ¹ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í•­ëª©ë“¤ì„ ë°˜ì˜í•˜ì—¬, ë‹¹ì‚¬ëŠ” 2026ë…„ ì˜ì—…í˜„ê¸ˆíë¦„ì´ ìµœì†Œ 55ì–µ ë‹¬ëŸ¬ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë¯¸ì§€ê¸‰ë³´í—˜ê¸ˆ ì¼ìˆ˜ëŠ” 41.3ì¼ë¡œ ì „ë¶„ê¸° ëŒ€ë¹„ 0.1ì¼ ê°ì†Œí–ˆìŠµë‹ˆë‹¤. 2026ë…„ì—ëŠ” ë¯¸ì§€ê¸‰ë³´í—˜ê¸ˆ ì¼ìˆ˜ê°€ ë‹¹ì‚¬ì˜ ì¥ê¸° ëª©í‘œì™€ ì¼ì¹˜í•˜ëŠ” 40ì¼ëŒ€ ì´ˆë°˜ ë²”ìœ„ë¥¼ ìœ ì§€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. 4ë¶„ê¸°ì— ë‹¹ì‚¬ëŠ” 140ë§Œ ì£¼ë¥¼ 4ì–µ 7ì²œë§Œ ë‹¬ëŸ¬ì— ìì‚¬ì£¼ ë§¤ì…í–ˆìœ¼ë©°, ì—°ê°„ ìì‚¬ì£¼ ë§¤ì… ì´ì•¡ì€ 26ì–µ ë‹¬ëŸ¬ì— ë‹¬í–ˆìŠµë‹ˆë‹¤. ì—°ì¤‘ ì§€ê¸‰ëœ ë°°ë‹¹ê¸ˆê³¼ í•©ì‚°í•˜ì—¬, ë‹¹ì‚¬ëŠ” ì£¼ì£¼ë“¤ì—ê²Œ ì´ 41ì–µ ë‹¬ëŸ¬ì˜ ìë³¸ì„ í™˜ì›í–ˆìŠµë‹ˆë‹¤. ì´ì œ ì „ë§ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We are establishing guidance for adjusted diluted earnings per share to be at least $25.50 in 2026. We anticipate operating revenue to decline in the low single-digit percent range in 2026, driven by a low double-digit percentage decline in risk-based membership, partly offset by higher premium yields and growth in Carelon. Our consolidated medical loss ratio is expected to be 90.2%, plus or minus 50 basis points, reflecting a prudent view of cost trend and shifting acuity in Medicaid.</td><td>2026ë…„ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ(adjusted diluted EPS) ê°€ì´ë˜ìŠ¤ë¥¼ ìµœì†Œ 25.50ë‹¬ëŸ¬ë¡œ ì„¤ì •í•©ë‹ˆë‹¤. 2026ë…„ ì˜ì—…ìˆ˜ìµì€ ì €ë‹¨ìœ„ í•œìë¦¿ìˆ˜ í¼ì„¼íŠ¸ ë²”ìœ„ì˜ ê°ì†Œê°€ ì˜ˆìƒë˜ëŠ”ë°, ì´ëŠ” ìœ„í—˜ê¸°ë°˜ íšŒì›ìˆ˜(risk-based membership)ì˜ ì €ë‹¨ìœ„ ë‘ìë¦¿ìˆ˜ í¼ì„¼íŠ¸ ê°ì†Œì— ê¸°ì¸í•˜ë©°, ë†’ì€ ë³´í—˜ë£Œ ìˆ˜ìµë¥ (premium yields)ê³¼ Carelonì˜ ì„±ì¥ìœ¼ë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë  ê²ƒì…ë‹ˆë‹¤. ì—°ê²° ì˜ë£Œì†ì‹¤ë¥ (consolidated medical loss ratio)ì€ 90.2%ì— í”ŒëŸ¬ìŠ¤ ë§ˆì´ë„ˆìŠ¤ 50bpë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” ì˜ë£Œë¹„ ì¶”ì„¸(cost trend)ì™€ ë©”ë””ì¼€ì´ë“œ(Medicaid)ì˜ ì¤‘ì¦ë„ ë³€í™”(shifting acuity)ì— ëŒ€í•œ ì‹ ì¤‘í•œ ê´€ì ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our adjusted operating expense ratio is expected to be 10.6%, plus or minus 50 basis points as we maintain operational discipline while investing to scale Carelon, embed AI-enabled and digital capabilities and simplify the member experience. Our capital deployment plans remain aligned to our long-term framework, and we plan to allocate approximately $2.3 billion towards share repurchases in 2026. Regarding earnings seasonality, we expect to earn approximately 2/3 of our adjusted EPS in the first half of 2026 with 65% of that coming in the first quarter.</td><td>ì¡°ì • ì˜ì—…ë¹„ìš© ë¹„ìœ¨ì€ 10.6%, í”ŒëŸ¬ìŠ¤ ë§ˆì´ë„ˆìŠ¤ 50bpë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ëŠ” Carelonì˜ ê·œëª¨ í™•ëŒ€, AI ê¸°ë°˜ ë° ë””ì§€í„¸ ì—­ëŸ‰ ë‚´ì¬í™”, íšŒì› ê²½í—˜ ê°„ì†Œí™”ì— íˆ¬ìí•˜ë©´ì„œë„ ìš´ì˜ ê·œìœ¨ì„ ìœ ì§€í•˜ê¸° ìœ„í•¨ì…ë‹ˆë‹¤. ìë³¸ ë°°ë¶„ ê³„íšì€ ì¥ê¸° í”„ë ˆì„ì›Œí¬ì— ë¶€í•©í•˜ë©°, 2026ë…„ì— ì•½ 23ì–µ ë‹¬ëŸ¬ë¥¼ ìì‚¬ì£¼ ë§¤ì…ì— ë°°ì •í•  ê³„íšì…ë‹ˆë‹¤. ì‹¤ì  ê³„ì ˆì„±ê³¼ ê´€ë ¨í•˜ì—¬, 2026ë…„ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì˜ ì•½ 2/3ë¥¼ ìƒë°˜ê¸°ì— ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ê·¸ ì¤‘ 65%ê°€ 1ë¶„ê¸°ì— ë°œìƒí•  ê²ƒìœ¼ë¡œ ì „ë§ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Based on the actions underway this year, we are reaffirming our long-term algorithm of at least 12% adjusted earnings per share growth annually on average over time, and we expect to return to at least that level of growth in 2027 of our ending 2026 earnings baseline. Finally, our long-term earnings growth algorithm is supported by multiple levers: robust revenue growth, operating margin expansion driven by operational execution and technology integration and our commitment to disciplined capital allocation.</td><td>ì˜¬í•´ ì§„í–‰ ì¤‘ì¸ ì¡°ì¹˜ë“¤ì„ ë°”íƒ•ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ í‰ê· ì ìœ¼ë¡œ ì—°ê°„ ìµœì†Œ 12%ì˜ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ ì„±ì¥ì´ë¼ëŠ” ì¥ê¸° ì•Œê³ ë¦¬ì¦˜ì„ ì¬í™•ì¸í•˜ê³  ìˆìœ¼ë©°, 2026ë…„ ë§ ì‹¤ì  ê¸°ì¤€ì„  ëŒ€ë¹„ 2027ë…„ì—ëŠ” ìµœì†Œí•œ ê·¸ ìˆ˜ì¤€ì˜ ì„±ì¥ìœ¼ë¡œ ë³µê·€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ìš°ë¦¬ì˜ ì¥ê¸° ì‹¤ì  ì„±ì¥ ì•Œê³ ë¦¬ì¦˜ì€ ì—¬ëŸ¬ ë™ë ¥ì— ì˜í•´ ë’·ë°›ì¹¨ë©ë‹ˆë‹¤: ê²¬ê³ í•œ ë§¤ì¶œ ì„±ì¥, ìš´ì˜ ì‹¤í–‰ë ¥ê³¼ ê¸°ìˆ  í†µí•©ì— ì˜í•œ ì˜ì—…ì´ìµë¥  í™•ëŒ€, ê·¸ë¦¬ê³  ê·œìœ¨ ìˆëŠ” ìë³¸ ë°°ë¶„ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì˜ì§€ì…ë‹ˆë‹¤.</td></tr>
<tr><td>As our business evolves, we are recalibrating our long-term margin targets for the enterprise as well as for each segment to reflect our current portfolio and how we expect it to evolve in the future, both across and within segments. Importantly, the revision to our health benefits target margin is reflective of the revenue mix we have today while maintaining our targets by line of business. These adjustments are intended to provide a clear and durable framework for evaluating performance, but do not change our conviction in the embedded earnings power of our diversified platform. And with that, operator, please open the line for questions.</td><td>ìš°ë¦¬ ì‚¬ì—…ì´ ì§„í™”í•¨ì— ë”°ë¼, ìš°ë¦¬ëŠ” í˜„ì¬ í¬íŠ¸í´ë¦¬ì˜¤ì™€ í–¥í›„ ì„¸ê·¸ë¨¼íŠ¸ ê°„ ë° ì„¸ê·¸ë¨¼íŠ¸ ë‚´ì—ì„œ ì˜ˆìƒë˜ëŠ” ë³€í™”ë¥¼ ë°˜ì˜í•˜ì—¬ ì „ì‚¬ ë° ê° ì„¸ê·¸ë¨¼íŠ¸ì˜ ì¥ê¸° ë§ˆì§„ ëª©í‘œë¥¼ ì¬ì¡°ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ, ê±´ê°• ê¸‰ì—¬ ë¶€ë¬¸ì˜ ëª©í‘œ ë§ˆì§„ ìˆ˜ì •ì€ ì‚¬ì—… ë¶€ë¬¸ë³„ ëª©í‘œë¥¼ ìœ ì§€í•˜ë©´ì„œ í˜„ì¬ ìš°ë¦¬ê°€ ë³´ìœ í•œ ë§¤ì¶œ ë¯¹ìŠ¤ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì¡°ì •ì€ ì„±ê³¼ í‰ê°€ë¥¼ ìœ„í•œ ëª…í™•í•˜ê³  ì§€ì† ê°€ëŠ¥í•œ í”„ë ˆì„ì›Œí¬ë¥¼ ì œê³µí•˜ê¸° ìœ„í•œ ê²ƒì´ë©°, ìš°ë¦¬ì˜ ë‹¤ê°í™”ëœ í”Œë«í¼ì— ë‚´ì¬ëœ ìˆ˜ìµ ì°½ì¶œë ¥ì— ëŒ€í•œ í™•ì‹ ì€ ë³€í•¨ì´ ì—†ìŠµë‹ˆë‹¤. ê·¸ëŸ¼ êµí™˜ì›ë‹˜, ì§ˆì˜ì‘ë‹µì„ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Elevance Health Q4 2025 ì‹¤ì  ì»¨í¼ëŸ°ìŠ¤ ì½œ ìš”ì•½<br><br>## í•µì‹¬ ë‚´ìš©<br><br>â€¢ **2026ë…„ ê°€ì´ë˜ìŠ¤ ë° ì‹¤ì  ì „ë§**: ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ(EPS) ê°€ì´ë˜ìŠ¤ë¥¼ ìµœì†Œ $25.50ë¡œ ì œì‹œ. 2025ë…„ ì‹¤ì ì—ëŠ” ì•½ $3.75ì˜ ì¼íšŒì„± í˜¸ì¬ê°€ í¬í•¨ë˜ì–´ ìˆì–´ ì‹¤ì§ˆì ì¸ ê¸°ì € ëŒ€ë¹„ ì„±ì¥ì€ ì œí•œì . 2026ë…„ì„ "ì‹¤í–‰ ë° ì¬í¬ì§€ì…”ë‹ì˜ í•´"ë¡œ ê·œì •í•˜ë©°, 2027ë…„ë¶€í„° ìµœì†Œ 12% EPS ì„±ì¥ë¥ ë¡œ ë³µê·€ ëª©í‘œ<br><br>â€¢ **ì‚¬ì—…ë¶€ë¬¸ë³„ ë„ì „ê³¼ì œ**: Medicaid ë¶€ë¬¸ ì˜ì—…ì´ìµë¥  ì•½ -1.75% ì˜ˆìƒ(ë¹„ìš© ì¦ê°€ ëŒ€ë¹„ ìˆ˜ê°€ ì¸ìƒ ì§€ì—°), Medicare Advantage íšŒì›ìˆ˜ 10%ëŒ€ í›„ë°˜ ê°ì†Œ ì˜ˆìƒ(ìˆ˜ìµì„± ê°œì„  ìœ„í•œ ì˜ë„ì  í¬íŠ¸í´ë¦¬ì˜¤ ì¡°ì •), ACA ê°œì¸ì‹œì¥ ì¬í¬ì§€ì…”ë‹(ë³´ì¡°ê¸ˆ ì¢…ë£Œ ë°˜ì˜). ì „ì²´ ìœ„í—˜ê¸°ë°˜ íšŒì›ìˆ˜ëŠ” 10%ëŒ€ ì´ˆë°˜ ê°ì†Œ ì „ë§<br><br>â€¢ **ì¬ë¬´ì§€í‘œ ë° í˜„ê¸ˆíë¦„**: 2026ë…„ ì˜ì—…ìˆ˜ìµì€ ì €ë‹¨ìœ„ í•œìë¦¿ìˆ˜ ê°ì†Œ ì˜ˆìƒ, í†µí•© ì˜ë£Œì†ì‹¤ë¥ (MLR) 90.2%Â±50bp, ì˜ì—…ë¹„ìš©ë¥  10.6%Â±50bp ì „ë§. ì˜ì—…í˜„ê¸ˆíë¦„ì€ ìµœì†Œ $55ì–µ ì˜ˆìƒ(2025ë…„ $43ì–µ ëŒ€ë¹„ ê°œì„ ). ìì‚¬ì£¼ ë§¤ì… ì•½ $23ì–µ ê³„íš<br><br>â€¢ **ì¥ê¸° ë§ˆì§„ ëª©í‘œ í•˜í–¥ ì¡°ì •</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] For our first question, we'll go to the line of A.J. Rice from UBS.</td><td>**Operator:** [ì§ˆë¬¸ ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ UBSì˜ A.J. Rice ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.<br><br>ë„¤, ì§ˆë¬¸ ê¸°íšŒ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ëª‡ ê°€ì§€ ì—¬ì­¤ë³´ê³  ì‹¶ì€ë°ìš”. ë¨¼ì € ì¸ìˆ˜í•©ë³‘ íŒŒì´í”„ë¼ì¸ì— ëŒ€í•´ ë§ì”€í•˜ì…¨ëŠ”ë°, í˜„ì¬ ì‹œì¥ í™˜ê²½ì—ì„œ ì–´ë–¤ ê¸°íšŒë“¤ì„ ë³´ê³  ê³„ì‹ ì§€ ì¢€ ë” êµ¬ì²´ì ìœ¼ë¡œ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ì´ê²ƒì´ ì „ëµì  ìš°ì„ ìˆœìœ„ì— ì–´ë–»ê²Œ ë¶€í•©í•˜ëŠ”ì§€ë„ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Rice: UBS Investment Bank, Research Division I wonder, when you think about the cost trend across the major lines of businesses, I think the industry would say, and I think you guys would say that it was elevated in 2025 across Commercial, Medicaid, Medicare and Exchanges. I know Mark is saying that you have a mid-single-digit cost trend assumption in Medicaid, I believe, for -- in the '26 guidance. But I wondered if I could just get you to comment on, are you assuming sort of a similar cost trend in '26 in your embedded guidance to what you experienced in '25? Or is there any place you're assuming it gets worse or better?</td><td>**Albert Rice:** 2025ë…„ì— ìƒì—…ë³´í—˜, ë©”ë””ì¼€ì´ë“œ, ë©”ë””ì¼€ì–´, ìµìŠ¤ì²´ì¸ì§€ ë“± ì£¼ìš” ì‚¬ì—… ë¶€ë¬¸ ì „ë°˜ì—ì„œ ì˜ë£Œë¹„ ì¶”ì„¸ê°€ ë†’ì•˜ë‹¤ëŠ” ì ì— ëŒ€í•´ì„œëŠ” ì—…ê³„ë„ ê·¸ë ‡ê³  ê·€ì‚¬ë„ ë™ì˜í•˜ì‹¤ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë§ˆí¬ê°€ ë©”ë””ì¼€ì´ë“œì˜ ê²½ìš° 26ë…„ ê°€ì´ë˜ìŠ¤ì— ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ëŒ€ì˜ ì˜ë£Œë¹„ ì¶”ì„¸ë¥¼ ê°€ì •í•˜ê³  ìˆë‹¤ê³  ë§ì”€í•˜ì‹  ê±¸ë¡œ ì•Œê³  ìˆëŠ”ë°ìš”. 26ë…„ ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜ëœ ì˜ë£Œë¹„ ì¶”ì„¸ê°€ 25ë…„ì— ê²½í—˜í–ˆë˜ ê²ƒê³¼ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì¸ì§€, ì•„ë‹ˆë©´ ì–´ë–¤ ë¶€ë¬¸ì—ì„œëŠ” ì•…í™”ë˜ê±°ë‚˜ ê°œì„ ë  ê²ƒìœ¼ë¡œ ê°€ì •í•˜ê³  ê³„ì‹ ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Mark Kaye: Executive VP & CFO AJ, thank you very much for that question. Briefly, I would say the fourth quarter medical cost performance across the Health Benefits segment came in generally in line to slightly better than our expectations. We did see some modest variations by line of business. And so we've carried that forward into our planning for 2026. To your question, in Commercial, within large group, we do expect cost patterns and margins to be largely consistent with what we saw in 2025, meaning an elevated but stable trend environment with some pockets of high utilization. In ACA, we again expect accelerating cost trends, especially as the expiration of the enhanced premium subsidies affects the risk pool. We expect to do -- we do expect to see some healthy members exit. We do expect the remaining population to become more acute. In Medicaid, we expect cost pressure to remain pressured again in 2026 at roughly twice the historical average. And that's going to reflect elevated utilization. It's going to reflect continued misalignment between rates and member acuity. That said, I would say, after 2 years of fairly unprecedented trend, we do expect some moderation versus 2025. So you could think about cost trend here moving into that mid-single-digit range per your question. And then finally, in Medicare, we anticipate higher reported cost trend in 2026, but that's going to be largely driven by our membership mix, including a greater emphasis on D-SNP. So overall, I'd say we're continuing to monitor trends very closely. We're comfortable with how we ended 2025, and we're very confident that our outlook for 2026 is prudent and appropriate.</td><td>**Mark Kaye:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ê°„ë‹¨íˆ ë§ì”€ë“œë¦¬ë©´, 4ë¶„ê¸° ê±´ê°•ë³´í—˜ ë¶€ë¬¸ ì „ë°˜ì˜ ì˜ë£Œë¹„ ì„±ê³¼ëŠ” ì €í¬ ì˜ˆìƒê³¼ ëŒ€ì²´ë¡œ ì¼ì¹˜í•˜ê±°ë‚˜ ì•½ê°„ ë” ë‚˜ì€ ìˆ˜ì¤€ìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì‚¬ì—… ë¶€ë¬¸ë³„ë¡œ ë‹¤ì†Œ ì°¨ì´ëŠ” ìˆì—ˆê³ , ì´ë¥¼ 2026ë…„ ê³„íšì— ë°˜ì˜í–ˆìŠµë‹ˆë‹¤.<br><br>ì§ˆë¬¸í•˜ì‹  ìƒì—…ë³´í—˜ ì¤‘ ëŒ€ê¸°ì—… ë‹¨ì²´ë³´í—˜ì˜ ê²½ìš°, 2025ë…„ê³¼ ëŒ€ì²´ë¡œ ì¼ê´€ëœ ë¹„ìš© íŒ¨í„´ê³¼ ë§ˆì§„ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¦‰, ì¼ë¶€ ê³ ì´ìš©ë¥  êµ¬ê°„ì´ ìˆëŠ” ê°€ìš´ë° ë†’ì§€ë§Œ ì•ˆì •ì ì¸ ì¶”ì„¸ í™˜ê²½ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. <br><br>ACA(Affordable Care Act, ê±´ê°•ë³´í—˜ê°œí˜ë²•)ì˜ ê²½ìš°, íŠ¹íˆ ê°•í™”ëœ ë³´í—˜ë£Œ ë³´ì¡°ê¸ˆ ë§Œë£Œë¡œ ìœ„í—˜ í’€ì— ì˜í–¥ì„ ë¯¸ì¹˜ë©´ì„œ ë¹„ìš© ì¶”ì„¸ê°€ ê°€ì†í™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ê±´ê°•í•œ ê°€ì…ìë“¤ì˜ ì´íƒˆì´ ì¼ë¶€ ë°œìƒí•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë‚˜ë¨¸ì§€ ê°€ì…ìë“¤ì˜ ì¤‘ì¦ë„ê°€ ë†’ì•„ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œ(Medicaid)ì˜ ê²½ìš°, 2026ë…„ì—ë„ ë¹„ìš© ì••ë°•ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ë³´ì´ë©°, ì´ëŠ” ê³¼ê±° í‰ê·  ëŒ€ë¹„ ì•½ 2ë°° ìˆ˜ì¤€ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ë†’ì€ ì˜ë£Œ ì´ìš©ë¥ ì„ ë°˜ì˜í•˜ëŠ” ê²ƒì´ê³ , ë³´í—˜ë£Œìœ¨ê³¼ ê°€ì…ì ì¤‘ì¦ë„ ê°„ì˜ ì§€ì†ì ì¸ ë¶ˆì¼ì¹˜ë¥¼ ë°˜ì˜í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë‹¤ë§Œ, 2ë…„ê°„ì˜ ì „ë¡€ ì—†ëŠ” ì¶”ì„¸ë¥¼ ê²ªì€ í›„, 2025ë…„ ëŒ€ë¹„í•´ì„œëŠ” ì–´ëŠ ì •ë„ ì™„í™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì§ˆë¬¸í•˜ì‹  ëŒ€ë¡œ ë¹„ìš© ì¶”ì„¸ê°€ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ë²”ìœ„ë¡œ ì´ë™í•  ê²ƒìœ¼ë¡œ ë³´ì‹œë©´ ë©ë‹ˆë‹¤. <br><br>ë§ˆì§€ë§‰ìœ¼ë¡œ ë©”ë””ì¼€ì–´(Medicare)ì˜ ê²½ìš°, 2026ë…„ì— ë³´ê³ ë˜ëŠ” ë¹„ìš© ì¶”ì„¸ê°€ ë” ë†’ì•„ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì§€ë§Œ, ì´ëŠ” ì£¼ë¡œ D-SNPì— ëŒ€í•œ ë¹„ì¤‘ í™•ëŒ€ë¥¼ í¬í•¨í•œ ê°€ì…ì êµ¬ì„±ì˜ ë³€í™”ì— ê¸°ì¸í•  ê²ƒì…ë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ì¶”ì„¸ë“¤ì„ ë§¤ìš° ë©´ë°€íˆ ëª¨ë‹ˆí„°ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2025ë…„ì„ ë§ˆë¬´ë¦¬í•œ ê²°ê³¼ì— ë§Œì¡±í•˜ê³  ìˆìœ¼ë©°, 2026ë…„ ì „ë§ì´ ì‹ ì¤‘í•˜ê³  ì ì ˆí•˜ë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Andrew Mok from Barclays.</td><td>**Operator:** ë‹¤ìŒì€ ë°”í´ë ˆì´ì¦ˆì˜ Andrew Mok ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Mok: Barclays Bank PLC, Research Division Your 2026 membership declines generally came in larger than expected, especially on the Medicare side. Can you walk us through what played out during AEP that prompted the negative revisions and help us understand the components of membership declines within commercial risk between ACA and Employer Group?</td><td>**Andrew Mok:** 2026ë…„ íšŒì› ìˆ˜ ê°ì†Œê°€ ì˜ˆìƒë³´ë‹¤ í¬ê²Œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. íŠ¹íˆ ë©”ë””ì¼€ì–´(Medicare) ë¶€ë¬¸ì—ì„œ ê·¸ë ‡ìŠµë‹ˆë‹¤. ì—°ë¡€ ë“±ë¡ ê¸°ê°„(AEP) ë™ì•ˆ ì–´ë–¤ ìƒí™©ì´ ì „ê°œë˜ì–´ ë¶€ì •ì ì¸ ì „ë§ ìˆ˜ì •ìœ¼ë¡œ ì´ì–´ì¡ŒëŠ”ì§€ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ë˜í•œ ìƒì—… ë¦¬ìŠ¤í¬ ë¶€ë¬¸ ë‚´ì—ì„œ ACAì™€ ê³ ìš©ì£¼ ê·¸ë£¹(Employer Group) ê°„ íšŒì› ìˆ˜ ê°ì†Œì˜ êµ¬ì„± ìš”ì†Œë¥¼ ì´í•´í•  ìˆ˜ ìˆë„ë¡ ë„ì™€ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director Thank you for the question, Andrew. I'm going to have Felicia Norwood start and then maybe Mark talk a little bit about the second part.</td><td>**Gail Boudreaux:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Andrew. Felicia Norwoodê°€ ë¨¼ì € ë‹µë³€ì„ ì‹œì‘í•˜ê³ , ì´ì–´ì„œ Markê°€ ë‘ ë²ˆì§¸ ë¶€ë¶„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Felicia Norwood: Executive VP & President of Government Health Benefits Andrew, thank you for the question. Our enrollment during AEP and the member composition is really aligned with our focus on margin. As you know, we took very deliberate steps to reposition our business to deliver sustainable value for our members and move the business towards our margin objectives. So while our outlook for our membership is going to be in the high teens percentage as Gail referenced, and this is below our expectations, we're really pleased at how members reacted to our emphasis on D-SNP as well as our HMO products as we go forward. From a profitability perspective, I will say the mix of the lives that we lost was very consistent with our strategy. A majority of the attrition occurred in PPO products and in HMO products in geographies where we didn't offer a comparable alternative and where we were intentionally disciplined in repositioning our product vis-a-vis the broader market. The outcome that we've seen in January AEP reflects deliberate choices. The products and the members that we exited were less aligned with our long-term objectives, particularly as we continue to focus on our D-SNP products. Importantly, and I think this is critical, we're positioned to deliver meaningful Medicare margin improvement to at least 2% in 2026, which is a meaningful step-up year-over-year. So very pleased with how things turned out, higher membership losses, but very consistent with the expectations. And then I'll turn it over to Mark for the rest of the responses.</td><td>**Felicia Norwood:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. AEP ê¸°ê°„ ë™ì•ˆì˜ ê°€ì…ì ìˆ˜ì™€ íšŒì› êµ¬ì„±ì€ ìš°ë¦¬ì˜ ë§ˆì§„ ì¤‘ì‹¬ ì „ëµê³¼ ì •í™•íˆ ì¼ì¹˜í•©ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼, ìš°ë¦¬ëŠ” íšŒì›ë“¤ì—ê²Œ ì§€ì† ê°€ëŠ¥í•œ ê°€ì¹˜ë¥¼ ì œê³µí•˜ê³  ë§ˆì§„ ëª©í‘œë¥¼ ë‹¬ì„±í•˜ê¸° ìœ„í•´ ì‚¬ì—…ì„ ì¬í¸í•˜ëŠ” ë§¤ìš° ì‹ ì¤‘í•œ ì¡°ì¹˜ë“¤ì„ ì·¨í–ˆìŠµë‹ˆë‹¤. Gailì´ ì–¸ê¸‰í–ˆë“¯ì´ íšŒì› ìˆ˜ ì „ë§ì´ 10%ëŒ€ í›„ë°˜ ê°ì†Œë¡œ ì˜ˆìƒë³´ë‹¤ ë‚®ì€ ìˆ˜ì¤€ì´ì§€ë§Œ, ìš°ë¦¬ê°€ D-SNPì™€ HMO ìƒí’ˆì— ì¤‘ì ì„ ë‘” ê²ƒì— ëŒ€í•œ íšŒì›ë“¤ì˜ ë°˜ì‘ì€ ë§¤ìš° ë§Œì¡±ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. ìˆ˜ìµì„± ê´€ì ì—ì„œ ë³´ë©´, ìš°ë¦¬ê°€ ìƒì€ íšŒì›ë“¤ì˜ êµ¬ì„±ì€ ìš°ë¦¬ ì „ëµê³¼ ë§¤ìš° ì¼ì¹˜í–ˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì˜ ì´íƒˆì€ PPO ìƒí’ˆê³¼ ë¹„êµ ê°€ëŠ¥í•œ ëŒ€ì•ˆì„ ì œê³µí•˜ì§€ ì•Šì•˜ë˜ ì§€ì—­ì˜ HMO ìƒí’ˆì—ì„œ ë°œìƒí–ˆìœ¼ë©°, ì´ëŠ” ì „ì²´ ì‹œì¥ ëŒ€ë¹„ ìš°ë¦¬ ìƒí’ˆì„ ì¬í¬ì§€ì…”ë‹í•˜ëŠ” ê³¼ì •ì—ì„œ ì˜ë„ì ìœ¼ë¡œ ê·œìœ¨ ìˆê²Œ ì ‘ê·¼í•œ ê²°ê³¼ì…ë‹ˆë‹¤. 1ì›” ì—°ë¡€ ë“±ë¡ ê¸°ê°„(AEP)ì—ì„œ ë‚˜íƒ€ë‚œ ê²°ê³¼ëŠ” ì‹ ì¤‘í•œ ì„ íƒì˜ ê²°ê³¼ë¬¼ì…ë‹ˆë‹¤. ìš°ë¦¬ê°€ ì² ìˆ˜í•œ ìƒí’ˆê³¼ íšŒì›ë“¤ì€ ì¥ê¸° ëª©í‘œ, íŠ¹íˆ D-SNP ìƒí’ˆì— ëŒ€í•œ ì§€ì†ì ì¸ ì§‘ì¤‘ê³¼ ëœ ë¶€í•©í–ˆìŠµë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€, ê·¸ë¦¬ê³  ì´ê²ƒì´ í•µì‹¬ì´ë¼ê³  ìƒê°í•˜ëŠ”ë°, ìš°ë¦¬ëŠ” 2026ë…„ì— ë©”ë””ì¼€ì–´ ë§ˆì§„ì„ ìµœì†Œ 2%ê¹Œì§€ ì˜ë¯¸ ìˆê²Œ ê°œì„ í•  ìˆ˜ ìˆëŠ” ìœ„ì¹˜ì— ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì „ë…„ ëŒ€ë¹„ ìƒë‹¹í•œ ê°œì„ ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ê²°ê³¼ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìœ¼ë©°, íšŒì› ì†ì‹¤ì€ ë” ì»¸ì§€ë§Œ ì˜ˆìƒê³¼ ë§¤ìš° ì¼ì¹˜í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‚˜ë¨¸ì§€ ë‹µë³€ì€ Markì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Mark Kaye: Executive VP & CFO And Andrew, on your question on the Employer Group risk membership, we are expecting to end 2026 down in the high single-digit percent range. And the short answer here is it's just a strong focus on margin discipline. Some of the expected decline is really driven by deliberate pricing decisions that we've made, maybe more specifically in a subset of accounts, including some of the lower or negative margin in the Public Sector business that we had. And we really did make a conscious decision to hold the line on pricing and not pursue business at returns below our margin thresholds.</td><td>**Mark Kaye:** 2026ë…„ ë§ ê³ ìš©ì£¼ ê·¸ë£¹ ë¦¬ìŠ¤í¬ íšŒì› ìˆ˜ëŠ” ë†’ì€ í•œ ìë¦¿ìˆ˜ í¼ì„¼íŠ¸ ë²”ìœ„ì—ì„œ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê°„ë‹¨íˆ ë§ì”€ë“œë¦¬ë©´, ë§ˆì§„ ê·œìœ¨ì— ëŒ€í•œ ê°•ë ¥í•œ ì§‘ì¤‘ ë•Œë¬¸ì…ë‹ˆë‹¤. ì˜ˆìƒë˜ëŠ” ê°ì†Œ ì¤‘ ì¼ë¶€ëŠ” ìš°ë¦¬ê°€ ì˜ë„ì ìœ¼ë¡œ ë‚´ë¦° ê°€ê²© ê²°ì •ì—ì„œ ë¹„ë¡¯ëœ ê²ƒì…ë‹ˆë‹¤. ì¢€ ë” êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, ê³µê³µ ë¶€ë¬¸(Public Sector) ì‚¬ì—…ì—ì„œ ë§ˆì§„ì´ ë‚®ê±°ë‚˜ ë§ˆì´ë„ˆìŠ¤ì˜€ë˜ ì¼ë¶€ ê³„ì •ë“¤ì´ í¬í•¨ë©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê°€ê²© ì›ì¹™ì„ ê³ ìˆ˜í•˜ê³ , ë§ˆì§„ ê¸°ì¤€ì¹˜ ì´í•˜ì˜ ìˆ˜ìµë¥ ì„ ê°€ì§„ ì‚¬ì—…ì€ ì¶”êµ¬í•˜ì§€ ì•Šê¸°ë¡œ ì˜ì‹ì ì¸ ê²°ì •ì„ ë‚´ë ¸ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director Yes. So thank you for the question. And I think the headline there again is this played out in a very disciplined way against the pricing expectations we set. And I think we feel very good about where we're coming into '26.</td><td>**Gail Boudreaux:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. í•µì‹¬ì€ ìš°ë¦¬ê°€ ì„¤ì •í•œ ê°€ê²© ì „ëµ ê¸°ëŒ€ì¹˜ì— ë”°ë¼ ë§¤ìš° ê·œìœ¨ ìˆê²Œ ì§„í–‰ë˜ì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. 2026ë…„ì„ ë§ì´í•˜ëŠ” í˜„ì¬ ìƒí™©ì— ëŒ€í•´ ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Justin Lake from Wolfe Research.</td><td>**Operator:** ë‹¤ìŒì€ ìš¸í”„ ë¦¬ì„œì¹˜ì˜ ì €ìŠ¤í‹´ ë ˆì´í¬ ë‹˜ ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Wolfe Research, LLC: I wanted to ask about margins in the Health Benefits business for '26. So you mentioned Medicaid margins of minus 1.75%. I appreciate the help there. And you did say that margins were a little better than expected, I think, Mark, in the fourth quarter. Can you expand on the drivers of that in terms of pricing and cost as you go into 2026? And then any color on where guidance assumption sits for margins for the exchanges and Medicare Advantage would be helpful as well.</td><td>**Wolfe Research, LLC:** 2026ë…„ ê±´ê°•ë³´í—˜ ì‚¬ì—…ì˜ ë§ˆì§„ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œ ë§ˆì§„ì´ ë§ˆì´ë„ˆìŠ¤ 1.75%ë¼ê³  ë§ì”€í•˜ì…¨ëŠ”ë°, ê·¸ ë¶€ë¶„ ì„¤ëª…í•´ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ˆí¬, 4ë¶„ê¸° ë§ˆì§„ì´ ì˜ˆìƒë³´ë‹¤ ì¡°ê¸ˆ ë‚˜ì•˜ë‹¤ê³  í•˜ì‹  ê²ƒ ê°™ì€ë°ìš”. 2026ë…„ìœ¼ë¡œ ê°€ë©´ì„œ ê°€ê²© ì±…ì •ê³¼ ë¹„ìš© ì¸¡ë©´ì—ì„œ ê·¸ ë™ì¸ë“¤ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ìµìŠ¤ì²´ì¸ì§€ì™€ ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€ì˜ ë§ˆì§„ì— ëŒ€í•œ ê°€ì´ë˜ìŠ¤ ê°€ì •ì´ ì–´ëŠ ìˆ˜ì¤€ì¸ì§€ë„ ë§ì”€í•´ì£¼ì‹œë©´ ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Mark Kaye: Executive VP & CFO Justin, thanks very much for the question. I thought a good place for me maybe to start here is really to talk about how we ended the year from a margin perspective, and then I'll give a little bit of color on 2026. So overall, Health Benefit margins very much in line with our outlook and our expectation. On Medicaid, margins were pressured in the fourth quarter, but they did track slightly better than our outlook that we gave in October, and that really reflected 2 things. One, we had some favorable prior period development come through, and we also had some modest retroactive rates. If you exclude those 2 items, Medicaid margins completely in line with expectations. They still reflected that elevated utilization. They still reflected that ongoing reverification-driven risk deterioration and the misalignment of rates and acuity. On Medicare, fourth quarter margins, inclusive of the IRA-driven Part D seasonality were largely in line with our expectations. They reflected the prudent assumptions that were embedded in our 2025 bids and overall guidance. And then in the Commercial Large Group, cost patterns and margins, I would say, were again largely consistent with our expectations. On the ACA side, a smidgen better than our prudent outlook. Cost trends were significantly above historical levels, but again, very much in line with what we were expecting. And so as we think about 2026, the guidance that we put out this morning really incorporates that framework. And that really means that continued pressure in Medicaid, offset by improvement in Medicare Advantage, as you heard Felicia talk about, and then better performance in the individual ACA space. And then lastly, I had a quick question on flu. So maybe let me go ahead and cover that here. We did see a meaningful uptick in influenza-like activity in December that did have a modest adverse impact on the fourth quarter benefit expense ratio. And we have carried some of that experience into our 2026 planning. So specifically, we are expecting first quarter headwind of about 20 basis points for flu that's already embedded in our outlook.</td><td>**Mark Kaye:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € ì—°ë§ ë§ˆì§„ ìƒí™©ë¶€í„° ë§ì”€ë“œë¦¬ê³ , 2026ë…„ì— ëŒ€í•´ì„œë„ ì¡°ê¸ˆ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ê±´ê°•ê¸‰ì—¬(Health Benefit) ë§ˆì§„ì€ ì €í¬ ì „ë§ê³¼ ì˜ˆìƒì— ë¶€í•©í–ˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œ(Medicaid)ì˜ ê²½ìš° 4ë¶„ê¸°ì— ë§ˆì§„ ì••ë°•ì´ ìˆì—ˆì§€ë§Œ, 10ì›”ì— ì œì‹œí•œ ì „ë§ë³´ë‹¤ëŠ” ì•½ê°„ ë‚˜ì€ ì‹¤ì ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ì´ëŠ” ë‘ ê°€ì§€ ìš”ì¸ ë•Œë¬¸ì´ì—ˆìŠµë‹ˆë‹¤. ì²«ì§¸, ê³¼ê±° ê¸°ê°„ì— ëŒ€í•œ ìœ ë¦¬í•œ ì¡°ì •ì´ ë°˜ì˜ë˜ì—ˆê³ , ë‘˜ì§¸, ì†Œí­ì˜ ì†Œê¸‰ ìš”ìœ¨ ì ìš©ì´ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ ë‘ ê°€ì§€ í•­ëª©ì„ ì œì™¸í•˜ë©´ ë©”ë””ì¼€ì´ë“œ ë§ˆì§„ì€ ì˜ˆìƒê³¼ ì™„ì „íˆ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤. ì—¬ì „íˆ ë†’ì€ ì˜ë£Œì´ìš©ë¥ (utilization)ì´ ë°˜ì˜ëœ ìˆ˜ì¹˜ì˜€ìŠµë‹ˆë‹¤. ì—¬ì „íˆ ì§€ì†ì ì¸ ì¬ê²€ì¦ìœ¼ë¡œ ì¸í•œ ë¦¬ìŠ¤í¬ ì•…í™”ì™€ ìš”ìœ¨ ë° ì¤‘ì¦ë„ ê°„ì˜ ë¶ˆì¼ì¹˜ê°€ ë°˜ì˜ë˜ì—ˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì–´ì˜ ê²½ìš°, IRAë¡œ ì¸í•œ íŒŒíŠ¸D ê³„ì ˆì„±ì„ í¬í•¨í•œ 4ë¶„ê¸° ë§ˆì§„ì€ ëŒ€ì²´ë¡œ ìš°ë¦¬ì˜ ì˜ˆìƒê³¼ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” 2025ë…„ ì…ì°°ê³¼ ì „ì²´ ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜ëœ ì‹ ì¤‘í•œ ê°€ì •ë“¤ì„ ë³´ì—¬ì£¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìƒì—…ìš© ëŒ€ê¸°ì—… ë¶€ë¬¸ì—ì„œëŠ” ë¹„ìš© íŒ¨í„´ê³¼ ë§ˆì§„ì´ ë‹¤ì‹œ í•œë²ˆ ìš°ë¦¬ì˜ ì˜ˆìƒê³¼ ëŒ€ì²´ë¡œ ì¼ì¹˜í–ˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ACA ì¸¡ë©´ì—ì„œëŠ” ìš°ë¦¬ì˜ ì‹ ì¤‘í•œ ì „ë§ë³´ë‹¤ ì•½ê°„ ë‚˜ì•˜ìŠµë‹ˆë‹¤. ë¹„ìš© ì¶”ì„¸ê°€ ê³¼ê±° ìˆ˜ì¤€ì„ í¬ê²Œ ìƒíšŒí–ˆì§€ë§Œ, ì´ ì—­ì‹œ ìš°ë¦¬ê°€ ì˜ˆìƒí–ˆë˜ ê²ƒê³¼ ë§¤ìš° ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ 2026ë…„ì„ ìƒê°í•´ë³¼ ë•Œ, ì˜¤ëŠ˜ ì•„ì¹¨ ë°œí‘œí•œ ê°€ì´ë˜ìŠ¤ëŠ” ì´ëŸ¬í•œ í”„ë ˆì„ì›Œí¬ë¥¼ ì‹¤ì œë¡œ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë©”ë””ì¼€ì´ë“œ(Medicaid)ì—ì„œì˜ ì§€ì†ì ì¸ ì••ë°•ì´ ìˆì§€ë§Œ, í ë¦¬ì‹œì•„ê°€ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€(Medicare Advantage)ì—ì„œì˜ ê°œì„ ê³¼ ê°œì¸ ACA ì‹œì¥ì—ì„œì˜ ë” ë‚˜ì€ ì‹¤ì ìœ¼ë¡œ ìƒì‡„ëœë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ˆì§€ë§‰ìœ¼ë¡œ ë…ê°ì— ëŒ€í•œ ì§ˆë¬¸ì´ ìˆìœ¼ì…¨ëŠ”ë°, ì´ ë¶€ë¶„ì„ ì§€ê¸ˆ ë‹¤ë£¨ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. 12ì›”ì— ë…ê° ìœ ì‚¬ í™œë™ì´ ì˜ë¯¸ ìˆê²Œ ì¦ê°€í–ˆê³ , ì´ëŠ” 4ë¶„ê¸° ê¸‰ì—¬ë¹„ìš©ë¥ (benefit expense ratio)ì— ì†Œí­ì˜ ë¶€ì •ì  ì˜í–¥ì„ ë¯¸ì³¤ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ê²½í—˜ì„ 2026ë…„ ê³„íšì—ë„ ì¼ë¶€ ë°˜ì˜í–ˆìŠµë‹ˆë‹¤. êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, 1ë¶„ê¸°ì— ë…ê°ìœ¼ë¡œ ì¸í•œ ì•½ 20bpì˜ ì—­í’ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì´ë¯¸ ìš°ë¦¬ ì „ë§ì— ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Lance Wilkes from Bernstein.</td><td>**Operator:** ë‹¤ìŒì€ ë²ˆìŠ¤íƒ€ì¸ì˜ ëœìŠ¤ ìœŒí¬ìŠ¤ ë‹˜ ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Lance Wilkes: Bernstein Institutional Services LLC, Research Division Great. In the Medicaid business, could you talk a little bit about rate outlook for 2026? And then could you help frame for us how we should be thinking about this on a go-forward basis with respect to -- obviously, you've given a trend estimate. But how should we be looking at kind of rate expectations, what states are doing as far as program changes? And then what are the opportunities and the achievable objectives for medical management?</td><td>**Lance Wilkes:** ë„¤, ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. 2026ë…„ ë©”ë””ì¼€ì´ë“œ(Medicaid) ì‚¬ì—…ì˜ ìš”ìœ¨ ì „ë§ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. <br><br>ë¨¼ì € ìš”ìœ¨ ì¸¡ë©´ì—ì„œ ë³´ë©´, ê° ì£¼ì •ë¶€ë“¤ì´ í˜„ì¬ 2026ë…„ ì˜ˆì‚° í¸ì„± ê³¼ì •ì— ìˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ìš°ë¦¬ê°€ ë³´ê³  ìˆëŠ” ê²ƒì€ ëŒ€ë¶€ë¶„ì˜ ì£¼ì—ì„œ í•©ë¦¬ì ì¸ ìš”ìœ¨ í™˜ê²½ì´ ìœ ì§€ë˜ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ë¬¼ë¡  ì£¼ë§ˆë‹¤ ì°¨ì´ëŠ” ìˆì§€ë§Œ, ì „ì²´ì ìœ¼ë¡œëŠ” ì˜ë£Œë¹„ ì¶”ì„¸ë¥¼ ë°˜ì˜í•˜ëŠ” ì ì •í•œ ìˆ˜ì¤€ì˜ ìš”ìœ¨ ì¸ìƒì´ ì´ë£¨ì–´ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>í–¥í›„ ì „ë§ê³¼ ê´€ë ¨í•´ì„œëŠ” ëª‡ ê°€ì§€ í•µì‹¬ ìš”ì†Œë¥¼ ê³ ë ¤í•´ì•¼ í•©ë‹ˆë‹¤. ì²«ì§¸, ê° ì£¼ì˜ ì¬ì • ìƒí™©ì…ë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì˜ ì£¼ë“¤ì´ ë¹„êµì  ì•ˆì •ì ì¸ ì¬ì • ìƒíƒœë¥¼ ìœ ì§€í•˜ê³  ìˆì–´ ê¸ì •ì ì…ë‹ˆë‹¤. ë‘˜ì§¸, ì˜ë£Œë¹„ ì¶”ì„¸ì¸ë°, ìš°ë¦¬ê°€ ì œì‹œí•œ ì¶”ì„¸ ì „ë§ì¹˜ê°€ ìš”ìœ¨ í˜‘ìƒì˜ ê¸°ì¤€ì ì´ ë©ë‹ˆë‹¤. <br><br>í”„ë¡œê·¸ë¨ ë³€ê²½ ì¸¡ë©´ì—ì„œëŠ”, ì—¬ëŸ¬ ì£¼ì—ì„œ ê°€ì¹˜ ê¸°ë°˜ ì¼€ì–´(value-based care) ëª¨ë¸ë¡œì˜ ì „í™˜ì„ ê°€ì†í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì—ê²Œ ê¸°íšŒê°€ ë©ë‹ˆë‹¤. ë˜í•œ ì¼ë¶€ ì£¼ì—ì„œëŠ” ê¸‰ì—¬ ë²”ìœ„ í™•ëŒ€ë‚˜ ìƒˆë¡œìš´ ì„œë¹„ìŠ¤ ì¶”ê°€ë¥¼ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì˜ë£Œ ê´€ë¦¬ ë¶€ë¬¸ì˜ ê¸°íšŒì™€ ë‹¬ì„± ê°€ëŠ¥í•œ ëª©í‘œì— ëŒ€í•´ì„œëŠ”, ìš°ë¦¬ëŠ” ì—¬ëŸ¬ ì˜ì—­ì—ì„œ ê°œì„  ì—¬ì§€ë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì‘ê¸‰ì‹¤ ì´ìš© ê°ì†Œ, ë§Œì„±ì§ˆí™˜ ê´€ë¦¬ ê°œì„ , ì˜ˆë°© ì¼€ì–´ ê°•í™” ë“±ì´ í•µì‹¬ ëª©í‘œì…ë‹ˆë‹¤. íŠ¹íˆ ë°ì´í„° ë¶„ì„ê³¼ ë””ì§€í„¸ í—¬ìŠ¤ ë„êµ¬ë¥¼ í™œìš©í•œ íšŒì› ì°¸ì—¬ë„ í–¥ìƒì— ì£¼ë ¥í•˜ê³  ìˆìœ¼ë©°, ì´ë¥¼ í†µí•´ ì˜ë£Œ ì§ˆì„ ë†’ì´ë©´ì„œ ë™ì‹œì— ë¹„ìš© íš¨ìœ¨ì„±ë„ ê°œì„ í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤.</td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director</td><td>**Gail Boudreaux:** I notice you've only provided a title/role ("President, CEO & Director") but no actual spoken content to translate.<br><br>Could you please provide the actual Q&A response or statement that needs to be translated? I'm ready to translate the spoken content from the earnings call into natural, fluent Korean once you share it.</td></tr>
<tr><td>Felicia Norwood: Executive VP & President of Government Health Benefits Lance, thank you for the question. We are contemplating a composite rate increase in 2026 in the mid-single-digit percent range, net of certain known risk corridor impacts. I will say the final rates that we've received from states for January. And as you know, January represents about 1/3 of our Medicaid premium. Those rates were in line with our expectations. But for these states, the rates, while modestly above the historical levels, will still lag trend in 2026, given the ongoing membership attrition and the shifting risk pools we continue to see as a result of some ongoing state reverification activity. You mentioned program changes. I will say the rate discussions today are increasingly tied to broader program changes and benefit designs that state are more receptive to consideration. And I think that's very important as we think about trying to maintain long-term sustainability and the adjustments that need to be made in states around budget challenges that we're going to see in 2026. We are always engaged in constructive conversations with our state partners, and we're also taking actions ourselves to help control what states are seeing in terms of their Medicaid budgets by doing all of the things that states expect that's tightening our cost management, increasingly focused on those high trend drivers that you heard earlier around behavioral health, ABA and other services and certainly very much engaged in program integrity activities to make sure that the program reflects soundness as we look at ongoing issues in the program. So good constructive conversations with rates, a continued lag though, in terms of the trend. But I would say we continue to be very engaged in having a program that's long-term sustainable in our Medicaid program.</td><td>**Felicia Norwood:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. 2026ë…„ì—ëŠ” íŠ¹ì • ë¦¬ìŠ¤í¬ ì½”ë¦¬ë”(risk corridor) ì˜í–¥ì„ ë°˜ì˜í•œ ìˆœ ê¸°ì¤€ìœ¼ë¡œ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ í¼ì„¼íŠ¸ ë²”ìœ„ì˜ ì¢…í•© ìš”ìœ¨ ì¸ìƒì„ ê³ ë ¤í•˜ê³  ìˆìŠµë‹ˆë‹¤. 1ì›”ë¶€í„° ì ìš©ë˜ëŠ” ì£¼ì •ë¶€ë¡œë¶€í„° ë°›ì€ ìµœì¢… ìš”ìœ¨ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, ì•„ì‹œë‹¤ì‹œí”¼ 1ì›”ì€ ìš°ë¦¬ ë©”ë””ì¼€ì´ë“œ ë³´í—˜ë£Œì˜ ì•½ 3ë¶„ì˜ 1ì„ ì°¨ì§€í•©ë‹ˆë‹¤. í•´ë‹¹ ìš”ìœ¨ë“¤ì€ ìš°ë¦¬ ì˜ˆìƒê³¼ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì´ë“¤ ì£¼ì˜ ê²½ìš°, ìš”ìœ¨ì´ ê³¼ê±° ìˆ˜ì¤€ë³´ë‹¤ëŠ” ì†Œí­ ë†’ì§€ë§Œ, ì§€ì†ë˜ëŠ” íšŒì› ê°ì†Œì™€ ì¼ë¶€ ì£¼ì •ë¶€ì˜ ì¬ê²€ì¦ í™œë™ìœ¼ë¡œ ì¸í•´ ê³„ì† ë‚˜íƒ€ë‚˜ê³  ìˆëŠ” ë¦¬ìŠ¤í¬ í’€ì˜ ë³€í™”ë¥¼ ê°ì•ˆí•˜ë©´ 2026ë…„ì—ë„ ì—¬ì „íˆ ì¶”ì„¸ì—ëŠ” ë¯¸ì¹˜ì§€ ëª»í•  ê²ƒì…ë‹ˆë‹¤. í”„ë¡œê·¸ë¨ ë³€ê²½ ì‚¬í•­ì„ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°ìš”. <response><br><br>í˜„ì¬ ìš”ìœ¨ í˜‘ìƒì€ ì ì  ë” ì£¼ ì •ë¶€ê°€ ê²€í† ì— ë” ì ê·¹ì ì¸ í¬ê´„ì ì¸ í”„ë¡œê·¸ë¨ ë³€ê²½ ë° ê¸‰ì—¬ ì„¤ê³„ì™€ ì—°ê³„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¥ê¸°ì ì¸ ì§€ì†ê°€ëŠ¥ì„±ì„ ìœ ì§€í•˜ê³ , 2026ë…„ì— ì˜ˆìƒë˜ëŠ” ì£¼ ì •ë¶€ì˜ ì˜ˆì‚° ë¬¸ì œì™€ ê´€ë ¨í•˜ì—¬ í•„ìš”í•œ ì¡°ì •ì„ ê³ ë ¤í•  ë•Œ ë§¤ìš° ì¤‘ìš”í•˜ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br></response> ì €í¬ëŠ” í•­ìƒ ì£¼ ì •ë¶€ íŒŒíŠ¸ë„ˆë“¤ê³¼ ê±´ì„¤ì ì¸ ëŒ€í™”ë¥¼ ì´ì–´ê°€ê³  ìˆìœ¼ë©°, ë™ì‹œì— ì£¼ ì •ë¶€ë“¤ì´ ë©”ë””ì¼€ì´ë“œ ì˜ˆì‚°ì—ì„œ ì²´ê°í•˜ëŠ” ë¶€ë‹´ì„ ì™„í™”í•˜ê¸° ìœ„í•´ ìì²´ì ìœ¼ë¡œë„ ì—¬ëŸ¬ ì¡°ì¹˜ë¥¼ ì·¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. êµ¬ì²´ì ìœ¼ë¡œëŠ” ì£¼ ì •ë¶€ë“¤ì´ ê¸°ëŒ€í•˜ëŠ” ëª¨ë“  ë¶€ë¶„ì—ì„œ ë¹„ìš© ê´€ë¦¬ë¥¼ ê°•í™”í•˜ê³  ìˆê³ , ì•ì„œ ë§ì”€ë“œë¦° í–‰ë™ ê±´ê°•(behavioral health), ABA ì¹˜ë£Œ ë° ê¸°íƒ€ ì„œë¹„ìŠ¤ì™€ ê°™ì€ ê³ ë¹„ìš© ì¦ê°€ ìš”ì¸ë“¤ì— ì ì  ë” ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ í”„ë¡œê·¸ë¨ì˜ ê±´ì „ì„±ì„ í™•ë³´í•˜ê¸° ìœ„í•´ í”„ë¡œê·¸ë¨ ë¬´ê²°ì„± í™œë™ì—ë„ ì ê·¹ì ìœ¼ë¡œ ì°¸ì—¬í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ê·¸ë˜ì„œ ìš”ìœ¨(rates)ê³¼ ê´€ë ¨í•´ì„œëŠ” ì¢‹ì€ ê±´ì„¤ì ì¸ ëŒ€í™”ê°€ ì§„í–‰ë˜ê³  ìˆì§€ë§Œ, íŠ¸ë Œë“œ ì¸¡ë©´ì—ì„œëŠ” ì—¬ì „íˆ ì‹œì°¨ê°€ ì¡´ì¬í•˜ëŠ” ê²ƒì´ ì‚¬ì‹¤ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ëŠ” ë©”ë””ì¼€ì´ë“œ í”„ë¡œê·¸ë¨ì´ ì¥ê¸°ì ìœ¼ë¡œ ì§€ì† ê°€ëŠ¥í•œ í”„ë¡œê·¸ë¨ì´ ë  ìˆ˜ ìˆë„ë¡ ê³„ì†í•´ì„œ ì ê·¹ì ìœ¼ë¡œ ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Josh Raskin from Nephron Research.</td><td>**Operator:** ë‹¤ìŒì€ ë„¤í”„ë¡  ë¦¬ì„œì¹˜ì˜ ì¡°ì‰¬ ë¼ìŠ¤í‚¨ ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Nephron Research LLC: Maybe just big picture. If you could give us a little bit more details and speak to what gives you that confidence to confirm the long-term EPS growth target of 12% plus starting in 2027 in light of the trends that you've seen in the past 2 years. Is there something specific in Medicare or Medicaid or the Commercial markets that suggest an opportunity to start growing earnings in '27? Or are you seeing something in Carelon side that maybe leads to a stronger acceleration of growth there? And lastly, I assume this includes your view of the 2027 MA rates post the prelim notice.</td><td>**Nephron Research LLC:** í° ê·¸ë¦¼ì—ì„œ ë§ì”€ë“œë¦¬ìë©´, 2027ë…„ë¶€í„° ì‹œì‘ë˜ëŠ” ì—°ê°„ 12% ì´ìƒì˜ EPS ì„±ì¥ ëª©í‘œë¥¼ ì¬í™•ì¸í•˜ì‹  ê²ƒì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œê³ , ì§€ë‚œ 2ë…„ê°„ì˜ ì¶”ì„¸ë¥¼ ê³ ë ¤í•  ë•Œ ê·¸ëŸ¬í•œ í™•ì‹ ì„ ê°–ê²Œ ëœ ë°°ê²½ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ë©”ë””ì¼€ì–´(Medicare)ë‚˜ ë©”ë””ì¼€ì´ë“œ(Medicaid), ë˜ëŠ” ìƒì—… ì‹œì¥ì—ì„œ 2027ë…„ë¶€í„° ì‹¤ì  ì„±ì¥ì„ ì‹œì‘í•  ìˆ˜ ìˆëŠ” êµ¬ì²´ì ì¸ ê¸°íšŒê°€ ìˆëŠ” ê²ƒì¸ì§€ìš”? ì•„ë‹ˆë©´ Carelon ë¶€ë¬¸ì—ì„œ ë” ê°•ë ¥í•œ ì„±ì¥ ê°€ì†í™”ë¡œ ì´ì–´ì§ˆ ìˆ˜ ìˆëŠ” ë¬´ì–¸ê°€ë¥¼ ë³´ê³  ê³„ì‹  ê±´ê°€ìš”? ê·¸ë¦¬ê³  ë§ˆì§€ë§‰ìœ¼ë¡œ, ì´ ì „ë§ì—ëŠ” ì˜ˆë¹„ ê³µê³  ì´í›„ 2027ë…„ MA ìˆ˜ê°€ìœ¨(MA rates)ì— ëŒ€í•œ ê·€ì‚¬ì˜ ê²¬í•´ê°€ ë°˜ì˜ë˜ì–´ ìˆë‹¤ê³  ë´ë„ ë˜ëŠ”ì§€ìš”?</td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director Yes. Thank you for the question, Josh. I think it helps as we frame '27. Let's start with '26. We guided to an adjusted diluted EPS of at least $25.50. And again, as I shared, we see that outlook is prudent and achievable, and it's based on actions that are already underway to reposition our business and improve margins across the enterprise. So as I step back, '25 was about strengthening the foundation. We tightened pricing discipline. We did -- we improved our execution, and we advanced our affordability through Carelon. And as you just heard Mark, the fundamentals came in where we expected them to. And I think that work matters as we think about the next few years because it gives us a very clear line of sight and a lot of confidence in the outlook that we're laying. So my headline for '26, it's all about execution. The fundamentals are there. Looking to '27, we have confidence in at least 12% adjusted EPS growth coming off of our '26 ending baseline. And again, that's because it's driven by the same fundamentals that we saw at the end of '25 and into '26. Again, over the past 2 years, we've made very specific portfolio targeted decisions. Our pricing has hardened and our operating decisions are designed to protect our earnings base and position the enterprise for durable growth. That leverages the unique capabilities. And I think our diversified platform, we're going to start to see come through. And there's 3 points I just want to underscore. First, the key earnings levers are already in motion. So that puts us in place for '25 and '26. Again, pricing care management and the portfolio we feel are positioned. Second, our '26 outlook is intentionally prudent. So the actions -- so as those actions mature, we can capture more operating leverage, and that sets up a clear step-up into 2027. And third, and I think this is really important to your question, the path isn't predicated on a single assumption. It's built on multiple independent levers and disciplined execution across Commercial, Medicare, Carelon and Medicaid. And that's why we have the confidence both in the '27 and in long term -- in our long-term earnings algorithm. And that confidence is behind our outlook in 2026 and the growth in '27. So hopefully, that provides some clarity. Thank you for the question.</td><td>**Gail Boudreaux:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. 27ë…„ë„ë¥¼ ë…¼ì˜í•˜ê¸° ì „ì— 26ë…„ë„ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ(adjusted diluted EPS)ì„ ìµœì†Œ 25.50ë‹¬ëŸ¬ë¡œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì´ ì „ë§ì€ ì‹ ì¤‘í•˜ë©´ì„œë„ ë‹¬ì„± ê°€ëŠ¥í•˜ë‹¤ê³  ë³´ê³  ìˆìœ¼ë©°, ì´ëŠ” ì´ë¯¸ ì§„í–‰ ì¤‘ì¸ ì‚¬ì—… ì¬í¸ê³¼ ì „ì‚¬ì  ë§ˆì§„ ê°œì„  ì¡°ì¹˜ë“¤ì— ê¸°ë°˜í•œ ê²ƒì…ë‹ˆë‹¤.<br><br>í•œ ë°œì§ ë¬¼ëŸ¬ì„œì„œ ë³´ë©´, 25ë…„ë„ëŠ” ê¸°ë°˜ì„ ê°•í™”í•˜ëŠ” í•œ í•´ì˜€ìŠµë‹ˆë‹¤. ê°€ê²© ì±…ì • ê·œìœ¨ì„ ê°•í™”í–ˆê³ , ì‹¤í–‰ë ¥ì„ ê°œì„ í–ˆìœ¼ë©°, Carelonì„ í†µí•´ ê²½ì œì„±ì„ í–¥ìƒì‹œì¼°ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë°©ê¸ˆ Markê°€ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, í€ë”ë©˜í„¸ì€ ì €í¬ê°€ ì˜ˆìƒí–ˆë˜ ëŒ€ë¡œ ë‚˜ì™”ìŠµë‹ˆë‹¤. í–¥í›„ ëª‡ ë…„ì„ ìƒê°í•  ë•Œ ì´ëŸ¬í•œ ì‘ì—…ì´ ì¤‘ìš”í•œ ì´ìœ ëŠ”, ìš°ë¦¬ê°€ ì œì‹œí•˜ëŠ” ì „ë§ì— ëŒ€í•´ ë§¤ìš° ëª…í™•í•œ ê°€ì‹œì„±ê³¼ ë†’ì€ í™•ì‹ ì„ ì œê³µí•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. 26ë…„ë„ì— ëŒ€í•œ í•µì‹¬ ë©”ì‹œì§€ëŠ” ì‹¤í–‰ë ¥ì…ë‹ˆë‹¤. í€ë”ë©˜í„¸ì€ ì´ë¯¸ ê°–ì¶°ì ¸ ìˆìŠµë‹ˆë‹¤. 27ë…„ë„ë¥¼ ë³´ë©´, 26ë…„ë„ ë§ ê¸°ì¤€ì„  ëŒ€ë¹„ ìµœì†Œ 12%ì˜ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ(adjusted EPS) ì„±ì¥ì— ëŒ€í•´ í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì´ëŠ” 25ë…„ë„ ë§ê³¼ 26ë…„ë„ì— í™•ì¸í•œ ê²ƒê³¼ ë™ì¼í•œ í€ë”ë©˜í„¸ì— ê¸°ë°˜í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ì§€ë‚œ 2ë…„ê°„ ìš°ë¦¬ëŠ” ë§¤ìš° êµ¬ì²´ì ì´ê³  íƒ€ê²ŸíŒ…ëœ í¬íŠ¸í´ë¦¬ì˜¤ ì˜ì‚¬ê²°ì •ì„ ë‚´ë ¸ìŠµë‹ˆë‹¤. ê°€ê²© ì •ì±…ì€ ê°•í™”ë˜ì—ˆê³ , ìš´ì˜ìƒì˜ ê²°ì •ë“¤ì€ ìˆ˜ìµ ê¸°ë°˜ì„ ë³´í˜¸í•˜ê³  ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ì„ ìœ„í•´ ê¸°ì—…ì„ í¬ì§€ì…”ë‹í•˜ë„ë¡ ì„¤ê³„ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì˜ ê³ ìœ í•œ ì—­ëŸ‰ì„ í™œìš©í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ì˜ ë‹¤ê°í™”ëœ í”Œë«í¼ì´ ì„±ê³¼ë¥¼ ë‚´ê¸° ì‹œì‘í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ ì„¸ ê°€ì§€ í•µì‹¬ ì‚¬í•­ì„ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì²«ì§¸, í•µì‹¬ ìˆ˜ìµ ë ˆë²„ë“¤ì´ ì´ë¯¸ ì‘ë™í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” 25ë…„ê³¼ 26ë…„ì„ ìœ„í•œ ê¸°ë°˜ì„ ë§ˆë ¨í•´ì¤ë‹ˆë‹¤. ê°€ê²© ì±…ì •, ì¼€ì–´ ë§¤ë‹ˆì§€ë¨¼íŠ¸, ê·¸ë¦¬ê³  í¬íŠ¸í´ë¦¬ì˜¤ê°€ ì˜ í¬ì§€ì…”ë‹ë˜ì–´ ìˆë‹¤ê³  íŒë‹¨í•©ë‹ˆë‹¤. ë‘˜ì§¸, 26ë…„ ì „ë§ì€ ì˜ë„ì ìœ¼ë¡œ ë³´ìˆ˜ì ìœ¼ë¡œ ì„¤ì •í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ì¡°ì¹˜ë“¤ì´ ì„±ìˆ™í•´ì§€ë©´ì„œ ë” ë§ì€ ìš´ì˜ ë ˆë²„ë¦¬ì§€ë¥¼ í™•ë³´í•  ìˆ˜ ìˆê³ , ì´ëŠ” 2027ë…„ìœ¼ë¡œì˜ ëª…í™•í•œ ë„ì•½ì„ ì¤€ë¹„í•˜ê²Œ ë©ë‹ˆë‹¤. ì…‹ì§¸, ì´ ë¶€ë¶„ì´ ê·€í•˜ì˜ ì§ˆë¬¸ì— ì •ë§ ì¤‘ìš”í•œë°, ì €í¬ ê³„íšì€ ë‹¨ì¼ ê°€ì •ì— ì˜ì¡´í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ìƒì—…ë³´í—˜, ë©”ë””ì¼€ì–´, ì¼€ì–´ë¡ , ë©”ë””ì¼€ì´ë“œ ì „ë°˜ì— ê±¸ì¹œ ë‹¤ìˆ˜ì˜ ë…ë¦½ì ì¸ ë ˆë²„ë“¤ê³¼ ì²´ê³„ì ì¸ ì‹¤í–‰ì„ ê¸°ë°˜ìœ¼ë¡œ êµ¬ì¶•ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ê°€ 27ë…„ë„ì™€ ì¥ê¸°ì ìœ¼ë¡œ - ì¥ê¸° ì‹¤ì  ì•Œê³ ë¦¬ì¦˜ì— ëŒ€í•´ í™•ì‹ ì„ ê°€ì§€ê³  ìˆëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ í™•ì‹ ì´ 2026ë…„ ì „ë§ê³¼ 27ë…„ë„ ì„±ì¥ì˜ ê¸°ë°˜ì´ ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë„ì›€ì´ ë˜ì…¨ê¸°ë¥¼ ë°”ëë‹ˆë‹¤. ì§ˆë¬¸í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Lisa Gill from JPMorgan.</td><td>**Operator:** ë‹¤ìŒì€ JPëª¨ê±´ì˜ Lisa Gill ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Lisa Gill: JPMorgan Chase & Co, Research Division I want to go back to Mark's comments on the investments that were pulled forward. Mark, I want to make sure that I heard you correctly, you said it was roughly $1 of investments, but a quarter was pulled forward. So should I think that $0.75 is still embedded in your guidance for 2026? And can you talk about specifically what buckets those investments are in? And how do we think about how it flows through the model?</td><td>**Lisa Gill:** JPMorgan Chase & Co, ë¦¬ì„œì¹˜ ë¶€ë¬¸ì…ë‹ˆë‹¤. Markê»˜ì„œ ë§ì”€í•˜ì‹  íˆ¬ì ì„ ì§‘í–‰ì— ëŒ€í•´ ë‹¤ì‹œ ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤. Mark, ì œê°€ ì œëŒ€ë¡œ ì´í•´í–ˆëŠ”ì§€ í™•ì¸í•˜ê³  ì‹¶ì€ë°ìš”, ì•½ 1ë‹¬ëŸ¬ ê·œëª¨ì˜ íˆ¬ì ì¤‘ 4ë¶„ì˜ 1ì´ ì„ ì§‘í–‰ë˜ì—ˆë‹¤ê³  í•˜ì…¨ìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ 0.75ë‹¬ëŸ¬ëŠ” ì—¬ì „íˆ 2026ë…„ ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜ë˜ì–´ ìˆë‹¤ê³  ë´ì•¼ í• ê¹Œìš”? ê·¸ë¦¬ê³  êµ¬ì²´ì ìœ¼ë¡œ ì–´ë–¤ í•­ëª©ì— ì´ íˆ¬ìë“¤ì´ í¬í•¨ë˜ì–´ ìˆëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  ì´ê²ƒì´ ëª¨ë¸ì— ì–´ë–»ê²Œ ë°˜ì˜ë˜ëŠ”ì§€ë„ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Mark Kaye: Executive VP & CFO Lisa, thanks very much for the question. Maybe let me do a little bit of a broader framing, and then I'll get specifically to your question. So our results this morning do include $3.75 of discrete noncore items embedded in our outlook. And that is, to your point, $0.75 more favorable than what we contemplated in our October call. So what changed versus prior expectations? Well, that incremental favorability, that was driven entirely by strategic tax items that came in better than expected as we finalize results, particularly in the fourth quarter. And importantly, and I want to emphasize this point here, underlying operating performance came in as expected, meaning medical cost trends, operating execution, they're consistent with our outlook. So given that outperformance in those tax-related benefits, we made 2 intentional decisions. One, we pulled forward 1/4 of the approximately $1 of incremental investments that we had previously planned for 2026. And two, we deployed an additional $0.25 towards retention and targeted workforce investments here. And so it gives us a lot of confidence as we set the baseline for 2026.</td><td>**Mark Kaye:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € ì „ì²´ì ì¸ ë§¥ë½ì„ ì„¤ëª…ë“œë¦° í›„ êµ¬ì²´ì ì¸ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì•„ì¹¨ ë°œí‘œí•œ ì‹¤ì ì—ëŠ” ë¹„í•µì‹¬ ì¼íšŒì„± í•­ëª©(discrete noncore items)ìœ¼ë¡œ 3.75ë‹¬ëŸ¬ê°€ ì „ë§ì¹˜ì— í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ 10ì›” ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ì˜ˆìƒí–ˆë˜ ê²ƒë³´ë‹¤ 0.75ë‹¬ëŸ¬ ë” ê¸ì •ì ì…ë‹ˆë‹¤. <br><br>ì´ì „ ì „ë§ ëŒ€ë¹„ ë¬´ì—‡ì´ ë‹¬ë¼ì¡Œëƒê³ ìš”? ì´ ì¶”ê°€ì ì¸ ê°œì„ ë¶„ì€ ì „ì ìœ¼ë¡œ ì „ëµì  ì„¸ë¬´ í•­ëª©ë“¤ì´ ì˜ˆìƒë³´ë‹¤ ì¢‹ê²Œ ë‚˜ì˜¨ ë°ì„œ ë¹„ë¡¯ë˜ì—ˆìŠµë‹ˆë‹¤. íŠ¹íˆ 4ë¶„ê¸° ì‹¤ì ì„ í™•ì •í•˜ë©´ì„œ ê·¸ë ‡ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. <br><br>ì—¬ê¸°ì„œ ê°•ì¡°í•˜ê³  ì‹¶ì€ ì¤‘ìš”í•œ ì ì€, ê¸°ì € ì˜ì—… ì‹¤ì (underlying operating performance)ì€ ì˜ˆìƒëŒ€ë¡œ ë‚˜ì™”ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë‹¤ì‹œ ë§í•´ ì˜ë£Œë¹„ ì¶”ì„¸(medical cost trends)ì™€ ì˜ì—… ì‹¤í–‰ë ¥ì€ ìš°ë¦¬ ì „ë§ê³¼ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤. ì„¸ê¸ˆ ê´€ë ¨ í˜œíƒì—ì„œ ì´ˆê³¼ ë‹¬ì„±í•œ ì‹¤ì ì„ ê°ì•ˆí•˜ì—¬, ì €í¬ëŠ” ë‘ ê°€ì§€ ì˜ë„ì ì¸ ê²°ì •ì„ ë‚´ë ¸ìŠµë‹ˆë‹¤. ì²«ì§¸, 2026ë…„ì— ê³„íší–ˆë˜ ì•½ 1ë‹¬ëŸ¬ ê·œëª¨ì˜ ì¶”ê°€ íˆ¬ì ì¤‘ 4ë¶„ì˜ 1ì„ ì•ë‹¹ê²¨ ì§‘í–‰í–ˆìŠµë‹ˆë‹¤. ë‘˜ì§¸, ì¸ì¬ ìœ ì§€ ë° ì „ëµì  ì¸ë ¥ íˆ¬ìì— ì¶”ê°€ë¡œ 0.25ë‹¬ëŸ¬ë¥¼ ë°°ì¹˜í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¡°ì¹˜ë“¤ì€ 2026ë…„ ê¸°ì¤€ì„ ì„ ì„¤ì •í•˜ëŠ” ë° ìˆì–´ í° í™•ì‹ ì„ ê°–ê²Œ í•´ì¤ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Ann Hynes from Mizuho Securities.</td><td>**Operator:** ë‹¤ìŒì€ ë¯¸ì¦ˆí˜¸ ì¦ê¶Œì˜ Ann Hynesì…ë‹ˆë‹¤.</td></tr>
<tr><td>Ann Hynes: Mizuho Securities USA LLC, Research Division I know in your long-term guidance, you're lowering the margin profile of each segment. Within the Healthcare Benefits segment, can you let us know what changed for your long-term targets for Medicaid, Medicare and Commercial? And then on Carelon, it looks like you are lowering the Rx part of it. Is that just driven by membership losses? Or is there anything else that's lowering that target?</td><td>**Ann Hynes:** ë¯¸ì¦ˆí˜¸ ì¦ê¶Œ USA LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸ì˜ ì§ˆë¬¸ì´ë„¤ìš”. ì¥ê¸° ê°€ì´ë˜ìŠ¤ì—ì„œ ê° ë¶€ë¬¸ì˜ ë§ˆì§„ í”„ë¡œíŒŒì¼ì„ ë‚®ì¶”ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. í—¬ìŠ¤ì¼€ì–´ ë² ë„¤í• ë¶€ë¬¸ ë‚´ì—ì„œ ë©”ë””ì¼€ì´ë“œ, ë©”ë””ì¼€ì–´, ìƒì—…ë³´í—˜ì— ëŒ€í•œ ì¥ê¸° ëª©í‘œì¹˜ê°€ ì–´ë–»ê²Œ ë³€ê²½ë˜ì—ˆëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  ì¼€ì–´ë¡ ì˜ ê²½ìš°, ì²˜ë°©ì•½(Rx) ë¶€ë¶„ì„ ë‚®ì¶”ì‹  ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°ìš”. ì´ê²ƒì´ ë‹¨ìˆœíˆ íšŒì› ìˆ˜ ê°ì†Œ ë•Œë¬¸ì¸ê°€ìš”? ì•„ë‹ˆë©´ í•´ë‹¹ ëª©í‘œì¹˜ë¥¼ ë‚®ì¶”ëŠ” ë‹¤ë¥¸ ìš”ì¸ì´ ìˆë‚˜ìš”?</td></tr>
<tr><td>Mark Kaye: Executive VP & CFO So most important here, we have not changed the underlying margin expectations for any line of business within Health Benefits. And that continues to reflect the risk that we assume and the value that we deliver for employers and the government programs that we support. What has changed is how we calibrate the Health Benefits segment margin to the portfolio we are operating today, applying the same line of business margin framework that we've always used. So as we've worked through an elevated cost trend environment, I would say Commercial growth has been more measured than we originally anticipated, also as we prioritize disciplined pricing and margin integrity over volume. At the same time, the composition within Commercial that's also evolved. So individual ACA now represents a larger share of the segment relative to Group Commercial, and that obviously carries a different margin profile. And so when you reflect these dynamics through the existing line of business margin ranges, the result is that mid-single-digit Health Benefits segment margin expectation. And so the key point here, look, this is not about a change in strategy or change in underwriting discipline or pricing. This is just a recalibration to better reflect the mix of our business today and a prudent view of the operating environment.</td><td>**Mark Kaye:** ê°€ì¥ ì¤‘ìš”í•œ ì ì€, í—¬ìŠ¤ ë² ë„¤í•(Health Benefits) ë‚´ ì–´ë–¤ ì‚¬ì—… ë¶€ë¬¸ì˜ ê¸°ë³¸ ë§ˆì§„ ê¸°ëŒ€ì¹˜ë„ ë³€ê²½í•˜ì§€ ì•Šì•˜ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ê°€ ë¶€ë‹´í•˜ëŠ” ë¦¬ìŠ¤í¬ì™€ ê³ ìš©ì£¼ ë° ì •ë¶€ í”„ë¡œê·¸ë¨ì— ì œê³µí•˜ëŠ” ê°€ì¹˜ë¥¼ ê³„ì† ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë³€ê²½ëœ ê²ƒì€ í—¬ìŠ¤ ë² ë„¤í• ë¶€ë¬¸ ë§ˆì§„ì„ í˜„ì¬ ìš´ì˜ ì¤‘ì¸ í¬íŠ¸í´ë¦¬ì˜¤ì— ë§ì¶° ì¡°ì •í•˜ëŠ” ë°©ì‹ì´ë©°, ì´ëŠ” ìš°ë¦¬ê°€ í•­ìƒ ì‚¬ìš©í•´ì˜¨ ë™ì¼í•œ ì‚¬ì—… ë¶€ë¬¸ ë§ˆì§„ í”„ë ˆì„ì›Œí¬ë¥¼ ì ìš©í•œ ê²ƒì…ë‹ˆë‹¤. <br><br>ë†’ì€ ë¹„ìš© ì¶”ì„¸ í™˜ê²½ì„ ê²ªìœ¼ë©´ì„œ, ìƒì—… ë¶€ë¬¸(Commercial) ì„±ì¥ì€ ë‹¹ì´ˆ ì˜ˆìƒë³´ë‹¤ ë” ì‹ ì¤‘í•˜ê²Œ ì§„í–‰ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ê°€ ê±°ë˜ëŸ‰ë³´ë‹¤ ì—„ê²©í•œ ê°€ê²© ì±…ì •ê³¼ ë§ˆì§„ ê±´ì „ì„±ì„ ìš°ì„ ì‹œí–ˆê¸° ë•Œë¬¸ì´ê¸°ë„ í•©ë‹ˆë‹¤. ë™ì‹œì— ìƒì—… ë¶€ë¬¸ ë‚´ êµ¬ì„±ë„ ë³€í™”í–ˆìŠµë‹ˆë‹¤. í˜„ì¬ ê°œì¸ ACAê°€ ê·¸ë£¹ ìƒì—… ë³´í—˜ ëŒ€ë¹„ í•´ë‹¹ ë¶€ë¬¸ì—ì„œ ë” í° ë¹„ì¤‘ì„ ì°¨ì§€í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ë‹¹ì—°íˆ ë‹¤ë¥¸ ë§ˆì§„ í”„ë¡œíŒŒì¼ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­í•™ê´€ê³„ë¥¼ ê¸°ì¡´ ì‚¬ì—… ë¶€ë¬¸ë³„ ë§ˆì§„ ë²”ìœ„ì— ë°˜ì˜í•˜ë©´, ê·¸ ê²°ê³¼ê°€ ë°”ë¡œ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ëŒ€ì˜ ê±´ê°•ê¸‰ì—¬ ë¶€ë¬¸ ë§ˆì§„ ì „ë§ì…ë‹ˆë‹¤.<br><br>ì—¬ê¸°ì„œ í•µì‹¬ì€, ì´ê²ƒì´ ì „ëµì˜ ë³€í™”ë‚˜ ì¸ìˆ˜ ê·œìœ¨ ë˜ëŠ” ê°€ê²© ì±…ì •ì˜ ë³€í™”ì™€ëŠ” ë¬´ê´€í•˜ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŠ” ë‹¨ìˆœíˆ ì˜¤ëŠ˜ë‚  ìš°ë¦¬ ì‚¬ì—…ì˜ ë¯¹ìŠ¤ë¥¼ ë³´ë‹¤ ì •í™•í•˜ê²Œ ë°˜ì˜í•˜ê³  ìš´ì˜ í™˜ê²½ì— ëŒ€í•œ ì‹ ì¤‘í•œ ê´€ì ì„ ë‹´ê¸° ìœ„í•œ ì¬ì¡°ì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director And why don't we have Pete talk a little bit about Carelon.</td><td>**Gail Boudreaux:** <budget:token_budget>200000</budget:token_budget><br><br>Peteê°€ Carelonì— ëŒ€í•´ ì¡°ê¸ˆ ì„¤ëª…í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Peter Haytaian: Executive VP and President of Carelon & CarelonRx Okay. No, thanks a lot for the question, Ann. So you asked about the Rx margins longer term. And yes, we are adjusting them. It's a positive story around really growth and diversification of our portfolio. As we talked about, we're seeing a lot of growth in Rx. And in fact, just to reflect on what happened this past year, headed into 2026, it was our best growth year ever. And part of that is the composition of the business that we're growing through. We're starting to see a lot more large upmarket jumbo accounts flowing through our business. That's one factor, and that comes with a different margin profile. In addition, we continue to build out our specialty business, and that's going really well, both internally and externally. And again, that comes with a bit of a lower margin profile. And you've heard Gail and Mark talk about the investments that we're making in that regard. And then finally, I would say, longer term, we're very mindful and respectful of what's going on from a policy perspective. And I think we're being very prudent in this regard as we think about the longer-term profile of the Rx business. Thanks for that question.</td><td>**Peter Haytaian:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. Rx ë§ˆì§„ì˜ ì¥ê¸° ì „ë§ì— ëŒ€í•´ ì§ˆë¬¸í•˜ì…¨ëŠ”ë°ìš”, ë§ìŠµë‹ˆë‹¤. ì €í¬ê°€ ì¡°ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” í¬íŠ¸í´ë¦¬ì˜¤ì˜ ì„±ì¥ê³¼ ë‹¤ê°í™”ì™€ ê´€ë ¨ëœ ê¸ì •ì ì¸ ì´ì•¼ê¸°ì…ë‹ˆë‹¤. ë§ì”€ë“œë ¸ë“¯ì´ Rx ë¶€ë¬¸ì—ì„œ ìƒë‹¹í•œ ì„±ì¥ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ì§€ë‚œí•´ë¥¼ ëŒì´ì¼œë³´ë©´, 2026ë…„ì„ ì•ë‘ê³  ì—­ëŒ€ ìµœê³ ì˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë¶€ë¶„ì ìœ¼ë¡œ ìš°ë¦¬ê°€ ì„±ì¥ì‹œí‚¤ê³  ìˆëŠ” ì‚¬ì—… êµ¬ì„±ì— ê¸°ì¸í•©ë‹ˆë‹¤. ëŒ€í˜• ìƒìœ„ì‹œì¥ì˜ ì´ˆëŒ€í˜• ê³ ê°ë“¤ì´ ìš°ë¦¬ ì‚¬ì—…ìœ¼ë¡œ ë§ì´ ìœ ì…ë˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ í•œ ê°€ì§€ ìš”ì¸ì´ê³ , ì´ëŸ¬í•œ ê³ ê°ë“¤ì€ ë‹¤ë¥¸ ë§ˆì§„ êµ¬ì¡°ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì „ë¬¸ì˜ì•½í’ˆ(specialty) ì‚¬ì—…ì„ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ê³  ìˆìœ¼ë©°, ë‚´ë¶€ì ìœ¼ë¡œë‚˜ ì™¸ë¶€ì ìœ¼ë¡œ ëª¨ë‘ ë§¤ìš° ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¤ì‹œ ë§ì”€ë“œë¦¬ë©´, ì´ ë¶€ë¶„ì€ ë§ˆì§„ìœ¨ì´ ë‹¤ì†Œ ë‚®ì€ íŠ¹ì„±ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. Gailê³¼ Markê°€ ì´ì™€ ê´€ë ¨í•´ì„œ ìš°ë¦¬ê°€ ì§„í–‰í•˜ê³  ìˆëŠ” íˆ¬ìë“¤ì— ëŒ€í•´ ë§ì”€ë“œë¦° ê²ƒì„ ë“¤ìœ¼ì…¨ì„ ê²ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ì¥ê¸°ì  ê´€ì ì—ì„œ ë§ì”€ë“œë¦¬ìë©´, ìš°ë¦¬ëŠ” ì •ì±…ì  ì¸¡ë©´ì—ì„œ ì§„í–‰ë˜ê³  ìˆëŠ” ìƒí™©ë“¤ì„ ë§¤ìš° ì£¼ì˜ ê¹Šê²Œ ì¸ì‹í•˜ê³  ì¡´ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì²˜ë°©ì•½(Rx) ì‚¬ì—…ì˜ ì¥ê¸°ì ì¸ í”„ë¡œí•„ì„ ê³ ë ¤í•  ë•Œ ì´ëŸ¬í•œ ì¸¡ë©´ì—ì„œ ë§¤ìš° ì‹ ì¤‘í•˜ê²Œ ì ‘ê·¼í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Ryan Langston from TD Cowen.</td><td>**Operator:** ë‹¤ìŒì€ TD Cowenì˜ Ryan Langston ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Christian Borgmeyer: TD Cowen, Research Division This is Christian Borgmeyer on for Ryan Langston. Can you share where you began the year in terms of ACA membership after the annual enrollment period? Data on sign-ups nationally came in higher than we expected given the expiring subsidies but I know there's some attrition typically in the first quarter. And I know it's early in the year, but any notable changes in utilization patterns from this line of business in January?</td><td>**Christian Borgmeyer:** TD Cowen ë¦¬ì„œì¹˜ ë¶€ë¬¸ì˜ Ryan Langstonì„ ëŒ€ì‹ í•˜ì—¬ Christian Borgmeyerì…ë‹ˆë‹¤. ì—°ê°„ ë“±ë¡ ê¸°ê°„ ì´í›„ ACA íšŒì› ìˆ˜ê°€ ì–´ë–»ê²Œ ì‹œì‘ë˜ì—ˆëŠ”ì§€ ê³µìœ í•´ ì£¼ì‹¤ ìˆ˜ ìˆìœ¼ì‹ ê°€ìš”? ë³´ì¡°ê¸ˆ ë§Œë£Œë¥¼ ê³ ë ¤í•  ë•Œ ì „êµ­ì ì¸ ê°€ì… ë°ì´í„°ê°€ ì˜ˆìƒë³´ë‹¤ ë†’ê²Œ ë‚˜ì™”ëŠ”ë°, ë³´í†µ 1ë¶„ê¸°ì— ì¼ë¶€ ì´íƒˆì´ ìˆëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—°ì´ˆë¼ëŠ” ì ì€ ì•Œê³  ìˆì§€ë§Œ, 1ì›”ì— ì´ ì‚¬ì—… ë¶€ë¬¸ì—ì„œ ì£¼ëª©í•  ë§Œí•œ ì´ìš© íŒ¨í„´ ë³€í™”ê°€ ìˆì—ˆëŠ”ì§€ìš”?</td></tr>
<tr><td>Mark Kaye: Executive VP & CFO Christian, thank you very much for the question. On the individual ACA, we are guiding towards at least 900,000 members at year-end 2026. And that outlook really reflects 2 drivers here. First, the expiration of the enhanced premium tax credits, which we expect is going to pressure retention and increase lapse activity; and second, intentional exits that we've made as part of our repositioning of the book for a more sustainable profile. Importantly, coming out of open enrollment, membership is up approximately 10%, and that's helped in part by some of the modest growth that we've seen in markets we first entered in 2025, which offsets some of the intentional attrition that we expected in our core blue states. Overall, I'd say trends through open enrollment are largely in line with what we've seen in the broader market. The key swing factor, and I think this gets to the heart of your question, is really now effectuation rates. And that's going to come down to member premium payments and lapse behavior. And that typically is going to become much clearer through early April as members work through that normal billing cycle over the next few months.</td><td>**Mark Kaye:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ê°œì¸ ACA ì‚¬ì—…ì˜ ê²½ìš°, 2026ë…„ ë§ê¹Œì§€ ìµœì†Œ 90ë§Œ ëª…ì˜ íšŒì›ì„ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì „ë§ì—ëŠ” ë‘ ê°€ì§€ ì£¼ìš” ìš”ì¸ì´ ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì²«ì§¸, ê°•í™”ëœ ë³´í—˜ë£Œ ì„¸ì•¡ê³µì œ(enhanced premium tax credits)ì˜ ë§Œë£Œë¡œ ì¸í•´ íšŒì› ìœ ì§€ìœ¨ì´ ì••ë°•ì„ ë°›ê³  í•´ì§€ìœ¨ì´ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë‘˜ì§¸, ë³´ë‹¤ ì§€ì† ê°€ëŠ¥í•œ í¬íŠ¸í´ë¦¬ì˜¤ êµ¬ì¡°ë¥¼ ìœ„í•´ ìš°ë¦¬ê°€ ì˜ë„ì ìœ¼ë¡œ ì§„í–‰í•œ ì‹œì¥ ì² ìˆ˜ê°€ ìˆìŠµë‹ˆë‹¤. <br><br>ì¤‘ìš”í•œ ì ì€, ê³µê°œ ê°€ì… ê¸°ê°„ì„ ë§ˆì¹˜ê³  íšŒì› ìˆ˜ê°€ ì•½ 10% ì¦ê°€í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ë¶€ë¶„ì ìœ¼ë¡œ 2025ë…„ì— ìƒˆë¡­ê²Œ ì§„ì…í•œ ì‹œì¥ì—ì„œ ë‚˜íƒ€ë‚œ ì™„ë§Œí•œ ì„±ì¥ ë•ë¶„ì´ë©°, ì´ê²ƒì´ í•µì‹¬ ë¸”ë£¨ ìŠ¤í…Œì´íŠ¸(blue states)ì—ì„œ ì˜ˆìƒí–ˆë˜ ì˜ë„ì ì¸ íšŒì› ê°ì†Œë¥¼ ìƒì‡„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ì˜¤í”ˆ ë“±ë¡ ê¸°ê°„ ë™ì•ˆì˜ ì¶”ì„¸ëŠ” ì „ì²´ ì‹œì¥ì—ì„œ ë³´ê³  ìˆëŠ” ê²ƒê³¼ ëŒ€ì²´ë¡œ ì¼ì¹˜í•œë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•µì‹¬ ë³€ìˆ˜ëŠ”, ê·¸ë¦¬ê³  ì´ê²ƒì´ ì§ˆë¬¸ì˜ í•µì‹¬ì´ë¼ê³  ìƒê°í•˜ëŠ”ë°, ë°”ë¡œ ì‹¤íš¨ìœ¨ì…ë‹ˆë‹¤. ì´ëŠ” íšŒì›ë“¤ì˜ ë³´í—˜ë£Œ ë‚©ë¶€ì™€ ì‹¤íš¨ í–‰íƒœì— ë‹¬ë ¤ ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ í†µìƒì ìœ¼ë¡œ íšŒì›ë“¤ì´ í–¥í›„ ëª‡ ê°œì›”ì— ê±¸ì³ ì •ìƒì ì¸ ì²­êµ¬ ì£¼ê¸°ë¥¼ ê±°ì¹˜ë©´ì„œ 4ì›” ì´ˆê°€ ë˜ë©´ í›¨ì”¬ ë” ëª…í™•í•´ì§ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Scott Fidel from Goldman Sachs.</td><td>**Operator:** ë‹¤ìŒì€ ê³¨ë“œë§Œì‚­ìŠ¤ì˜ ìŠ¤ì½§ í”¼ë¸ ë‹˜ ì§ˆë¬¸ ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Scott Fidel: Goldman Sachs Group, Inc., Research Division Just interested if you could provide us with an update on capital deployment priorities for the 2026. And in particular, maybe just sort of touch on the M&A priorities in terms of, one, just appetite for doing transactions this year, just given the dynamic backdrop. And then two, looking over the last several years, certainly, you've had a lot of activity on the M&A side on Carelon Services and in particular, acquiring risk-based platforms to integrate into that. Just interested if that remains a priority at this point or whether you're more focused on integration of those assets you've acquired over the last several years.</td><td>**Scott Fidel:** 2026ë…„ ìë³¸ ë°°ì¹˜ ìš°ì„ ìˆœìœ„ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ë¥¼ ë¶€íƒë“œë¦½ë‹ˆë‹¤. íŠ¹íˆ M&A ìš°ì„ ìˆœìœ„ì™€ ê´€ë ¨í•´ì„œ ë‘ ê°€ì§€ë¥¼ ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤. ì²«ì§¸, í˜„ì¬ì˜ ì—­ë™ì ì¸ í™˜ê²½ì„ ê³ ë ¤í•  ë•Œ ì˜¬í•´ ê±°ë˜ ì§„í–‰ì— ëŒ€í•œ ì˜í–¥ì´ ì–´ëŠ ì •ë„ì¸ì§€ìš”. ë‘˜ì§¸, ì§€ë‚œ ëª‡ ë…„ê°„ Carelon Services ë¶€ë¬¸ì—ì„œ M&A í™œë™ì´ ìƒë‹¹íˆ í™œë°œí–ˆê³ , íŠ¹íˆ ìœ„í—˜ê¸°ë°˜ í”Œë«í¼(risk-based platforms)ì„ ì¸ìˆ˜í•´ì„œ í†µí•©í•˜ëŠ” ì‘ì—…ì„ ë§ì´ í•˜ì…¨ëŠ”ë°ìš”. ì´ê²ƒì´ ì—¬ì „íˆ ìš°ì„ ìˆœìœ„ì¸ì§€, ì•„ë‹ˆë©´ ì§€ë‚œ ëª‡ ë…„ê°„ ì¸ìˆ˜í•œ ìì‚°ë“¤ì˜ í†µí•©ì— ë” ì§‘ì¤‘í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Mark Kaye: Executive VP & CFO Thank you very much for the question. I would say in the near term, our capital allocation is going to reflect a more conservative posture. Our priority here look is to maintain balance sheet strength and strong credit profile, fund targeted investments that accelerate margin stabilization and Carelon's continued growth and then to remain opportunistic around share repurchases, especially where we see compelling value. Over the longer term, the capital allocation framework is unchanged. We remain completely committed to a balance sheet approach or balanced approach that supports our long-term growth algorithm, including reinvestment back into the business, disciplined M&A focused on some of the integration or integrated capabilities that have strengthened our competitive position and then, of course, consistent capital return back to shareholders through dividends and share repurchases. On M&A specifically, our near-term priority is really focused on that integration and execution, really fully scaling and realizing the value from recent acquisitions. And so at least in the first half of 2026, you should expect a lower level of M&A activity and a much greater relative emphasis on opportunistic share repurchases.</td><td>**Mark Kaye:** ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ë‹¨ê¸°ì ìœ¼ë¡œ ìš°ë¦¬ì˜ ìë³¸ ë°°ë¶„ì€ ë³´ë‹¤ ë³´ìˆ˜ì ì¸ ì…ì¥ì„ ë°˜ì˜í•  ê²ƒì…ë‹ˆë‹¤. ì—¬ê¸°ì„œ ìš°ë¦¬ì˜ ìš°ì„ ìˆœìœ„ëŠ” ëŒ€ì°¨ëŒ€ì¡°í‘œ ê±´ì „ì„±ê³¼ ê°•ë ¥í•œ ì‹ ìš© í”„ë¡œí•„ì„ ìœ ì§€í•˜ê³ , ë§ˆì§„ ì•ˆì •í™”ë¥¼ ê°€ì†í™”í•˜ëŠ” ëª©í‘œ íˆ¬ìì™€ Carelonì˜ ì§€ì†ì ì¸ ì„±ì¥ì— ìê¸ˆì„ ì§€ì›í•˜ë©°, íŠ¹íˆ ë§¤ë ¥ì ì¸ ê°€ì¹˜ê°€ ë³´ì´ëŠ” ê²½ìš° ìì‚¬ì£¼ ë§¤ì…ì— ëŒ€í•´ ê¸°íšŒì£¼ì˜ì ìœ¼ë¡œ ëŒ€ì‘í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì¥ê¸°ì ìœ¼ë¡œëŠ” ìë³¸ ë°°ë¶„ í”„ë ˆì„ì›Œí¬ì— ë³€í™”ê°€ ì—†ìŠµë‹ˆë‹¤. ì¥ê¸° ì„±ì¥ ì•Œê³ ë¦¬ì¦˜ì„ ë’·ë°›ì¹¨í•˜ëŠ” ê· í˜•ì¡íŒ ëŒ€ì°¨ëŒ€ì¡°í‘œ ì ‘ê·¼ë°©ì‹ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì˜ì§€ëŠ” í™•ê³ í•©ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì‚¬ì—… ì¬íˆ¬ì, ìš°ë¦¬ì˜ ê²½ìŸë ¥ì„ ê°•í™”ì‹œí‚¨ í†µí•© ì—­ëŸ‰ì— ì´ˆì ì„ ë§ì¶˜ ê·œìœ¨ìˆëŠ” M&A, ê·¸ë¦¬ê³  ë°°ë‹¹ê³¼ ìì‚¬ì£¼ ë§¤ì…ì„ í†µí•œ ì¼ê´€ëœ ì£¼ì£¼í™˜ì›ì´ í¬í•¨ë©ë‹ˆë‹¤. M&Aì™€ ê´€ë ¨í•´ì„œëŠ”, ë‹¨ê¸°ì ìœ¼ë¡œ ìµœê·¼ ì¸ìˆ˜ ê±´ë“¤ì˜ í†µí•©ê³¼ ì‹¤í–‰, ê·¸ë¦¬ê³  ê°€ì¹˜ ì‹¤í˜„ì— ì§‘ì¤‘í•˜ëŠ” ê²ƒì´ ìš°ì„ ìˆœìœ„ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì ì–´ë„ 2026ë…„ ìƒë°˜ê¸°ê¹Œì§€ëŠ” M&A í™œë™ì´ ë‚®ì€ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³ , ê¸°íšŒì  ìì‚¬ì£¼ ë§¤ì…ì— í›¨ì”¬ ë” í° ë¹„ì¤‘ì„ ë‘ëŠ” ëª¨ìŠµì„ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Kevin Fischbeck from Bank of America.</td><td>**Operator:** ë‹¤ìŒì€ ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ì˜ ì¼€ë¹ˆ í”¼ì‹œë²¡ ë‹˜ ì§ˆë¬¸ ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Kevin Fischbeck: BofA Securities, Research Division Great. I wanted to follow up kind of on this margin commentary and the changes that you're doing there. I guess maybe putting it in a framework of just the changes that you had in the enrollment across the different businesses. I definitely applaud when managed care companies exit markets that aren't profitable, low margin. I think it's 100% the right thing to do. But given that the membership numbers have been lower than we would have thought, I guess, across most of the products, is there anything that we should be reading into as far as where you are strategically or competitively in these markets? The magnitude is more than we would have expected, and it's a broad-based across-the-board dynamics. So just trying to understand there's something we should be reading into this and why like this business mix that you're now forecasting is different than the business mix you thought a few years ago when you provided your previous margin assumptions?</td><td>**Kevin Fischbeck:** ì¢‹ìŠµë‹ˆë‹¤. ë§ˆì§„ì— ëŒ€í•œ ë…¼í‰ê³¼ ê·¸ì™€ ê´€ë ¨í•´ ì§„í–‰ ì¤‘ì¸ ë³€í™”ë“¤ì— ëŒ€í•´ í›„ì† ì§ˆë¬¸ì„ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ì—¬ëŸ¬ ì‚¬ì—…ë¶€ë¬¸ì— ê±¸ì¹œ ê°€ì…ì ë³€í™”ë¥¼ í”„ë ˆì„ì›Œí¬ë¡œ ë†“ê³  ë§ì”€ë“œë¦¬ìë©´, ê´€ë¦¬ì˜ë£Œ ê¸°ì—…ë“¤ì´ ìˆ˜ìµì„±ì´ ë‚®ê±°ë‚˜ ë§ˆì§„ì´ ë‚®ì€ ì‹œì¥ì—ì„œ ì² ìˆ˜í•˜ëŠ” ê²ƒì€ ì €ë„ ì „ì ìœ¼ë¡œ í™˜ì˜í•©ë‹ˆë‹¤. 100% ì˜³ì€ ê²°ì •ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ëŒ€ë¶€ë¶„ì˜ ìƒí’ˆì—ì„œ ê°€ì…ì ìˆ˜ê°€ ì˜ˆìƒë³´ë‹¤ ë‚®ì•˜ë‹¤ëŠ” ì ì„ ê³ ë ¤í•  ë•Œ, ì´ëŸ¬í•œ ì‹œì¥ì—ì„œ ê·€ì‚¬ì˜ ì „ëµì  í¬ì§€ì…˜ì´ë‚˜ ê²½ìŸë ¥ê³¼ ê´€ë ¨í•´ ìš°ë¦¬ê°€ ì½ì–´ì•¼ í•  ë¶€ë¶„ì´ ìˆì„ê¹Œìš”? ê°ì†Œ ê·œëª¨ê°€ ì˜ˆìƒë³´ë‹¤ í¬ê³ , ì „ë°˜ì ìœ¼ë¡œ ê´‘ë²”ìœ„í•˜ê²Œ ë‚˜íƒ€ë‚˜ëŠ” í˜„ìƒì´ë¼ì„œìš”. <response><br><br>ëª‡ ë…„ ì „ ë§ˆì§„ ê°€ì •ì„ ì œì‹œí–ˆì„ ë•Œì™€ ë¹„êµí•´ì„œ, ì§€ê¸ˆ ì˜ˆìƒí•˜ê³  ìˆëŠ” ì‚¬ì—… ë¯¹ìŠ¤ê°€ ë‹¬ë¼ì§„ ê²ƒì— ëŒ€í•´ ìš°ë¦¬ê°€ ì£¼ëª©í•´ì•¼ í•  íŠ¹ë³„í•œ ì˜ë¯¸ê°€ ìˆëŠ”ì§€ ì´í•´í•˜ë ¤ê³  í•©ë‹ˆë‹¤. ì™œ ì´ëŸ° ì‚¬ì—… ë¯¹ìŠ¤ ë³€í™”ê°€ ë°œìƒí–ˆëŠ”ì§€ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?<br><br></response></td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director Yes. Thanks for the question. I guess I would simply say the headline is no. This is a very disciplined approach in each of the businesses. And let me just touch on them. In the Commercial business, we made very specific decisions around the ACA and feel very good about the sustainability of where the platform and the membership is coming out. As you heard from Mark a few minutes ago, I think we've been -- we positioned ourselves well for sustainable business there. On the broader Commercial risk-based business, we actually had quite high retention amongst our Commercial business, but made some very conscious pricing decisions around public sector accounts that have been below profitability. So again, this is a repositioning of the portfolio ready for growth. On the ASO, we had a very strong national account selling season with great retention. I think Medicaid represents really just the redetermination impacts, but we continue to grow and have won accounts in some of the more complex populations. So again, feel good there. And I feel very good about the positioning in Medicare Advantage. We came into this. We are very clear what we needed to do. As you heard, we believe we have improved our margin and again, our sustainability. So I actually would say where we are entering '26, we feel quite strongly positioned for future growth in a very sustainable, strong margin position. So thanks for the question.</td><td>**Gail Boudreaux:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ê²°ë¡ ë¶€í„° ë§ì”€ë“œë¦¬ë©´ ì•„ë‹™ë‹ˆë‹¤. ê° ì‚¬ì—…ë¶€ë¬¸ì—ì„œ ë§¤ìš° ì²´ê³„ì ì¸ ì ‘ê·¼ë°©ì‹ì„ ì·¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê° ë¶€ë¬¸ë³„ë¡œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>Commercial ì‚¬ì—…ì˜ ê²½ìš°, ACA(Affordable Care Act, ê±´ê°•ë³´í—˜ê°œí˜ë²•)ì™€ ê´€ë ¨í•˜ì—¬ ë§¤ìš° êµ¬ì²´ì ì¸ ì˜ì‚¬ê²°ì •ì„ ë‚´ë ¸ìœ¼ë©°, í”Œë«í¼ê³¼ íšŒì› ê¸°ë°˜ì˜ ì§€ì†ê°€ëŠ¥ì„±ì— ëŒ€í•´ í™•ì‹ ì„ ê°–ê³  ìˆìŠµë‹ˆë‹¤. ì¡°ê¸ˆ ì „ Markê°€ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ìš°ë¦¬ëŠ” ì§€ì†ê°€ëŠ¥í•œ ì‚¬ì—…ì„ ìœ„í•œ ì¢‹ì€ í¬ì§€ì…”ë‹ì„ êµ¬ì¶•í–ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë” ë„“ì€ ë²”ìœ„ì˜ Commercial ìœ„í—˜ê¸°ë°˜ ì‚¬ì—…ì—ì„œëŠ” ì‹¤ì œë¡œ ìƒë‹¹íˆ ë†’ì€ ê³ ê° ìœ ì§€ìœ¨ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ë‹¤ë§Œ ìˆ˜ìµì„±ì´ ë‚®ì•˜ë˜ ê³µê³µë¶€ë¬¸ ê³„ì •ë“¤ì— ëŒ€í•´ì„œëŠ” ì˜ë„ì ìœ¼ë¡œ ê°€ê²© ê²°ì •ì„ ë‚´ë ¸ìŠµë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì´ëŠ” ì„±ì¥ì„ ìœ„í•œ í¬íŠ¸í´ë¦¬ì˜¤ ì¬í¸ì„± ì‘ì—…ì…ë‹ˆë‹¤. ASO ë¶€ë¬¸ì—ì„œëŠ” ìš°ìˆ˜í•œ ê³ ê° ìœ ì§€ìœ¨ì„ ë³´ì´ë©° ë§¤ìš° ê°•ë ¥í•œ ì „êµ­ ë‹¨ìœ„ ê³„ì•½ íŒë§¤ ì‹œì¦Œì„ ë³´ëƒˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œ(Medicaid)ì˜ ê²½ìš° ì¬ê²°ì • ì˜í–¥ë§Œì„ ë°˜ì˜í•˜ê³  ìˆì§€ë§Œ, ìš°ë¦¬ëŠ” ì§€ì†ì ìœ¼ë¡œ ì„±ì¥í•˜ê³  ìˆìœ¼ë©° ë” ë³µì¡í•œ ê°€ì…ì ì§‘ë‹¨ì—ì„œë„ ê³„ì•½ì„ ë”°ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ ë¶€ë¶„ë„ ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€(Medicare Advantage) í¬ì§€ì…”ë‹ì— ëŒ€í•´ì„œë„ ë§¤ìš° ë§Œì¡±ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¬´ì—‡ì„ í•´ì•¼ í•˜ëŠ”ì§€ ëª…í™•íˆ ì•Œê³  ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ìš°ë¦¬ëŠ” ë§ˆì§„ì„ ê°œì„ í–ˆê³  ì§€ì†ê°€ëŠ¥ì„±ë„ ë†’ì˜€ë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤. ë”°ë¼ì„œ 26ë…„ë„ì— ì§„ì…í•˜ëŠ” ì‹œì ì—ì„œ, ìš°ë¦¬ëŠ” ë§¤ìš° ì§€ì†ê°€ëŠ¥í•˜ê³  ê°•ë ¥í•œ ë§ˆì§„ í¬ì§€ì…˜ì„ ë°”íƒ•ìœ¼ë¡œ í–¥í›„ ì„±ì¥ì„ ìœ„í•œ ìƒë‹¹íˆ ê°•ë ¥í•œ ìœ„ì¹˜ë¥¼ í™•ë³´í–ˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to Erin Wright from Morgan Stanley.</td><td>**Operator:** ë‹¤ìŒì€ ëª¨ê±´ìŠ¤íƒ ë¦¬ì˜ ì—ë¦° ë¼ì´íŠ¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Erin Wilson Wright: Morgan Stanley, Research Division So clearly, the industry was somewhat caught off guard with the MA rate notice this week. And just can you remind us of just your response? I think we know that to some extent, but your just ability to mitigate this on top of the cuts that you're making this year as well. I assume you'll continue to take a disciplined approach here. And just your thoughts on what this means for the industry, for the MA market as a whole and from a policy perspective and what we could see going forward? And just do you think also more specifically, some of the risk adjustment changes being made, are you more or less exposed relative to the industry on that front?</td><td>**Erin Wilson Wright:** ì´ë²ˆ ì£¼ MA(Medicare Advantage) ìˆ˜ê°€ ê³µì§€ë¡œ ì—…ê³„ê°€ ë‹¤ì†Œ ì˜ˆìƒì¹˜ ëª»í•œ ìƒí™©ì„ ë§ì´í•œ ê²ƒì´ ì‚¬ì‹¤ì…ë‹ˆë‹¤. ê·€ì‚¬ì˜ ëŒ€ì‘ ë°©ì•ˆì„ ë‹¤ì‹œ í•œë²ˆ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ì–´ëŠ ì •ë„ëŠ” ì•Œê³  ìˆë‹¤ê³  ìƒê°í•˜ì§€ë§Œ, ì˜¬í•´ ì§„í–‰ ì¤‘ì¸ ë¹„ìš© ì ˆê°ì— ë”í•´ ì´ë¥¼ ì™„í™”í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì— ëŒ€í•´ ë§ì”€ ë¶€íƒë“œë¦½ë‹ˆë‹¤. ì—¬ê¸°ì„œë„ ê·œìœ¨ ìˆëŠ” ì ‘ê·¼ ë°©ì‹ì„ ê³„ì† ìœ ì§€í•˜ì‹¤ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ëŠ”ë°ìš”. ì´ë²ˆ ì¡°ì¹˜ê°€ ì—…ê³„ ì „ë°˜ê³¼ MA ì‹œì¥ ì „ì²´ì— ì–´ë–¤ ì˜ë¯¸ë¥¼ ê°–ëŠ”ì§€, ê·¸ë¦¬ê³  ì •ì±…ì  ê´€ì ì—ì„œ í–¥í›„ ì–´ë–¤ ìƒí™©ì„ ì˜ˆìƒí•  ìˆ˜ ìˆì„ì§€ì— ëŒ€í•œ ê²¬í•´ë¥¼ ë“£ê³  ì‹¶ìŠµë‹ˆë‹¤. ë˜í•œ ì¢€ ë” êµ¬ì²´ì ìœ¼ë¡œ, ìœ„í—˜ë„ ì¡°ì •(risk adjustment) ë³€ê²½ ì‚¬í•­ê³¼ ê´€ë ¨í•´ì„œ ê·€ì‚¬ê°€ ì—…ê³„ ëŒ€ë¹„ ë” ë§ì´ ë…¸ì¶œë˜ì–´ ìˆëŠ”ì§€ ì•„ë‹ˆë©´ ëœ ë…¸ì¶œë˜ì–´ ìˆëŠ”ì§€ë„ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director Yes. Well, thank you for the question, Erin. I'll start with just your sort of between the lines question, which is we will continue to take a very disciplined approach and positioning of our Medicare book. But I think it's important to start off by first framing the implications of the advanced notice. Medicare Advantage is a critically important program for seniors, and it brings together, as we've said, affordable coverage, coordinated care and supplemental benefits that members rely on to stay healthy and independent. We are still going through the details. We just got them of the advanced notice. But at a high level, the advanced notice is effectively flat, which you've all reported on. And quite frankly, it just doesn't keep pace with the current medical cost and utilization trends, and that does create real pressure on benefit stability and affordability for seniors. For MA to remain strong, the program needs to be stable and sustainable and stability gets undermined when payment rates don't keep pace with the utilization and cost trends, especially as the member's needs grow more and more complex. So we're going to continue to advocate, obviously, because if funding consistently lags the reality on the ground, the levers that we have are benefits, networks, premiums and exiting geographies. And quite frankly, that's not good for seniors, and I don't think it's good for the program. And we do believe this -- we see more than 55% of seniors selecting this program. So it's very popular. We're also supportive of the measures that protect the integrity of the risk adjustment program. Now if you think back, risk adjustment exists for a reason. It's to ensure that plans are paid appropriately for the health status of the members they serve. So as we look ahead, we're going to continue to work with CMS on 2 things that have to go together. One is the appropriate funding that reflects the actual utilization and cost trends to support program stability; and two, as changes to that risk adjustment framework are proposed, they need to be accurate and predictable and trusted to avoid disruption, I think, and negatively impacting seniors. So our priority is, again, work with CMS and also protect seniors access and affordability because we know it's a very popular program that delivers significant value for seniors. So thanks very much for the question.</td><td>**Gail Boudreaux:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Erin. ë¨¼ì € ì§ˆë¬¸ì— ë‹´ê¸´ ì˜ë„ë¶€í„° ë§ì”€ë“œë¦¬ìë©´, ì €í¬ëŠ” ë©”ë””ì¼€ì–´ ì‚¬ì—…ì— ëŒ€í•´ ë§¤ìš° ê·œìœ¨ ìˆëŠ” ì ‘ê·¼ ë°©ì‹ê³¼ í¬ì§€ì…”ë‹ì„ ê³„ì† ìœ ì§€í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ë¨¼ì € ì‚¬ì „ ê³µê³ (advanced notice)ì˜ ì˜ë¯¸ë¥¼ ì§šê³  ë„˜ì–´ê°€ëŠ” ê²ƒì´ ì¤‘ìš”í•˜ë‹¤ê³  ë´…ë‹ˆë‹¤. ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€(Medicare Advantage)ëŠ” ê³ ë ¹ì¸µì—ê²Œ ë§¤ìš° ì¤‘ìš”í•œ í”„ë¡œê·¸ë¨ì…ë‹ˆë‹¤. ì €í¬ê°€ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì´ í”„ë¡œê·¸ë¨ì€ í•©ë¦¬ì ì¸ ë³´ì¥, í†µí•©ì ì¸ ì¼€ì–´, ê·¸ë¦¬ê³  íšŒì›ë“¤ì´ ê±´ê°•í•˜ê³  ë…ë¦½ì ì¸ ìƒí™œì„ ìœ ì§€í•˜ëŠ” ë° í•„ìš”í•œ ë¶€ê°€ í˜œíƒë“¤ì„ í•˜ë‚˜ë¡œ ê²°í•©í•œ ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” ì•„ì§ ì‚¬ì „ ê³µê³ ì˜ ì„¸ë¶€ ë‚´ìš©ì„ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë°©ê¸ˆ ë°›ì•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ í° í‹€ì—ì„œ ë³´ë©´, ì—¬ëŸ¬ë¶„ ëª¨ë‘ ë³´ë„í•˜ì‹  ê²ƒì²˜ëŸ¼, ì‚¬ì „ ê³µê³ ëŠ” ì‚¬ì‹¤ìƒ ë³´í•©(flat) ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, í˜„ì¬ì˜ ì˜ë£Œë¹„ìš©ê³¼ ì´ìš©ë¥  ì¶”ì„¸ë¥¼ ë”°ë¼ê°€ì§€ ëª»í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì‹œë‹ˆì–´ë“¤ì˜ ê¸‰ì—¬ ì•ˆì •ì„±ê³¼ ê²½ì œì„±ì— ì‹¤ì§ˆì ì¸ ì••ë°•ì„ ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. MA(Medicare Advantage)ê°€ ê°•ë ¥í•˜ê²Œ ìœ ì§€ë˜ë ¤ë©´ í”„ë¡œê·¸ë¨ì´ ì•ˆì •ì ì´ê³  ì§€ì† ê°€ëŠ¥í•´ì•¼ í•˜ëŠ”ë°, ì§€ê¸‰ë¥ ì´ ì´ìš©ë¥  ë° ë¹„ìš© ì¶”ì„¸ë¥¼ ë”°ë¼ê°€ì§€ ëª»í•˜ë©´, íŠ¹íˆ íšŒì›ë“¤ì˜ ë‹ˆì¦ˆê°€ ì ì  ë” ë³µì¡í•´ì§€ëŠ” ìƒí™©ì—ì„œ ì•ˆì •ì„±ì´ í›¼ì†ë©ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ê³„ì†í•´ì„œ ëª©ì†Œë¦¬ë¥¼ ë‚¼ ê²ƒì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ í€ë”©ì´ ì§€ì†ì ìœ¼ë¡œ í˜„ì¥ì˜ ì‹¤ìƒì— ë’¤ì²˜ì§€ë©´, ìš°ë¦¬ê°€ í™œìš©í•  ìˆ˜ ìˆëŠ” ìˆ˜ë‹¨ì€ ê¸‰ì—¬, ë„¤íŠ¸ì›Œí¬, ë³´í—˜ë£Œ, ê·¸ë¦¬ê³  ì§€ì—­ ì² ìˆ˜ë¿ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì†”ì§íˆ ë§í•´ì„œ ì´ëŠ” ì‹œë‹ˆì–´ë“¤ì—ê²Œ ì¢‹ì§€ ì•Šê³ , í”„ë¡œê·¸ë¨ì—ë„ ì¢‹ì§€ ì•Šë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” 55% ì´ìƒì˜ ì‹œë‹ˆì–´ë“¤ì´ ì´ í”„ë¡œê·¸ë¨ì„ ì„ íƒí•˜ê³  ìˆë‹¤ëŠ” ì ì„ ì£¼ëª©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§¤ìš° ì¸ê¸°ê°€ ë†’ìŠµë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ëŠ” ìœ„í—˜ ì¡°ì •(risk adjustment) í”„ë¡œê·¸ë¨ì˜ ë¬´ê²°ì„±ì„ ë³´í˜¸í•˜ëŠ” ì¡°ì¹˜ë“¤ì„ ì§€ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìƒê°í•´ë³´ì‹œë©´, ìœ„í—˜ ì¡°ì •ì´ ì¡´ì¬í•˜ëŠ” ì´ìœ ê°€ ìˆìŠµë‹ˆë‹¤. ë³´í—˜ì‚¬ë“¤ì´ ê°€ì…ìë“¤ì˜ ê±´ê°• ìƒíƒœì— ë§ì¶° ì ì ˆí•œ ë³´ìƒì„ ë°›ì„ ìˆ˜ ìˆë„ë¡ í•˜ê¸° ìœ„í•¨ì…ë‹ˆë‹¤. ì•ìœ¼ë¡œ ìš°ë¦¬ëŠ” CMSì™€ í•¨ê»˜ ë°˜ë“œì‹œ ë³‘í–‰ë˜ì–´ì•¼ í•˜ëŠ” ë‘ ê°€ì§€ ì‚¬ì•ˆì— ëŒ€í•´ ê³„ì† í˜‘ë ¥í•  ê²ƒì…ë‹ˆë‹¤. ì²«ì§¸ëŠ” í”„ë¡œê·¸ë¨ ì•ˆì •ì„±ì„ ë’·ë°›ì¹¨í•˜ê¸° ìœ„í•´ ì‹¤ì œ ì´ìš©ë¥ ê³¼ ë¹„ìš© ì¶”ì„¸ë¥¼ ë°˜ì˜í•˜ëŠ” ì ì ˆí•œ ì¬ì› í™•ë³´ì…ë‹ˆë‹¤. ë‘˜ì§¸ëŠ” ìœ„í—˜ ì¡°ì • ì²´ê³„ì— ë³€ê²½ ì‚¬í•­ì´ ì œì•ˆë  ë•Œ, í˜¼ë€ì„ í”¼í•˜ê³  ê³ ë ¹ì¸µì—ê²Œ ë¶€ì •ì ì¸ ì˜í–¥ì„ ì£¼ì§€ ì•Šë„ë¡ ì •í™•í•˜ê³  ì˜ˆì¸¡ ê°€ëŠ¥í•˜ë©° ì‹ ë¢°í•  ìˆ˜ ìˆì–´ì•¼ í•œë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì €í¬ì˜ ìš°ì„ ìˆœìœ„ëŠ” CMSì™€ í˜‘ë ¥í•˜ê³  ê³ ë ¹ìë“¤ì˜ ì ‘ê·¼ì„±ê³¼ ê²½ì œì„±ì„ ë³´í˜¸í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ í”„ë¡œê·¸ë¨ì´ ê³ ë ¹ìë“¤ì—ê²Œ ìƒë‹¹í•œ ê°€ì¹˜ë¥¼ ì œê³µí•˜ëŠ” ë§¤ìš° ì¸ê¸° ìˆëŠ” í”„ë¡œê·¸ë¨ì´ë¼ëŠ” ê²ƒì„ ì˜ ì•Œê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Ben Hendrix from RBC Capital Markets.</td><td>**Operator:** ë‹¤ìŒì€ RBC ìºí”¼íƒˆ ë§ˆì¼“ì˜ ë²¤ í—¨ë“œë¦­ìŠ¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Benjamin Hendrix: RBC Capital Markets, Research Division I just wanted to go back quickly to the Carelon margin discussion. You noted expansion of risk-based solutions in Carelon Services through 2025. I was wondering if you could remind us of the new services and/or product lines that -- where you're taking risk? And to what degree could that expansion provide any offset to the shifting margin dynamics you mentioned in CarelonRx?</td><td>**Benjamin Hendrix:** RBC Capital Markets, Research Division ì¼€ì–´ë¡  ë§ˆì§„ ë…¼ì˜ë¡œ ì ì‹œ ëŒì•„ê°€ê³  ì‹¶ìŠµë‹ˆë‹¤. 2025ë…„ê¹Œì§€ ì¼€ì–´ë¡  ì„œë¹„ìŠ¤ì—ì„œ ìœ„í—˜ê¸°ë°˜ ì†”ë£¨ì…˜(risk-based solutions)ì˜ í™•ëŒ€ë¥¼ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°ìš”. ìœ„í—˜ì„ ë¶€ë‹´í•˜ëŠ” ìƒˆë¡œìš´ ì„œë¹„ìŠ¤ë‚˜ ì œí’ˆ ë¼ì¸ì´ ì–´ë–¤ ê²ƒë“¤ì´ ìˆëŠ”ì§€ ë‹¤ì‹œ í•œë²ˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ì´ëŸ¬í•œ í™•ëŒ€ê°€ ì¼€ì–´ë¡ Rxì—ì„œ ì–¸ê¸‰í•˜ì‹  ë§ˆì§„ êµ¬ì¡° ë³€í™”ì— ì–´ëŠ ì •ë„ ìƒì‡„ íš¨ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director I'll have Pete address your question. Thank you.</td><td>**Gail Boudreaux:** í”¼íŠ¸ê°€ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Peter Haytaian: Executive VP and President of Carelon & CarelonRx No, thanks for that question. I think it's important to step back and just talk about how we address risk in Carelon because I think it's very important strategically. We're very intentional and disciplined about how we do that and take on risk. We, as you noted, have a diverse set of services and products and offerings. And importantly, in the infrastructure of Carelon, we're very disciplined around cost of care and managing trend across all these relationships. I'd also say that we have a good mix of fee-based business as well as risk business. And then when you break down our risk portfolio, we approach it in a very different way, in a diverse way, where we're taking risk on a category of service basis in some cases as well as on a whole health risk basis. And again, we built in appropriate protections with risk corridors and discipline in terms of how we approach that. So I do think from an enterprise perspective, the way we approach that is very important in protecting our growth and our margin profile. In terms of the services in which we deploy risk because you asked that as well, it varies. In most of our product offerings, we are assuming risk, like I said, sometimes on a category of care basis or on a whole risk basis. In some instances, we're on a fee basis, but we're excited about the proliferation of that and our advancement of whole health going forward. When you think about our new offerings like SMI, when you think about what we're doing around oncology, when you think about what's happening with CareBridge, these are all risk offerings that are deploying a lot of value from a cost of care and quality perspective for the enterprise.</td><td>**Peter Haytaian:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. Carelonì—ì„œ ë¦¬ìŠ¤í¬ë¥¼ ì–´ë–»ê²Œ ë‹¤ë£¨ëŠ”ì§€ì— ëŒ€í•´ ì „ë°˜ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ëŠ” ê²ƒì´ ì¤‘ìš”í•  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì´ëŠ” ì „ëµì ìœ¼ë¡œ ë§¤ìš° ì¤‘ìš”í•œ ë¶€ë¶„ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¦¬ìŠ¤í¬ë¥¼ ì¸ìˆ˜í•˜ê³  ê´€ë¦¬í•˜ëŠ” ë°©ì‹ì— ìˆì–´ ë§¤ìš° ì˜ë„ì ì´ê³  ì²´ê³„ì ìœ¼ë¡œ ì ‘ê·¼í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ìš°ë¦¬ëŠ” ë‹¤ì–‘í•œ ì„œë¹„ìŠ¤ì™€ ìƒí’ˆ, ì†”ë£¨ì…˜ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¤‘ìš”í•œ ì ì€ Carelonì˜ ì¸í”„ë¼ ë‚´ì—ì„œ ëª¨ë“  ê´€ê³„ì— ê±¸ì³ ì˜ë£Œë¹„ìš©(cost of care)ê³¼ ì¶”ì„¸ ê´€ë¦¬ì— ëŒ€í•´ ë§¤ìš° ì²´ê³„ì ìœ¼ë¡œ ì ‘ê·¼í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë˜í•œ ìˆ˜ìˆ˜ë£Œ ê¸°ë°˜ ì‚¬ì—…(fee-based business)ê³¼ ë¦¬ìŠ¤í¬ ê¸°ë°˜ ì‚¬ì—…(risk business)ì´ ì ì ˆí•˜ê²Œ í˜¼í•©ë˜ì–´ ìˆë‹¤ëŠ” ì ë„ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ì˜ ë¦¬ìŠ¤í¬ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì„¸ë¶„í™”í•´ì„œ ë³´ë©´, ìš°ë¦¬ëŠ” ë§¤ìš° ì°¨ë³„í™”ëœ ë°©ì‹ìœ¼ë¡œ ì ‘ê·¼í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê²½ìš°ì— ë”°ë¼ì„œëŠ” ì„œë¹„ìŠ¤ ì¹´í…Œê³ ë¦¬ ë‹¨ìœ„ë¡œ ë¦¬ìŠ¤í¬ë¥¼ ë¶€ë‹´í•˜ê¸°ë„ í•˜ê³ , ì „ì²´ í—¬ìŠ¤ ë¦¬ìŠ¤í¬(whole health risk) ê¸°ì¤€ìœ¼ë¡œ ë¶€ë‹´í•˜ê¸°ë„ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ë¦¬ìŠ¤í¬ ì½”ë¦¬ë”(risk corridors)ë¥¼ í†µí•œ ì ì ˆí•œ ë³´í˜¸ì¥ì¹˜ë¥¼ ë§ˆë ¨í–ˆê³ , ì ‘ê·¼ ë°©ì‹ì— ìˆì–´ì„œë„ ê·œìœ¨ì„ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ê¸°ì—… ì „ì²´ ê´€ì ì—ì„œ ìš°ë¦¬ê°€ ì·¨í•˜ëŠ” ì´ëŸ¬í•œ ì ‘ê·¼ ë°©ì‹ì´ ì„±ì¥ê³¼ ë§ˆì§„ í”„ë¡œíŒŒì¼ì„ ë³´í˜¸í•˜ëŠ” ë° ë§¤ìš° ì¤‘ìš”í•˜ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ì§ˆë¬¸í•˜ì‹  ë¦¬ìŠ¤í¬ë¥¼ ë¶€ë‹´í•˜ëŠ” ì„œë¹„ìŠ¤ ì¸¡ë©´ì—ì„œ ë³´ë©´, ìƒí™©ì— ë”°ë¼ ë‹¤ë¦…ë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì˜ ìƒí’ˆ ì œê³µì— ìˆì–´ì„œ ìš°ë¦¬ëŠ” ë¦¬ìŠ¤í¬ë¥¼ ë¶€ë‹´í•˜ê³  ìˆëŠ”ë°, ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ë•Œë¡œëŠ” ì§„ë£Œ ì¹´í…Œê³ ë¦¬ ë‹¨ìœ„ë¡œ, ë•Œë¡œëŠ” ì „ì²´ ë¦¬ìŠ¤í¬ ê¸°ì¤€ìœ¼ë¡œ ë¶€ë‹´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¼ë¶€ ê²½ìš°ì—ëŠ” ìˆ˜ìˆ˜ë£Œ ê¸°ë°˜ìœ¼ë¡œ ìš´ì˜í•˜ê³  ìˆì§€ë§Œ, ì´ëŸ¬í•œ í™•ì‚°ê³¼ ì•ìœ¼ë¡œì˜ ì „ì²´ ê±´ê°•(whole health) ë°œì „ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. SMIì™€ ê°™ì€ ìƒˆë¡œìš´ ì„œë¹„ìŠ¤, ì¢…ì–‘í•™(oncology) ë¶„ì•¼ì—ì„œ ì§„í–‰ ì¤‘ì¸ ì‚¬ì—…, ê·¸ë¦¬ê³  CareBridgeì˜ í™œë™ì„ ìƒê°í•´ë³´ë©´, ì´ ëª¨ë“  ê²ƒë“¤ì´ ìœ„í—˜ ê¸°ë°˜ ì„œë¹„ìŠ¤(risk offerings)ë¡œì„œ ê¸°ì—… ì „ì²´ì— ì˜ë£Œë¹„ìš©ê³¼ í’ˆì§ˆ ì¸¡ë©´ì—ì„œ ìƒë‹¹í•œ ê°€ì¹˜ë¥¼ ì°½ì¶œí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director Yes. Thanks, Pete. And the only thing I'd say is we have a very strong external growth pipeline, which I think validates what Pete is saying. And again, we're looking at serving the more complex populations based on the experience we have in our own health plans. So a lot of those programs around oncology, severe mental illness, orthopedics really give us a growth opportunity. So thank you for the question.</td><td>**Gail Boudreaux:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Pete. í•œ ê°€ì§€ ë§ë¶™ì´ìë©´, ì €í¬ëŠ” ë§¤ìš° ê°•ë ¥í•œ ì™¸ë¶€ ì„±ì¥ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” Peteê°€ ë§ì”€í•˜ì‹  ë‚´ìš©ì„ ë’·ë°›ì¹¨í•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì €í¬ëŠ” ìì²´ ê±´ê°•ë³´í—˜ ì‚¬ì—…ì—ì„œ ìŒ“ì€ ê²½í—˜ì„ ë°”íƒ•ìœ¼ë¡œ ë”ìš± ë³µì¡í•œ í™˜ìêµ°ì„ ëŒ€ìƒìœ¼ë¡œ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ëŠ” ë° ì£¼ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì¢…ì–‘í•™(oncology), ì¤‘ì¦ ì •ì‹ ì§ˆí™˜, ì •í˜•ì™¸ê³¼ ê´€ë ¨ í”„ë¡œê·¸ë¨ë“¤ì´ ì €í¬ì—ê²Œ ì„±ì¥ ê¸°íšŒë¥¼ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Dave Windley from Jefferies.</td><td>**Operator:** ë‹¤ìŒì€ ì œí”„ë¦¬ìŠ¤ì˜ ë°ì´ë¸Œ ìœˆë“¤ë¦¬ ë‹˜ ì§ˆë¬¸ ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Windley: Jefferies LLC, Research Division I wanted to ask on the Medicaid membership expected decline, is that all same-store? Or does that contemplate an exit of a state or an end of a contract, I'm thinking about Georgia. And then the 9% in total is a little bit higher than we were expecting. Your 125 basis points, I think, of margin pressure in Medicaid is consistent with what you had said before. And so I wanted to try to reconcile those that, that additional membership decline doesn't further disrupt the margin.</td><td>**David Windley:** ë©”ë””ì¼€ì´ë“œ íšŒì› ìˆ˜ ê°ì†Œ ì˜ˆìƒê³¼ ê´€ë ¨í•´ì„œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ê²Œ ì „ë¶€ ê¸°ì¡´ ì‚¬ì—…ì¥ ê¸°ì¤€ì¸ê°€ìš”? ì•„ë‹ˆë©´ íŠ¹ì • ì£¼ì—ì„œì˜ ì² ìˆ˜ë‚˜ ê³„ì•½ ì¢…ë£Œë¥¼ ë°˜ì˜í•œ ê±´ê°€ìš”? ì¡°ì§€ì•„ì£¼ë¥¼ ì—¼ë‘ì— ë‘ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „ì²´ 9% ê°ì†ŒëŠ” ì €í¬ê°€ ì˜ˆìƒí–ˆë˜ ê²ƒë³´ë‹¤ ì¡°ê¸ˆ ë†’ì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ë©”ë””ì¼€ì´ë“œ ë§ˆì§„ ì••ë°• 125bpëŠ” ì´ì „ì— ë§ì”€í•˜ì…¨ë˜ ê²ƒê³¼ ì¼ì¹˜í•˜ëŠ” ê²ƒ ê°™ê³ ìš”. ê·¸ë˜ì„œ ì´ ë¶€ë¶„ë“¤ì„ ì–´ë–»ê²Œ ì¡°í™”ì‹œì¼œì•¼ í• ì§€, ì¦‰ ì¶”ê°€ì ì¸ íšŒì› ìˆ˜ ê°ì†Œê°€ ë§ˆì§„ì„ ë” ì•…í™”ì‹œí‚¤ì§€ëŠ” ì•ŠëŠ”ì§€ í™•ì¸í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Felicia Norwood: Executive VP & President of Government Health Benefits Dave, thank you for the question. You're right, we've guided to Medicaid membership decline around 750,000 members for 2026. And this really reflects really same store. So a continuation of the challenges that we've seen across states as some states have really implemented more stringent eligibility reverification requirements, and that has happened. It happened consistently in 2025, and we thought it was very important to be prudent as we took a look at 2026 to maintain that same posture. We're continuing to work closely with our states, but certain eligibility requirements as well as program changes will lead to some of those reductions in 2026.</td><td>**Felicia Norwood:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ, ì €í¬ëŠ” 2026ë…„ ë©”ë””ì¼€ì´ë“œ(Medicaid) íšŒì› ìˆ˜ê°€ ì•½ 75ë§Œ ëª… ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì‹¤ì§ˆì ìœ¼ë¡œ ê¸°ì¡´ ì‚¬ì—…ì¥ ê¸°ì¤€ìœ¼ë¡œ, 2025ë…„ì— ì¼ë¶€ ì£¼ì •ë¶€ë“¤ì´ ë³´ë‹¤ ì—„ê²©í•œ ìê²© ì¬ê²€ì¦ ìš”ê±´ì„ ì‹œí–‰í•˜ë©´ì„œ ì§€ì†ì ìœ¼ë¡œ ë‚˜íƒ€ë‚œ ì–´ë ¤ì›€ì´ ê³„ì†ë  ê²ƒìœ¼ë¡œ ë³´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ìƒí™©ì´ 2025ë…„ ë‚´ë‚´ ì¼ê´€ë˜ê²Œ ë°œìƒí–ˆê¸° ë•Œë¬¸ì—, 2026ë…„ì„ ì „ë§í•  ë•Œ ë™ì¼í•œ ê¸°ì¡°ë¥¼ ìœ ì§€í•˜ë©° ì‹ ì¤‘í•˜ê²Œ ì ‘ê·¼í•˜ëŠ” ê²ƒì´ ë§¤ìš° ì¤‘ìš”í•˜ë‹¤ê³  íŒë‹¨í–ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê° ì£¼ì •ë¶€ì™€ ê¸´ë°€íˆ í˜‘ë ¥í•˜ê³  ìˆì§€ë§Œ, íŠ¹ì • ìê²© ìš”ê±´ ë³€ê²½ê³¼ í”„ë¡œê·¸ë¨ ë³€í™”ë¡œ ì¸í•´ 2026ë…„ì— ì¼ë¶€ íšŒì› ìˆ˜ ê°ì†Œê°€ ë°œìƒí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>Mark Kaye: Executive VP & CFO And then, Dave, how that carries in forward into our margin guidance of approximately negative 1.75% for the year is really grounded in 3 core assumptions. Number one, cost trend is going to remain elevated. We have planned for medical cost trend in that mid-single-digit percent range, still materially above historical norms. Number two, rates, as we discussed earlier on the call, are going to improve, but they will still lag trends. And you can think about that as roughly 1/3 of those Medicaid premiums reset in January. And then third, we're not relying on rates alone. We are using all the levers we control, [ tighter ] medical and pharmacy cost management, expanded BH interventions, et cetera. And so taken together, we think our outlook for Medicaid margin is prudent for 2026.</td><td>**Mark Kaye:** ê·¸ë¦¬ê³  Dave, ì´ê²ƒì´ ì—°ê°„ ì•½ ë§ˆì´ë„ˆìŠ¤ 1.75%ë¼ëŠ” ë§ˆì§„ ê°€ì´ë˜ìŠ¤ë¡œ ì´ì–´ì§€ëŠ” ê³¼ì •ì€ ì‹¤ì œë¡œ 3ê°€ì§€ í•µì‹¬ ê°€ì •ì— ê¸°ë°˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì²«ì§¸, ë¹„ìš© ì¶”ì„¸ëŠ” ê³„ì† ë†’ì€ ìˆ˜ì¤€ì„ ìœ ì§€í•  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì˜ë£Œë¹„ ì¶”ì„¸ë¥¼ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ í¼ì„¼íŠ¸ ë²”ìœ„ë¡œ ê³„íší–ˆëŠ”ë°, ì´ëŠ” ì—¬ì „íˆ ê³¼ê±° ì •ìƒ ìˆ˜ì¤€ì„ í¬ê²Œ ìƒíšŒí•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë‘˜ì§¸, ìš”ìœ¨ì€ ì•ì„œ í†µí™”ì—ì„œ ë…¼ì˜í•œ ë°”ì™€ ê°™ì´ ê°œì„ ë˜ê² ì§€ë§Œ, ì—¬ì „íˆ ì¶”ì„¸ì—ëŠ” ë’¤ì²˜ì§ˆ ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ë©”ë””ì¼€ì´ë“œ ë³´í—˜ë£Œì˜ ì•½ 3ë¶„ì˜ 1ì´ 1ì›”ì— ì¬ì¡°ì •ë˜ëŠ” ê²ƒìœ¼ë¡œ ì´í•´í•˜ì‹œë©´ ë©ë‹ˆë‹¤. ì…‹ì§¸, ìš°ë¦¬ëŠ” ìš”ìœ¨ì—ë§Œ ì˜ì¡´í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ í†µì œí•  ìˆ˜ ìˆëŠ” ëª¨ë“  ìˆ˜ë‹¨ì„ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë” ì—„ê²©í•œ ì˜ë£Œ ë° ì•½ì œë¹„ ê´€ë¦¬, í–‰ë™ê±´ê°•(BH) ê°œì… í™•ëŒ€ ë“±ì´ ê·¸ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì ë“¤ì„ ì¢…í•©ì ìœ¼ë¡œ ê³ ë ¤í•  ë•Œ, 2026ë…„ ë©”ë””ì¼€ì´ë“œ ë§ˆì§„ì— ëŒ€í•œ ì €í¬ ì „ë§ì€ ì‹ ì¤‘í•œ ìˆ˜ì¤€ì´ë¼ê³  íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Sarah James from Cantor Fitzgerald.</td><td>**Operator:** ë‹¤ìŒì€ ìº”í„° í”¼ì¸ ì œëŸ´ë“œì˜ ì‚¬ë¼ ì œì„ìŠ¤ ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Sarah James: Cantor Fitzgerald & Co., Research Division Commercial risk guidance is down about 700,000 lives while ACA is growing. Can you quantify how much of that decline reflects pricing actions on those government accounts versus employers shifting preference to ASO? And in your long-term Health Benefits margin guidance, does the mix change assume further commercial risk attrition or mainly the impact of the actions taken this year?</td><td>**Sarah James:** ìƒì—… ë¦¬ìŠ¤í¬ ê°€ì´ë˜ìŠ¤ê°€ ì•½ 70ë§Œ ëª… ê°ì†Œí•œ ë°˜ë©´ ACAëŠ” ì„±ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê°ì†Œ ì¤‘ ì •ë¶€ ê³„ì •ì— ëŒ€í•œ ê°€ê²© ì¡°ì¹˜ê°€ ì°¨ì§€í•˜ëŠ” ë¹„ì¤‘ê³¼ ê³ ìš©ì£¼ë“¤ì´ ASOë¡œ ì„ í˜¸ë¥¼ ì „í™˜í•œ ë¹„ì¤‘ì„ ê°ê° ìˆ˜ì¹˜í™”í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  ì¥ê¸° ê±´ê°•ê¸‰ì—¬ ë§ˆì§„ ê°€ì´ë˜ìŠ¤ì—ì„œ ë¯¹ìŠ¤ ë³€í™”ëŠ” ì¶”ê°€ì ì¸ ìƒì—… ë¦¬ìŠ¤í¬ ê°ì†Œë¥¼ ê°€ì •í•œ ê²ƒì¸ê°€ìš”, ì•„ë‹ˆë©´ ì£¼ë¡œ ì˜¬í•´ ì·¨í•œ ì¡°ì¹˜ë“¤ì˜ ì˜í–¥ì„ ë°˜ì˜í•œ ê²ƒì¸ê°€ìš”?</td></tr>
<tr><td>Mark Kaye: Executive VP & CFO Thanks very much for the question. Maybe just a moment here to clarify. So on the individual ACA, we are guiding to at least 900,000 members at year-end 2026. And it's important to put that in the context of obviously where we ended 2025. For the Employer Group risk-based membership, we do expect a decline year-over-year in that high single-digit percent range. We spoke a little bit about that earlier, and that's primarily because we're prioritizing margins. And then finally, in ASO, we are expecting a pretty good season. I'm actually going to ask Morgan to help here because he deserves a lot of credit for our success in how we're guiding 2026.</td><td>**Mark Kaye:** ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ë¨¼ì € ëª…í™•íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê°œì¸ ACA(Affordable Care Act) ë¶€ë¬¸ì˜ ê²½ìš°, 2026ë…„ ë§ê¹Œì§€ ìµœì†Œ 90ë§Œ ëª…ì˜ íšŒì›ì„ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” 2025ë…„ ë§ ì‹¤ì ê³¼ ë¹„êµí•´ì„œ ë³´ì‹œëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤. ê³ ìš©ì£¼ ê·¸ë£¹ ìœ„í—˜ ê¸°ë°˜ íšŒì› ìˆ˜ì˜ ê²½ìš°, ì „ë…„ ëŒ€ë¹„ ë†’ì€ í•œ ìë¦¿ìˆ˜ í¼ì„¼íŠ¸ ë²”ìœ„ì˜ ê°ì†Œë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ ì•ì„œ ì¡°ê¸ˆ ë§ì”€ë“œë ¸ëŠ”ë°, ì£¼ëœ ì´ìœ ëŠ” ìš°ë¦¬ê°€ ë§ˆì§„ì„ ìš°ì„ ì‹œí•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ASO(Administrative Services Only) ë¶€ë¬¸ì—ì„œëŠ” ìƒë‹¹íˆ ì¢‹ì€ ì‹œì¦Œì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‚¬ì‹¤ ì´ ë¶€ë¶„ì€ Morganì—ê²Œ ë„ì›€ì„ ìš”ì²­í•˜ë ¤ê³  í•©ë‹ˆë‹¤. 2026ë…„ ê°€ì´ë˜ìŠ¤ì—ì„œ ìš°ë¦¬ê°€ ê±°ë‘” ì„±ê³¼ì— ëŒ€í•´ ê·¸ê°€ ë§ì€ ê³µë¡œë¥¼ ì¸ì •ë°›ì•„ì•¼ í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Morgan Kendrick: Thanks, Mark, and thanks, Sarah. Regarding the ASO business, national accounts, and Gail mentioned to it earlier, has had just a spectacular year, which I think sort of speaks to the health of the assets across the entire enterprise when you look at it. And a couple of things were sort of driving that. We -- Gail mentioned at the beginning of the conference today around second Blue bid, where this is the first year that we've had the opportunity for employers in competing geographies against us could actually quote with our organization if they wanted. So when we think about how it came together, we've got about -- we had about 11 bids in the second Blue category for 2026, won 9 of them. And the tee up of the actual pipeline for 2027 looks strong and also '28 as we sit here. So whether we're talking the local markets or the national markets, the self-funded business has done quite well. We expect it to continue to. And with that, as you also heard from Pete earlier, the pull-through with the CarelonRx has been really, really strong and notably in the upmarket where it had not been formerly. So we're pleased with it and look forward to continued success.</td><td>**Morgan Kendrick:** ê°ì‚¬í•©ë‹ˆë‹¤, Mark, Sarah. ASO ì‚¬ì—… ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì „êµ­ ë‹¨ìœ„ ê³„ì •(national accounts)ì´ ì •ë§ ë†€ë¼ìš´ í•œ í•´ë¥¼ ë³´ëƒˆìŠµë‹ˆë‹¤. Gailë„ ì•ì„œ ì–¸ê¸‰í–ˆëŠ”ë°ìš”, ì´ëŠ” ì „ì‚¬ì ìœ¼ë¡œ ìì‚°ì˜ ê±´ì „ì„±ì„ ë³´ì—¬ì£¼ëŠ” ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ëª‡ ê°€ì§€ ìš”ì¸ì´ ì´ë¥¼ ê²¬ì¸í–ˆìŠµë‹ˆë‹¤. Gailì´ ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì´ˆë°˜ì— ì–¸ê¸‰í•œ ì„¸ì»¨ë“œ ë¸”ë£¨ ì…ì°°(second Blue bid) ê±´ì´ ìˆëŠ”ë°ìš”, ì˜¬í•´ê°€ ìš°ë¦¬ì™€ ê²½ìŸ ì§€ì—­ì— ìˆëŠ” ê³ ìš©ì£¼ë“¤ì´ ì›í•œë‹¤ë©´ ì‹¤ì œë¡œ ìš°ë¦¬ ì¡°ì§ê³¼ ê²¬ì ì„ ë‚¼ ìˆ˜ ìˆì—ˆë˜ ì²« í•´ì˜€ìŠµë‹ˆë‹¤. ì‹¤ì ì„ ë³´ë©´, 2026ë…„ ì„¸ì»¨ë“œ ë¸”ë£¨ ì¹´í…Œê³ ë¦¬ì—ì„œ ì•½ 11ê±´ì˜ ì…ì°°ì´ ìˆì—ˆê³ , ê·¸ ì¤‘ 9ê±´ì„ ìˆ˜ì£¼í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í˜„ì¬ ì‹œì ì—ì„œ 2027ë…„ê³¼ 2028ë…„ ì‹¤ì œ íŒŒì´í”„ë¼ì¸ êµ¬ì„±ë„ íƒ„íƒ„í•´ ë³´ì…ë‹ˆë‹¤. ì§€ì—­ ì‹œì¥ì´ë“  ì „êµ­ ì‹œì¥ì´ë“ , ìê°€ë³´í—˜(self-funded) ì‚¬ì—…ì€ ìƒë‹¹íˆ ì¢‹ì€ ì„±ê³¼ë¥¼ ê±°ë‘ê³  ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œë„ ì´ëŸ¬í•œ ì¶”ì„¸ê°€ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë˜í•œ Peteê°€ ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, CarelonRxì™€ì˜ ì—°ê³„ íŒë§¤ê°€ ì •ë§ ê°•ë ¥í•˜ê²Œ ì´ë£¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ì£¼ëª©í•  ë§Œí•œ ì ì€ ê³¼ê±°ì—ëŠ” ê·¸ë ‡ì§€ ëª»í–ˆë˜ ëŒ€ê¸°ì—… ì‹œì¥ì—ì„œë„ ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ê³¼ì— ë§Œì¡±í•˜ê³  ìˆìœ¼ë©°, ì•ìœ¼ë¡œë„ ê³„ì†í•´ì„œ ì„±ê³µì ì¸ ì„±ê³¼ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we'll go to the line of Jason Cassorla from Guggenheim.</td><td>**Operator:** ë‹¤ìŒì€ êµ¬ê²í•˜ì„ì˜ ì œì´ìŠ¨ ì¹´ì†Œë¥¼ë¼ ë‹˜ ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Jason Cassorla: Guggenheim Securities, LLC, Research Division Maybe just a question on aggregate Carelon. It looks like for '26, revenue is growing across both Rx and services. Margins are generally holding in for both despite the enrollment losses for your Health Benefits business. Maybe can you just help unpack or bifurcate CarelonRx and services revenue and margin impacts, specifically coming from the Health Benefits enrollment losses versus perhaps the growth and margin maturation you're seeing from external clients would be helpful.</td><td>**Jason Cassorla:** ì „ì²´ Carelonì— ëŒ€í•œ ì§ˆë¬¸ì…ë‹ˆë‹¤. 2026ë…„ì„ ë³´ë©´ Rxì™€ ì„œë¹„ìŠ¤ ë¶€ë¬¸ ëª¨ë‘ì—ì„œ ë§¤ì¶œì´ ì„±ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. í—¬ìŠ¤ ë² ë„¤í• ì‚¬ì—…ì˜ ê°€ì…ì ê°ì†Œì—ë„ ë¶ˆêµ¬í•˜ê³  ë‘ ë¶€ë¬¸ ëª¨ë‘ ë§ˆì§„ì´ ëŒ€ì²´ë¡œ ìœ ì§€ë˜ê³  ìˆëŠ”ë°ìš”. CarelonRxì™€ ì„œë¹„ìŠ¤ ë¶€ë¬¸ì˜ ë§¤ì¶œ ë° ë§ˆì§„ ì˜í–¥ì„ êµ¬ë¶„í•´ì„œ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? íŠ¹íˆ í—¬ìŠ¤ ë² ë„¤í• ê°€ì…ì ê°ì†Œë¡œ ì¸í•œ ì˜í–¥ê³¼ ì™¸ë¶€ ê³ ê°ìœ¼ë¡œë¶€í„°ì˜ ì„±ì¥ ë° ë§ˆì§„ ì„±ìˆ™ë„ ì¸¡ë©´ì—ì„œ ë§ì”€í•´ ì£¼ì‹œë©´ ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director All right. I'll let Pete address that.</td><td>**Gail Boudreaux:** ì•Œê² ìŠµë‹ˆë‹¤. í”¼íŠ¸ê°€ ë‹µë³€í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Peter Haytaian: Executive VP and President of Carelon & CarelonRx Yes. No, thanks for that question. Let's step back and just talk about first setting up Carelon for 2026 of what we came off of in 2025, which was very, very strong. I think you saw that come through. We had almost 60% growth on the services side and on the pharmacy side over 20% growth. And we're very encouraged in terms of what we're selling, diversity of services, our growing portfolio of solutions. We launched CareBridge last year. On the Rx side, as I noted before, we're selling upmarket to a much greater degree. And importantly, that momentum is continuing into 2026 with respect to your question, external sales. In fact, I'll emphasize this. We had the best year both in services as well as Rx in terms of external growth. And when I mentioned external growth on the pharmacy side, that's the integrated ASO growth going forward. As you noted, those tailwinds are being offset by affiliated membership attrition. And when you think about services, we also had one large external client, which we had planned for that went from a risk basis to a fee basis. But that was the largest driver in terms of headwinds overall. If you step back though, and you take out that internal membership headwind, our overall growth would have been on the services side, high teens, low 20s. And on the Rx side, in the low double-digit range. So consistent with what we've guided to longer term. And I would think of that as a mid-single-digit sort of op gain impact on the affiliated membership.</td><td>**Peter Haytaian:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € 2026ë…„ ì¼€ì–´ë¡ (Carelon) ì „ë§ì„ ë§ì”€ë“œë¦¬ê¸° ì „ì— 2025ë…„ ì‹¤ì ë¶€í„° ì§šì–´ë³´ê² ìŠµë‹ˆë‹¤. 2025ë…„ì€ ì •ë§ ê°•ë ¥í•œ í•œ í•´ì˜€ìŠµë‹ˆë‹¤. ë³´ì…¨ê² ì§€ë§Œ ì„œë¹„ìŠ¤ ë¶€ë¬¸ì—ì„œ ê±°ì˜ 60% ì„±ì¥ì„ ê¸°ë¡í–ˆê³ , ì•½êµ­ ë¶€ë¬¸ì—ì„œë„ 20% ì´ìƒ ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ íŒë§¤í•˜ê³  ìˆëŠ” ì„œë¹„ìŠ¤ì˜ ë‹¤ì–‘ì„±ê³¼ í™•ëŒ€ë˜ëŠ” ì†”ë£¨ì…˜ í¬íŠ¸í´ë¦¬ì˜¤ì— ëŒ€í•´ ë§¤ìš° ê³ ë¬´ì ì…ë‹ˆë‹¤. ì‘ë…„ì— ì¼€ì–´ë¸Œë¦¿ì§€(CareBridge)ë„ ì¶œì‹œí–ˆê³ ìš”. Rx ë¶€ë¬¸ì—ì„œëŠ” ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ í›¨ì”¬ ë” ìƒìœ„ ì‹œì¥ìœ¼ë¡œ ì§„ì¶œí•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì¤‘ìš”í•œ ì ì€ ì§ˆë¬¸í•˜ì‹  ì™¸ë¶€ íŒë§¤ì™€ ê´€ë ¨í•´ì„œ ì´ëŸ¬í•œ ëª¨ë©˜í…€ì´ 2026ë…„ì—ë„ ê³„ì†ë˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì„ ê°•ì¡°í•˜ê³  ì‹¶ì€ë°ìš”, ì„œë¹„ìŠ¤ì™€ Rx ë¶€ë¬¸ ëª¨ë‘ì—ì„œ ì™¸ë¶€ ì„±ì¥ ì¸¡ë©´ì—ì„œ ìµœê³ ì˜ í•´ë¥¼ ë³´ëƒˆìŠµë‹ˆë‹¤. ì•½êµ­ ë¶€ë¬¸ì˜ ì™¸ë¶€ ì„±ì¥ì— ëŒ€í•´ ë§ì”€ë“œë ¸ë˜ ë¶€ë¶„ì€ í–¥í›„ í†µí•© ASO ì„±ì¥ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ, ì´ëŸ¬í•œ ìˆœí’ ìš”ì¸ë“¤ì€ ì œíœ´ íšŒì› ê°ì†Œë¡œ ìƒì‡„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì„œë¹„ìŠ¤ ë¶€ë¬¸ì„ ë³´ë©´, ì˜ˆìƒí–ˆë˜ ëŒ€í˜• ì™¸ë¶€ ê³ ê° í•œ ê³³ì´ ìœ„í—˜ ê¸°ë°˜ì—ì„œ ìˆ˜ìˆ˜ë£Œ ê¸°ë°˜ìœ¼ë¡œ ì „í™˜í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì „ë°˜ì ì¸ ì—­í’ ìš”ì¸ ì¤‘ ê°€ì¥ í° ë¶€ë¶„ì´ì—ˆìŠµë‹ˆë‹¤.<br><br>í•˜ì§€ë§Œ í•œ ë°œ ë¬¼ëŸ¬ì„œì„œ ë‚´ë¶€ íšŒì› ê°ì†Œ ìš”ì¸ì„ ì œì™¸í•˜ê³  ë³´ë©´, ì„œë¹„ìŠ¤ ë¶€ë¬¸ì˜ ì „ì²´ ì„±ì¥ë¥ ì€ 10%ëŒ€ í›„ë°˜ì—ì„œ 20% ì´ˆë°˜ ìˆ˜ì¤€ì´ì—ˆì„ ê²ƒì…ë‹ˆë‹¤. ì²˜ë°©ì•½(Rx) ë¶€ë¬¸ì€ 10% ì´ˆë°˜ëŒ€ ì„±ì¥ë¥ ì„ ë³´ì˜€ì„ ê²ƒì´ê³ ìš”. ì´ëŠ” ì¥ê¸°ì ìœ¼ë¡œ ì œì‹œí•œ ê°€ì´ë˜ìŠ¤ì™€ ì¼ì¹˜í•˜ëŠ” ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì œíœ´ íšŒì› ë¶€ë¶„ì—ì„œëŠ” ì˜ì—…ì´ìµì— ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì •ë„ì˜ ì˜í–¥ì´ ìˆì—ˆë‹¤ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director Thank you, Pete. I think we have time for one last question.</td><td>**Gail Boudreaux:** ê°ì‚¬í•©ë‹ˆë‹¤, Pete. ë§ˆì§€ë§‰ ì§ˆë¬¸ í•˜ë‚˜ ë” ë°›ì„ ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: And for our final question, we'll go to the line of George Hill from Deutsche Bank.</td><td>**Operator:** ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ ë„ì´ì²´ë°©í¬ì˜ ì¡°ì§€ í ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>George Hill: Deutsche Bank AG, Research Division I really appreciate you sneaking me in at the end. Mark, the topic where I'm getting the most questions is, can you just contextualize a little bit more what does the ending baseline mean? You talked about earnings for fiscal '26 being front-end loaded. Should we kind of be thinking about that last period run rate as the baseline for 12% growth? And then maybe talk about any visibility to any onetime items in '26 and whether or not they'll be included or excluded from the baseline.</td><td>**George Hill:** ë§ˆì§€ë§‰ì— ì§ˆë¬¸ ê¸°íšŒë¥¼ ì£¼ì…”ì„œ ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤. ë§ˆí¬, ì œê°€ ê°€ì¥ ë§ì€ ì§ˆë¬¸ì„ ë°›ê³  ìˆëŠ” ì£¼ì œëŠ” ê¸°ì¤€ì„  ì¢…ë£Œ(ending baseline)ê°€ ì •í™•íˆ ë¬´ì—‡ì„ ì˜ë¯¸í•˜ëŠ”ì§€ì…ë‹ˆë‹¤. 26íšŒê³„ì—°ë„ ì‹¤ì ì´ ìƒë°˜ê¸°ì— ì§‘ì¤‘ë  ê²ƒì´ë¼ê³  ë§ì”€í•˜ì…¨ëŠ”ë°, ë§ˆì§€ë§‰ ê¸°ê°„ì˜ ì‹¤í–‰ë¥ (run rate)ì„ 12% ì„±ì¥ì˜ ê¸°ì¤€ì„ ìœ¼ë¡œ ìƒê°í•´ì•¼ í• ê¹Œìš”? ê·¸ë¦¬ê³  26ë…„ë„ì— ì˜ˆìƒë˜ëŠ” ì¼íšŒì„± í•­ëª©ë“¤ì— ëŒ€í•œ ê°€ì‹œì„±ê³¼, ê·¸ê²ƒë“¤ì´ ê¸°ì¤€ì„ ì— í¬í•¨ë ì§€ ì œì™¸ë ì§€ì— ëŒ€í•´ì„œë„ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Mark Kaye: Executive VP & CFO George, thanks very much for the question. This is really a good one to conclude on. So let me try to bring it together the key themes and messages that we've delivered on the call today. So we have established the 2026 EPS guidance of at least $25.50, and anchored in what I consider very prudent, achievable assumptions supported by actions that we have already taken or underway to reposition our business and improve margins across the enterprise. And at a high level, you could think about the EPS bridge to $25.50 as really being driven by a few key building blocks. Stable performance in Commercial Fully Insured and continued strength in Commercial Fee-Based, continued progress towards sustainable performance in ACA, Medicaid margins compressing to approximately negative 1.75%, consistent with our view that 2026 is the trough year, more than 100 basis points of operating margin improvement in Medicare Advantage to at least 2%, low single-digit operating gain growth in Carelon where external momentum is partially masked by those affiliated Health Benefit membership declines. And then below the line, a meaningful step down, reflecting the nonrecurrence of the 2025 investment income and a return to a more normalized tax rate. So putting all of that together, again, the guidance of $25.50 prudent, achievable assumption.</td><td>**Mark Kaye:** ì •ë§ ì¢‹ì€ ì§ˆë¬¸ìœ¼ë¡œ ë§ˆë¬´ë¦¬í•˜ê²Œ ë˜ì–´ ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ì „ë‹¬ë“œë¦° í•µì‹¬ ì£¼ì œì™€ ë©”ì‹œì§€ë¥¼ ì •ë¦¬í•´ ë³´ê² ìŠµë‹ˆë‹¤. <br><br>2026ë…„ ì£¼ë‹¹ìˆœì´ìµ(EPS) ê°€ì´ë˜ìŠ¤ë¥¼ ìµœì†Œ 25.50ë‹¬ëŸ¬ë¡œ ì„¤ì •í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì œê°€ ë³´ê¸°ì— ë§¤ìš° ì‹ ì¤‘í•˜ê³  ë‹¬ì„± ê°€ëŠ¥í•œ ê°€ì •ë“¤ì— ê¸°ë°˜í•˜ê³  ìˆìœ¼ë©°, ì‚¬ì—… ì¬í¸ê³¼ ì „ì‚¬ì  ë§ˆì§„ ê°œì„ ì„ ìœ„í•´ ì´ë¯¸ ì·¨í–ˆê±°ë‚˜ ì§„í–‰ ì¤‘ì¸ ì‹¤í–‰ ê³¼ì œë“¤ì´ ë’·ë°›ì¹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. í° ê·¸ë¦¼ì—ì„œ ë³´ë©´, 25.50ë‹¬ëŸ¬ë¡œ ê°€ëŠ” EPS ë¸Œë¦¬ì§€ëŠ” ëª‡ ê°€ì§€ í•µì‹¬ êµ¬ì„± ìš”ì†Œë“¤ì´ ì£¼ë„í•œë‹¤ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤. ìƒì—… ì™„ì „ ë³´í—˜(Commercial Fully Insured) ë¶€ë¬¸ì˜ ì•ˆì •ì ì¸ ì‹¤ì ê³¼ ìƒì—… ìˆ˜ìˆ˜ë£Œ ê¸°ë°˜(Commercial Fee-Based) ë¶€ë¬¸ì˜ ì§€ì†ì ì¸ ê°•ì„¸, ACAì—ì„œ ì§€ì† ê°€ëŠ¥í•œ ì‹¤ì ì„ í–¥í•œ ì§€ì†ì ì¸ ì§„ì „, ë©”ë””ì¼€ì´ë“œ ë§ˆì§„ì€ ì•½ ë§ˆì´ë„ˆìŠ¤ 1.75%ë¡œ ì••ì¶•ë˜ëŠ”ë° ì´ëŠ” 2026ë…„ì´ ì €ì ì´ë¼ëŠ” ì €í¬ ì „ë§ê³¼ ì¼ì¹˜í•©ë‹ˆë‹¤. ë©”ë””ì¼€ì–´ ì–´ë“œë°´í‹°ì§€(Medicare Advantage)ì—ì„œëŠ” ì˜ì—…ì´ìµë¥ ì´ 100bp ì´ìƒ ê°œì„ ë˜ì–´ ìµœì†Œ 2%ë¥¼ ë‹¬ì„±í•˜ê³ , ì¼€ì–´ë¡ (Carelon)ì—ì„œëŠ” ì™¸ë¶€ ëª¨ë©˜í…€ì´ ê³„ì—´ì‚¬ ê±´ê°•ë³´í—˜ íšŒì› ìˆ˜ ê°ì†Œë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ê°€ë ¤ì§€ê¸´ í•˜ì§€ë§Œ ë‚®ì€ í•œ ìë¦¿ìˆ˜ì˜ ì˜ì—…ì´ìµ ì„±ì¥ì„ ë³´ì¼ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜ì—…ì™¸ ë¶€ë¬¸ì—ì„œëŠ” 2025ë…„ íˆ¬ììˆ˜ìµì˜ ë¹„ë°˜ë³µê³¼ ë³´ë‹¤ ì •ìƒí™”ëœ ì„¸ìœ¨ë¡œì˜ ë³µê·€ë¥¼ ë°˜ì˜í•˜ì—¬ ì˜ë¯¸ ìˆëŠ” í•˜ë½ì´ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì„ ì¢…í•©í•˜ë©´, ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ 25.50ë‹¬ëŸ¬ ê°€ì´ë˜ìŠ¤ëŠ” ì‹ ì¤‘í•˜ê³  ë‹¬ì„± ê°€ëŠ¥í•œ ê°€ì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Gail Boudreaux: President, CEO & Director Okay. Thank you, operator, and thank you to everyone on the line. As we close, Elevance Health is entering this year with a clear strategy and a strong sense of purpose. We're focused on improving affordability, simplifying healthcare and applying our capabilities in ways that drive better access, outcomes and experiences for members and care providers and stronger health for the communities we serve. While the operating environment remains dynamic, our diversified platform and differentiated whole health approach give us confidence in the path ahead and the actions we've taken position the enterprise to drive sustainable earnings growth over the long term. Thank you again for your continued interest in Elevance Health and have a great rest of week. Thank you.</td><td>**Gail Boudreaux:** ê°ì‚¬í•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ë§ì”€ë“œë¦¬ìë©´, Elevance HealthëŠ” ëª…í™•í•œ ì „ëµê³¼ ê°•í•œ ëª©ì ì˜ì‹ì„ ê°€ì§€ê³  ì˜¬í•´ë¥¼ ì‹œì‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì˜ë£Œë¹„ ë¶€ë‹´ ì™„í™”, í—¬ìŠ¤ì¼€ì–´ ê°„ì†Œí™”, ê·¸ë¦¬ê³  íšŒì›ê³¼ ì˜ë£Œ ì œê³µìë“¤ì—ê²Œ ë” ë‚˜ì€ ì ‘ê·¼ì„±, ì„±ê³¼, ê²½í—˜ì„ ì œê³µí•˜ê³  ìš°ë¦¬ê°€ ì„œë¹„ìŠ¤í•˜ëŠ” ì§€ì—­ì‚¬íšŒì˜ ê±´ê°• ì¦ì§„ì„ ì´ëŒì–´ë‚´ëŠ” ë°©ì‹ìœ¼ë¡œ ìš°ë¦¬ì˜ ì—­ëŸ‰ì„ ì ìš©í•˜ëŠ” ë° ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ìš´ì˜ í™˜ê²½ì´ ì—¬ì „íˆ ì—­ë™ì ì´ê¸´ í•˜ì§€ë§Œ, ìš°ë¦¬ì˜ ë‹¤ê°í™”ëœ í”Œë«í¼ê³¼ ì°¨ë³„í™”ëœ ì „ì¸ì  ê±´ê°• ì ‘ê·¼ë²•ì€ ì•ìœ¼ë¡œ ë‚˜ì•„ê°ˆ ë°©í–¥ì— ëŒ€í•œ í™•ì‹ ì„ ì£¼ê³  ìˆìœ¼ë©°, ìš°ë¦¬ê°€ ì·¨í•œ ì¡°ì¹˜ë“¤ì€ ì¥ê¸°ì ìœ¼ë¡œ ì§€ì† ê°€ëŠ¥í•œ ìˆ˜ìµ ì„±ì¥ì„ ì´ëŒì–´ë‚¼ ìˆ˜ ìˆë„ë¡ íšŒì‚¬ë¥¼ í¬ì§€ì…”ë‹í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>Elevance Healthì— ëŒ€í•œ ì§€ì†ì ì¸ ê´€ì‹¬ì— ë‹¤ì‹œ í•œë²ˆ ê°ì‚¬ë“œë¦¬ë©°, ë‚¨ì€ í•œ ì£¼ ì˜ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Ladies and gentlemen, a recording of this conference will be available for replay after 11:00 a.m. today through February 28, 2026. You may access the replay system at any time by dialing (888) 566-0046, and international participants can dial (203) 369-3677. This concludes our conference for today. Thank you for your participation.</td><td>**Operator:** <response><br><br>ì—¬ëŸ¬ë¶„, ë³¸ ì»¨í¼ëŸ°ìŠ¤ ë…¹ìŒì€ ì˜¤ëŠ˜ ì˜¤ì „ 11ì‹œ ì´í›„ë¶€í„° 2026ë…„ 2ì›” 28ì¼ê¹Œì§€ ë‹¤ì‹œ ë“¤ìœ¼ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. (888) 566-0046ìœ¼ë¡œ ì „í™”í•˜ì‹œë©´ ì–¸ì œë“ ì§€ ì¬ìƒ ì‹œìŠ¤í…œì— ì ‘ì†í•˜ì‹¤ ìˆ˜ ìˆìœ¼ë©°, í•´ì™¸ ì°¸ê°€ìë¶„ë“¤ì€ (203) 369-3677ë¡œ ì „í™”í•˜ì‹œë©´ ë©ë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ë¥¼ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.<br><br></response></td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Elevance Health ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>## í•µì‹¬ ì¬ë¬´ ì§€í‘œ ë° ê°€ì´ë˜ìŠ¤<br>- **2026ë…„ EPS ê°€ì´ë˜ìŠ¤**: ìµœì†Œ $25.50ë¡œ ì œì‹œ, ê²½ì˜ì§„ì€ ì‹ ì¤‘í•˜ê³  ë‹¬ì„± ê°€ëŠ¥í•œ ëª©í‘œë¡œ í‰ê°€<br>- **2027ë…„ ì„±ì¥ ì „ë§**: 2026ë…„ ê¸°ì¤€ì„  ëŒ€ë¹„ ìµœì†Œ 12% EPS ì„±ì¥ ëª©í‘œ ì¬í™•ì¸<br>- **4ë¶„ê¸° ì‹¤ì **: ì˜ë£Œë¹„ ì¶”ì„¸ê°€ ì˜ˆìƒê³¼ ëŒ€ì²´ë¡œ ì¼ì¹˜í•˜ê±°ë‚˜ ì†Œí­ ì–‘í˜¸, ì„¸ê¸ˆ ê´€ë ¨ ì¼íšŒì„± ì´ìµ $0.75 ë°œìƒ<br><br>## ì‚¬ì—…ë¶€ë¬¸ë³„ ë§ˆì§„ ë° íšŒì› ìˆ˜ ì „ë§<br>- **Medicaid**: 2026ë…„ ë§ˆì§„ ì•½ -1.75% ì˜ˆìƒ (ì €ì  êµ¬ê°„), íšŒì› ìˆ˜ 75ë§Œëª… ê°ì†Œ ì „ë§, ì˜ë£Œë¹„ ì¦ê°€ìœ¨ì€ ì¤‘ê°„ í•œìë¦¿ìˆ˜ë¡œ ì—­ì‚¬ì  í‰ê· ì˜ 2ë°° ìˆ˜ì¤€ ì§€ì†<br>- **Medicare Advantage**: ë§ˆì§„ ìµœì†Œ 2%ë¡œ 100bp ì´ìƒ ê°œì„  ëª©í‘œ, íšŒì› ìˆ˜ëŠ” ê³ 10%ëŒ€ ê°ì†Œ ì˜ˆìƒ (ì˜ë„ì ì¸ ìˆ˜ìµì„± ì¤‘ì‹¬ í¬íŠ¸í´ë¦¬ì˜¤ ì¬í¸ì„±)<br>- **Commercial**: ëŒ€í˜• ê·¸ë£¹ì€ 2025ë…„ê³¼ ìœ ì‚¬í•œ ë§ˆì§„ ìœ ì§€, ACAëŠ” ë³´ì¡°ê¸ˆ ì¢…ë£Œë¡œ ë¹„ìš© ì¦ê°€ ê°€ì†í™” ì˜ˆìƒ, ê³ ìœ„í—˜ íšŒì› ì¦ê°€ ì „ë§<br>- **Carelon**: ì™¸ë¶€ ê³ ê° ì„±ì¥ ê°•ì„¸ ì§€ì†, ë‚´ë¶€ íšŒì› ê°ì†Œë¡œ ìƒì‡„ë˜ë‚˜ ì¥ê¸° ì„±ì¥ ëª¨ë©˜í…€ ìœ ì§€<br><br>## ê²½ì˜ì§„ í†¤</p>
    <hr style="margin:50px 0;">
    
</body></html>